

CURRICULUM VITAE

NAME: Ronald H. Kerman, Ph.D.

PRESENT TITLE:

1987- Professor
 Department of Surgery, and Director, Histocompatibility and Immune Evaluation Laboratories, Division of Immunology and Organ Transplantation, The University of Texas Medical School at Houston

1977- Member, Program in Immunology, Graduate School of Biomedical Sciences, The University of Texas Health Science Center at Houston

ADDRESS: 36 Wynden Oaks Drive
 Houston, Texas 77056

BIRTHDATE: June 10, 1943
 Chicago, Illinois

CITIZEN: U.S. Citizen

UNDERGRADUATE EDUCATION:

B.S. (with Honors), University of Illinois, 1965

GRADUATE EDUCATION: M.S. (Immunology), University of Illinois, 1967
 Ph.D. (Immunology), University of Illinois, 1969

POSTGRADUATE TRAINING:

1969-1971 Postdoctoral Fellow (Immunology)
 Children's Hospital of Philadelphia and The University of Pennsylvania School of Medicine

ACADEMIC APPOINTMENTS:

1987- Professor
 Department of Surgery, and Director, Histocompatibility and Immune Evaluation Laboratories, Division of Immunology and Organ Transplantation, The University of Texas Medical School at Houston

1981-1986 Associate Professor
 Department of Surgery, and Director, Histocompatibility and Immune Evaluation Laboratories, Division of Immunology and Organ Transplantation, The University of Texas Medical School at Houston

1977-1980	Assistant Professor Department of Surgery, and Assistant Director, Histocompatibility and Immune Evaluation Laboratories, Division of Immunology and Organ Transplantation, The University of Texas Medical School at Houston
1974-1977	Assistant Professor Department of Surgery, Loyola University Stritch School of Medicine, Hines, Illinois
1973-1977	Research Immunologist Chief, Immunobiology Research Laboratory, Research Service, V.A. Hospital, Hines, Illinois
1972-1973	Assistant Professor Department of Microbiology, Jefferson Medical College, Philadelphia, PA.

BOARD CERTIFICATION:

1993 -	Board Certified Clinical Laboratory Director (#6402) American Board of Bioanalysis
2007	National Provider Identifier: 1962603217

**PROFESSIONAL
ORGANIZATIONS:**

The Transplantation Society
American Association of Immunologists
International Society for Heart and Lung Transplantation
Board of Directors (2004-2007)
American Association for the Advancement of Science
United Network for Organ Sharing
Histocompatibility Committee (1989-1991)
Membership Committee (1990-1991)
American Society of Transplantation
Scientific Studies Committee (1984-1986)
Secretary-Treasurer (1986-1990)
President-Elect (1990-1991)
President (1991-1992)
Past President (1992-1993)
Co-Chairman, Organ Donation Committee (1996 - 1998)
Co-Chairman, Histocompatibility Committee (1997 - 1999)
At-Large Member AST Nominating Committee (1998-1999)
American Society of Transplant Surgeons

American Society for Histocompatibility and Immunogenetics
Member, Laboratory Accreditation Committee (1983 - 1986)
Chairman, Finance and Audit Committee (1984 - 1988)
Chairman, Subcommittee for Flow Cytometry Testing (1986-1990)
Chairman, Proficiency Testing Committee (1986-1990)
Clinical Affairs Committee (1989 - 1999)
Laboratory Directors Steering Committee (1993 - 1999)
Scientific Planning Committee for Immune Monitoring
Recipient of ASHI Scholar Award (1998)
Co-Chairman, ASHI Task Force on The Future Practice of
Transplant Laboratory Medicine
Committee Member, ASHI Task Force on Clinical Studies
Board of Directors (2004-2007)
Co-Chair, Scientific and Clinical Affairs Committee (2007 -)

HONORS AND AWARDS:

Bachelor of Science with General Honors in the
College (University of Illinois)
Recipient of Public Health Service Predoctoral
Traineeship (University of Illinois)
Phi Sigma National Biological Honorary
Recipient of Public Health Service Postdoctoral
Traineeship (Children's Hospital of Philadelphia)
Guest Editor, Transplantation Proceedings,
December 1984, Volume 16(6), Proceedings of The Fourth
International Symposium on Immunological Monitoring of the
Transplant Recipient
Dean's Teaching Excellence Award (UTMS-H) (1985-1986)
American Society of Transplant Physicians:
Secretary-Treasurer (1986-1990)
President-Elect (1990-1991)
President, (1991-1992)
Past President (1992-1993)
ASHI Scholar (American Society for Histocompatibility and
Immunogenetics) (1998)
Elected to the Board of Directors, The International Society for Heart
and Lung Transplantation (2004-2007)
Elected to the Board of Directors, The American Society for
Histocompatibility and Immunogenetics (2004-2007)

**EDITORIAL
POSITIONS:**

Editorial Board, Transplantation (1984 -)
Editorial Board, Graft (1998 - 2001)
Editorial Board: Clinical Transplantation (1999 -)
Editorial Board: Human Immunology (2004 -)
Editorial Board: Journal of Heart and Lung Transplantation (2007 -)

Manuscript Reviewer for:

Cancer (1985)
Clinical Transplantation (1993 -)
American Journal of Kidney Diseases (1995 -)

Journal of Heart and Lung Transplantation (1995 -)
Human Immunology (1995 -)
Circulation (1996 -)
Journal of Immunology (1997 -)
American Journal of Transplantation (1999 -)
Journal American Society of Nephrology (2002-)
Transplantation Proceedings (2003 -)
American Journal of Kidney Disease (2005 -)

**SERVICE ON NATIONAL OR INTERNATIONAL GRANT REVIEW PANELS,
STUDY SECTIONS, COMMITTEES:**

Grant Reviewer for The American Cancer Society (1980 - 1983)
Invited Participant (as a testing laboratory) in the International
Collaborative Transplant Study (1980-1986)
Consultant in Immunology (AIDS) to the Epidemiology and Disease Control
Study Section, NIH-NIAID (1982 - 1983)
Chairman, Organizing Committee and Host for The Fourth Interna-
tional Immune Monitoring Symposium: Immunological Evaluation and
Monitoring of the Transplant Recipient (1983)
Laboratory Inspector for Clinical Laboratory
Accreditation in Histocompatibility for The American Society for
Histocompatibility and Immunogenetics and The College of American
Pathologists (1983-1986).
Member, Acquired Immune Deficiency Syndrome (AIDS) Working
Group for the Houston Area (1984-1988)
Consultant in Immunology and Histocompatibility Testing
to the Department of Laboratory Medicine, M.D. Anderson Hospital and
Tumor Institute (1984-1988)
Participant (as a testing laboratory) in The Third
American HLA Workshop
Participant (as a testing laboratory) in the Eighth Histocompatibility
Workshop "Relevance of DR typing to renal allograft survival"
Participant (as a testing laboratory) in The International
Transfusion and Transplantation Workshop
Participant (as a testing laboratory) for the Ninth
International Histocompatibility Workshop
Member, Organizing Committee for the International Symposium
on Relevant Immunological Factors in Clinical Kidney Transplantation,
Heidelberg, West Germany, 1985
Member, Scientific Advisory Committee for an International Sym-
posium: The Immune Response in Autoimmune Disease and Organ Trans-
plantation, Chateau Montebello, Canada, 1985

Chairman, Advisory Committee to the Division of Kidney, Urologic

and Hematologic Diseases on "Pretransplant Crossmatching in High-Risk Transplant Recipients," National Institute of Arthritis, Diabetes and Digestive and Kidney Diseases, Department of Health and Human Services, 1985-1986

Grant Reviewer in Transplantation Immunology for The March of Dimes - Birth Defects Foundation (1985 - 1987)

Reviewer of Research Proposals in Immunology for the Research and Development Committee, The Veterans Administration Research Service (1985 - 1989)

Grant Reviewer for the Kidney Foundation of Canada (1985 - 1995)

Member, Working Committee for: Renal Transplantation in Children, Division of Kidney, Urologic and Hematologic Diseases (DKUHD), NIH, HHS. (1986)

Member, Diagnostic Immunology Resource Committee, College of American Pathologists (1986-1991).

Member, Medicare Task Force on Histocompatibility Testing in Transplantation. (1992- 2000)

Member, NIH-NIAID Special Study Sections for Transplantation, (1992 -)

Grant Reviewer of Research Proposals for The Division of Transplantation, NIH (1992-1994; 1999 -)

Member, Board of Directors, National Coalition on Donation (1996 - 1999)

Executive Director, HLA Laboratory Directors Steering Committee - American Society for Histocompatibility and Immunogenetics (1997-1999).

Invited Participant, American Society of Transplant Physicians/American Society of Transplant Surgeons Task Force on Transplantation Tolerance (1997)

Co-Chairman, ASTP Working Group to Evaluate HLA Laboratory Regionalization/Consolidation (1998 - 2000)

Member, Collaborative Working Group (ASTP/ASTS/ASHI) to Develop Evidence Based Guidelines for Clinically Relevant Histocompatibility Assays (1998 -)

Invited Participant and Presenter, ASTP-ASTS Interdisciplinary Conference on Corticosteroid Withdrawal (1998)

Chairman, ASHI Working Group to Evaluate HLA Laboratory Reimbursement Options (1999 -)

Co-Chair, ASHI Task Force on Future Practice of Transplant Laboratory Medicine (2001 -)

Committee Member, ASHI Task Force on Clinical Studies (2001 -)

Member, Collaborative Working Group (AST, ASTS, NKF, ASHI) to Analyze Humoral Rejection in Solid Organ Transplantation", NIH, Bethesda, Maryland. April 2003.

Chairperson, Six-Year Faculty Review Committee, Department of Surgery (1999-2000).
Preceptor for an NIH Summer Fellowship Program for High School Students (1998-1999)
Member, UTMSH Faculty, Promotion and Tenure Committee (1998 - 2004)
Member, Texas Children's Hospital Renal Transplant Medical Review Board (1998 -)

Participant in a Mentoring Program for Surgery Department Junior Faculty (1998 -)
Member, UTMSH Admissions Interview Committee (1997 - 2001)
Member, UTMSH Ad-Hoc FAPTC Review Committee (1996-1998)
Chairman, By-Laws Committee, Program in Immunology UT-GSBS (1985-1986)
Course Director, "Methods in Cellular Immunology," a Program in Immunology Course, UT-GSBS
Member, Ambulatory Care Lab Committee, UTMSH (1985-1986)
Member, The Organ Transplant Services, St. Luke's Episcopal Hospital, Houston, Texas (1984 -).
Member, Committee on Subject Selection for The University of Texas System Agent Orange Study (1982-1985)
Member, UTMSH Admissions Committee (1980-1983)
Member, UTMSH Admissions Interview Committee (1979-1983)
Member, Steering Committee, Program in Immunology UT-GSBS (1977-1983)
Member, Program in Immunology, Graduate School of Biomedical Sciences, The University of Texas Health Science Center at Houston (1977 -)
Member, UTMSH Organ Transplantation Center Medical Review Boards (kidney, heart, liver and pancreas) (1977 -).

SERVICE ON UTMSH

HOSPITAL COMMITTEES: None

**SERVICE TO THE
COMMUNITY:**

Past Member, Acquired Immune Deficiency Syndrome (AIDS) Working Group for the Houston Area (1984-1988)

CANDIDATES FOR POSTGRADUATE DEGREE: None

**SPONSORSHIP OF
POSTDOCTORAL
FELLOWS:**

Takahiro Oka, M.D., Ph.D.
Takaaki Nishijima, M.D.
Yoshinari Ono, M.D.

Guy Agostino, Ph.D.
Ancel J. Rogers, M.D.
Mark Jarowenko, M.D.
Chris Jensen, M.D.
Anthony Y. Smith, M.D.
Joseph Lawen, M.D.
Vathsala Anatharaman, M.D.
David Van Buren, M.D.
John Dunn, M.D.
Richard Knight, M.D.
Michelle Meehan, M.D.
Pamela M. Kimball, Ph.D.
Stephen Katz, M.D.
Barry Browne, M.D.
Tom Johnston, M.D.
Omar Barakat, M.D.
Angel Amante, M.D.
Rafik El-Sabrou, M.D., Ph.D.
Rafik Gohbrial, M.D., Ph.D.
Brian Susskind, Ph.D.
Inge Buyse, Ph.D.
Elisa Greco, Ph.D.
Ellen M. Grimm, M.D.
Peter Przybylowski, M.D., Ph.D.

CURRENT TEACHING RESPONSIBILITIES:

Participation in Teaching:

Clinical Transplantation Fellows

Clinical Renal Fellows

Third and Fourth Year Medical Students Transplant Rotation

Medical Technology Students

Blood Bank Specialist Students

Pathology Residents

Participant in a Mentoring Program for Surgery Department Junior
Faculty (1998 -)

A. VISITING PROFESSOR

1. University of Miami School of Medicine, Presented at Surgical Grand Rounds, "Immune monitoring of renal allograft recipients", March 1980.

2. Children's Hospital of Los Angeles, Division of Dialysis and Transplantation, Medical Grand Rounds, Presented "Pre- and postoperative immune monitoring of allograft recipients". April 1980.
3. University of Chicago, Surgical Grand Rounds Presented "Immune monitoring of renal allograft recipients". June 1981.
4. The Children's Memorial Hospital, Chicago Illinois. Clinical Immunology Grand Rounds, Presented "Role of immune evaluation in clinical medicine". December 1982.
5. University of Pittsburgh School of Medicine, Pittsburgh, PA. Pathology Grand Rounds. Presented "Cyclosporine improves allograft survival in immunologically high risk renal allograft recipients". February 1983.
6. St. Louis University Medical Center, St. Louis, Missouri, Surgical Grand Rounds. Presented "Immune evaluation of renal failure patients and allograft recipients". March 1983.
7. University of Nebraska Medical School, Departments of Surgery and Medicine, "Immune evaluation of renal transplant recipients", Omaha Nebraska, October 1985.
8. Yale University, Department of Surgery, Division of Organ Transplantation, New Haven, Connecticut, July, 1986.
9. Henry Ford Hospital, Department of Pathology, Detroit Michigan. Presented: "Immune evaluation of the transplant recipient". October 1986.
10. UCLA Hospitals and Clinics, Department of Pediatric Nephrology and Transplantation, Los Angeles, CA., January 1987.
11. Department of Surgery-Division of Organ Transplantation, Montefiore Hospital, Bronx, New York, March, 1987.
12. Department of Surgery-Division of Organ Transplantation, Yale School of Medicine, New Haven, Conn., March, 1987
13. Department of Surgery, Division of Organ Transplantation, The University of Texas Medical School at San Antonio, August, 1987.
14. The University of Texas Health Science Center-Dallas, Texas. Presentation of Neurology Grand Rounds "Immune Monitoring of Cyclosporine treated Multiple Sclerosis Patients" February, 1988.
15. UCLA School of Medicine, Department of Pediatric Nephrology and Transplantation. Los Angeles, California, March 1988.
16. University of Southern California, Department of Surgery and St. Vincent's Medical Center, Los Angeles, California. Surgical Grand Rounds presentation: "Immune considerations pre and post transplant in cyclosporine treated allograft recipients". March 1988.
17. Yale School of Medicine, Department of Surgery, Division of Organ Transplantation, New Haven

Connecticut, February 1989.

18. University of Minnesota Medical School, Department of Surgery, Division of Organ Transplantation. Minneapolis MN. Transplant Conference Presentation "Post-transplant immunosuppression based upon responsiveness: Steroid withdrawal study".. April 1989.
19. The Midwest Organ Bank. Kansas City, Mo. Presentation of "Immune considerations for transplantation". March 1990.
20. Department of Pediatric Nephrology and Transplantation, UCLA Hospitals and Clinics, Los Angeles, CA, October 1990.
21. The Amgen Corporation, Thousand Oaks CA. Presented "Immunological impact of recombinant erythropoietin on ESRD patients. October 1990.
22. Fujisawa Pharmaceutical Company. Deerfield Illinois. Presentation of "Immunological evaluation pre and post transplantation of renal allograft recipients treated with cyclosporine and azathroprine". February 1991.
23. The Organ Procurement Agency of Michigan. Detroit Michigan. Presentation of "Comparative studies of crossmatch procedures". February 1991.
24. The University of Tennessee, Department of Surgery - Organ Transplantation. Memphis Tennessee. Presented "Preoperative histocompatibility considerations for organ transplantation". September, 1991.
25. The Department of Renal Medicine, Singapore General Hospital. Singapore. Presentation of "Relevance of Crossmatch Assays to Renal Transplant Outcome". April 1993.
26. St. Louis University School of Medicine, Department of Surgery, Division of Organ Transplantation, St. Louis MO. Presentation at Surgery Grand Rounds "Relevance of correct interpretations of pretransplant crossmatch testing to solid organ transplant outcome". November 1993.
27. Regional Organ Bank of Illinois and Loyola University Stritch School of Medicine, Department of Surgery, Division of Organ Transplantation. Chicago Illinois. Presented "To match or not to match? That is the question!" April 1994.
28. University of Minnesota Medical School, Department of Surgery, Division of Organ Transplantation. Minneapolis Minnesota. Presented "The clinical relevance of a positive crossmatch or when is a positive crossmatch not a contraindication to transplantation". April 1994.
29. Sandoz Pharmaceuticals Corporation. Presentation of "Posttransplant hyporesponsive-ness". July 1994.
30. Loyola University Stritch School of Medicine. Department of Surgery, Division of Organ Transplantation. Chicago Illinois. Presented "New methodologies to delineate allosensitization". March 1996.
31. University of Chicago Medical School, Department of Surgery, Division of Organ Transplantation. Chicago Illinois. Presented "Use of an ELISA detection procedure to identify

- IgG anti-HLA allosensitization". March 1996.
32. Northwestern University Medical School, Department of Surgery, Division of Organ Transplantation. Chicago Illinois. Presented "Delineation of anti-HLA antibodies pre and post-transplantation. March 1996.
 34. Rush-Presbyterian - St. Luke's Medical Center, Department of Surgery, Division of Organ Transplantation. Chicago Illinois. Presented "Use of PRA-STAT to delineate clinically relevant IgG anti-HLA antibodies in renal allograft recipients". March 1996.
 35. University of Toronto Hospital, Royal Victoria Hospital, Division of Transplantation Toronto Canada. Presented "Clinical Significance of PRA-STAT determined anti-HLA reactivity to renal allograft rejection and survival". September, 1996.
 36. Royal Victoria Hospital, McGill University Centre for Clinical Immunobiology and Transplantation. Montreal Canada. Presented "Clinical relevance of anti-HLA antibodies in transplantation". September 1996.
 37. Queen Elizabeth II Health Sciences Center, Department of Urology, Division of Transplantation. Halifax Nova Scotia. Presented "Pre and post-transplant immunologic considerations". September 1996.
 38. Baylor College of Medicine - Texas Children's Hospital. Houston Texas Pediatric Dialysis and Transplantation Rounds. Presented "Immunologic considerations for successful donor-recipient pairings". October 1996.
 39. Washington Hospital Center. Washington DC. Presentation at Transplantation Services Grand Rounds "Pre-Transplant Detection of Anti-HLA Sensitization in Transplant Recipients". Washington, D.C., October 30, 1996.
 40. Hadassah Medical Organization, Transplantation Unit. Jerusalem Israel. Presentation of "Anti-HLA antibodies and their correlation to renal allograft rejection and graft loss". December 1996.
 41. Chaim Sheba Medical Center - Tissue Typing Laboratory. Tel-Aviv, Israel. Presentation of "Humoral and cellular markers identifying immunologically high-risk renal allograft recipients". December, 1996.
 42. Department of Surgery, Univ of Minnesota Medical School. Minneapolis, Minnesota. Presentation of "Measurement of clinically relevant anti-HLA antibodies in renal allograft transplant recipients". January 1997.
 43. Midwest Organ Bank, Kansas City, Missouri. Presentation of "The role of anti-HLA antibodies in transplantation rejection". April 1997.
 44. Saint Francis Hospital, Tulsa, Oklahoma. Presentation at Transplantation Rounds. "Correlation of pretransplant immune assessment to renal allograft survival". August 1997.
 45. The University of Chicago Medical School, Department of Surgery, Division of Organ Transplantation. Chicago Illinois. Presented "Immune Parameters Identifying Hypo Responsive Recipients as Candidates for Steroid Withdrawal". August 1998.

46. The New Jersey Transplant Society. Livingston, New Jersey. Presented "A new ELISA procedure to identify anti-HLA antibodies: Clinical correlation". January 1999.
47. Saint Barnabas Medical Center, The Transplant Division, Livingston New Jersey. Presented Transplant Nephrology Grand Rounds "Immune parameters identifying hypo-responsive renal allograft recipients: Candidates for withdrawal of immunosuppressives?" January 1999.
48. Vanderbilt University Medical Center, The Renal Transplant Program. Nashville TN. Presented "Delineation of posttransplant immunoregulation". February 1999.
49. Duke University Medical Center. Durham North Carolina. Presented at Surgery Grand Rounds "Immune parameters identifying hypo-responsive renal allograft recipients". March 1999.
50. UCLA Medical Center, Department of Pathology and Laboratory Medicine. Los Angeles California. Presented "Beneficial and harmful recipient immune reactivity before and after renal allotransplantation". March 1999.
51. Division of Nephrology, Transplant Services, University Hospitals of Cleveland, Case Western Reserve University, Cleveland Ohio. Presented "Immune parameters identifying hyporesponsive renal allograft recipients". October 1999.
52. Ohio State University Medical Center, Department of Surgery, Division of Transplantation. Columbus, Ohio, "Cellular and humoral immune reactivity delineating posttransplant renal allograft recipient hyporesponsiveness". November 1999.
53. The Transplant Center, Princess Margaret Hospital, The University of Toronto. Toronto, Canada, "Monitoring post renal transplant development of hyporesponsiveness". January 2000.
54. Jagellonian University Medical School, Krakow, Poland. Surgery Grand Rounds Krakow, Poland, "Clinical relevance of pre and post-transplant immune evaluation to identify immunoregulated recipients". June 2000.
55. Yale University School of Medicine, Division of Organ Transplantation: Presented at Transplant Rounds New Haven, CT, "Posttransplant immune reactivity". July 2000.
56. Hoxworth Blood Center, University of Cincinnati Medical Center. Cincinnati Ohio. Presented at Organ Transplant Rounds. "Posttransplant immune monitoring identifies reactive and/or hypo-responsive renal allograft recipients". August 2000.
57. Queen Elizabeth II Health Sciences Center, Department of Urology, Division of Transplantation Services, Dalhousie University, Halifax, Nova Scotia. Presented "Clinical relevance of HLA antibody and/or donor reactivity in renal transplantation". November, 2002.
58. Columbia University-Presbyterian Medical Center, Division of Transplantation, Department of Surgery, New York, New York. Presented "HLA antibody and donor reactivity define patients at risk for rejection and/or graft loss". November, 2002.
59. Washington Regional Transplant Consortium, Washington, DC Presented "HLA Antibody, Donor Reactivity and Graft Rejection/Loss". January,

2003.

60. Semmelweis University, Budapest, Hungary. Transplantation Grand Rounds: Presented "The role of the clinical immunologist in the transplantation of solid organs". April 2003.
61. Thomas Jefferson University, Department of Surgery – Organ Transplantation, Philadelphia, PA. Transplantation Grand Rounds: Presented "The Clinical Relevance of HLA Antibodies and Donor Specific Reactivity in Solid Organ Transplantation". June, 2004.
62. The Texas Transplant Institute, San Antonio, Texas. The Heart Transplant Lecture Series: Presented "Detection and Clinical Relevance of HLA Antibodies in Heart Transplantation", July 2004.
63. The Division of Transplantation, The Department of Surgery, The University of Miami School of Medicine. Presented "The Clinical Relevance of HLA antibodies pre and post renal transplantation". November 2004.
64. Transplant Grand Rounds "Antibody Specificity and Relevance to Crossmatch Results". Texas Heart Institute, Transplant Center, Houston, Texas, July 2005.
65. Transplant Grand Rounds "Pretransplant antibody evaluation methodologies". Yale University School of Medicine. Division of Organ Transplantation. September, 2005.
66. The University of Minnesota Medical School, Department of Surgery, Division of Organ Transplantation, Minneapolis, MN. Transplant Conference "The Uses and Abuses of Newer Laboratory Methodologies Identifying Antibodies Involved in Solid Organ Transplantation. October 2005.
67. The University of Utah Medical School and Health Science Center, Department of Surgery, Division of Organ Transplantation. Transplant Conference "To transplant or not to transplant, that is the question: Are all antibodies bad?" November, 2007.

B. INVITED PRESENTATIONS

1. Determination and prognostic value of immunocompetence in patients with lung cancer treated by radiotherapy. Presented at The Third International Symposium on: Detection and Prevention of Cancer, New York, April 1976.

2. T-RFC monitoring of CMI events in renal allograft recipients. Presented at the Sixth International Congress of the Transplantation Society Special Session: Immunological Monitoring of Transplant Recipients, New York, August, 1976.
3. Relevance of immunologic analysis for patients with inoperable lung cancer treated by radiotherapy. Presented at an NCI sponsored Symposium "The Second Conference on Lung Cancer Treatment," at Airlie House, Virginia, May 22-24, 1977.
4. Immunological considerations in renal transplantation. Clinical Oncology Grand Rounds, M.D. Anderson Hospital and Tumor Institute, Houston, Texas. September, 1979.
5. Assessment of immune parameters of transplant recipients on immunosuppressive therapy. Presented at an NIH Workshop on "The Biological Relevance of Immune Suppression as Induced by Genetic, Therapeutic and Environmental Factors," Williamsburg, Virginia, November, 1979.
6. Invited participant in a working cadre for the NIH to develop a "Consensus On Immunotoxicology" for the National Toxicology Program, November, 1979, Research Triangle Park, N.C., NIEHS, NIH.
7. Histocompatibility testing in transplantation. Pathology Grand Rounds, St. Luke's Hospital, Houston, Texas. January 1980.
8. Invited presenter at two workshops on 1) Immune monitoring of allograft recipients and 2) The effect of transfused blood and blood products on uremic hosts. Presented at The North American Transplant Coordinators Organization, San Antonio, Texas, May, 1982.
9. Invited presenter at a workshop on: "Human T lymphocyte subpopulations: Their role in rejection and immunosuppression." Presented at the International Congress of The Transplantation Society, Brighton, England, August, 1982.
10. Invited presenter at a workshop on: "Mechanisms responsible for blood transfusion effects." Presented at The International Congress of The Transplantation Society, Brighton, England, August, 1982.
11. Invited plenary speaker: "Optimizing immunosuppression: Mode of action of cyclosporine". First Annual Meeting of The American Society of Transplant Physicians, Chicago, December 1982.

12. "Immunologic effects of toxic materials". Presented at Toxicology - Clinical Update, University of Texas Medical Branch, Galveston, Texas, January, 1983.
13. "Immunological evaluation of hemophiliacs". Presented at a Symposium on Current Problems in the Management of Hemophiliac Complications, Houston, Texas, April 1983.
14. "Relationship of immunocompetence of hemophiliac patients and acquired immune deficiency syndrome (AIDS)". Presented at the Gulf Coast Hemophilia Chapter Meeting, Houston, Texas, October, 1983.
15. "Cyclosporine immunosuppression for renal transplantation". Presented to Sandoz Pharmaceuticals, Inc., East Hanover, New Jersey, December, 1983.
16. "New horizons in transplantation: Influence of cyclosporine on renal transplantation". Western Dialysis and Transplantation Society, Park City, Utah, January, 1984.
17. Moderator and presenter at a symposium: "Use of Cyclosporine in Organ Transplantation -- A Multispecialty Perspective". Los Angeles California. June 1984.
18. "The current and future role of the HLA typing and immune evaluation laboratory in organ transplantation". Gulf Coast Regional Blood Center, Houston Texas. June 1984.
19. "Immunologic considerations in renal transplantation using cyclosporine". The South-Eastern Organ Procurement Foundation (SEOPF) Tri-Annual Meeting, Orlando Florida. September 1984.
20. "Immunological considerations of hemophiliacs and AIDS". Presented at an AIDS Symposium sponsored by The City of Houston, Department of Health, Houston, Texas, October, 1984.
21. "Transplant Immunology," presented to The Transplant-Unit Nurses, Texas Heart Institute, Houston, Texas October, 1984.
22. "Modes of immunosuppression in organ transplantation". The Southeastern Immunology Conference, Stone Mountain, Georgia, November, 1984.
23. Co-Chairman and Presenter: "Assessment of cell-mediated immunotoxicity". Presented at The Second Meeting of The Immunotoxicology Discussion Group, Uniformed Services University of the Health Sciences Center, Bethesda, Maryland, November, 1984.
24. Workshop on Immunological Monitoring for Bone Marrow and Renal Transplantation. Presented at The American Society for Histocompatibility and Immunogenetics, Miami, Florida, November, 1984.

25. "Relevant immunotoxicology considerations for industry". Presented at The Toxicology Laboratory, Shell Development Company, Houston, Texas, February, 1985.
26. Cyclosporine Associated Renal Injury Symposium, San Juan, Puerto Rico, March, 1985.
27. "Clinical laboratory immune assessment". Presented at the Tenth Annual George Gudenrath Memorial Symposium, Diagnostic Clinic of Houston, Houston, Texas, April, 1985.
28. "Current methodologies for immune monitoring of transplant recipients". Presented at The South Eastern Procurement Foundation (SEOPF) Tri-Annual Meeting, Durham, North Carolina, April, 1985.
29. "The beneficial effect of cyclosporine on renal transplantation at a single U.S. transplant center" (Plenary session presentation). Co-chairman for session on Immune Monitoring, The International Symposium on Relevant Immunological Factors in Clinical Kidney Transplantation, Heidelberg, West Germany, June, 1985.
30. "Successful renal allograft survival for cyclosporine treated recipients displaying positive historical crossmatches". Co-chairman for sessions on Pre- and Post-transplant Immune Monitoring, The International Symposium on Monitoring and Manipulation in Autoimmune Disease and Organ Transplantation, Chateau Montebello, Canada, July, 1985.
31. Invited plenary presenter: "Immunological considerations in renal transplantation using cyclosporine". Presented at the Transplantation Symposium of the Seventh European Immunology Meeting, Jerusalem, Israel, September, 1985.
32. "Cyclosporine as an immunosuppressive drug". Medical Laboratory Immunology Symposium, Clearwater, Florida. November 1985.
33. Chairman, Medicare Task Force on Histocompatibility Laboratories, New York, New York, February, 1986.
34. "Immune evaluation of chronic progressive multiple sclerosis patients treated with cyclosporine". Presented at a Multiple Sclerosis Cyclosporine Study Group, Vail Colorado, June, 1986.
35. Workshop on Renal Transplantation in Children. "Immune parameters of pediatric allograft recipients." NIH, HHS, Bethesda, Maryland, June, 1986.
36. Symposium plenary speaker: "Immune evaluation in organ transplantation". American Association for Clinical Chemistry and Canadian Society for Clinical Chemists, Chicago Illinois, July 1986.
37. Special Workshop: "Use of monoclonal antibodies to evaluate transplant recipients". The American Society of Nephrology, Washington, D.C., December, 1986.
38. Presenter and Chairman of The 1987 Histocompatibility and Kidney Transplant Research Workshop, Palm Springs, CA., January, 1987.

39. Educational Workshop of The American Society for Histocompatibility and Immunogenetics on: "Relevance of pre-transplant crossmatch testing". New Orleans LA., April 1987.
40. Participant in Neurology Grand Rounds, The University of Texas Medical School, Houston Texas, September 1987.
41. Plenary Speaker: "Effects of cyclosporine immunosuppression in-vivo in man". Presented at the Second International Congress on Cyclosporine, Washington, D.C., November, 1987.
42. Plenary Speaker: "Transfusion in Clinical transplantation: Non-renal transplantation". Presented at the Symposium on The Biology of Transfusion Induced Immunosuppression, Snowbird, Utah, January, 1988.
43. Harvard Medical School Continuing Education Course "Renal Transplantation: Immunology and Clinical Aspects". Harvard Medical School, Department of Medicine, Boston, MA, March, 1988.
44. Plenary Presentation: "Crossmatch considerations in the cyclosporine era". Presented at the Annual Meeting of The American Society for Histocompatibility and Immunogenetics, San Francisco, California, October 1988.
45. Symposium Presenter: "Immunological Aspects of Organ Transplantation". Presented at The American Society of Clinical Pathologists, Chicago, Illinois, March 1989.
46. Symposium Presenter: "The recent policies of The United Network for Organ Sharing (UNOS) related to histocompatibility". Educational Workshop of The American Society for Histocompatibility and Immunogenetics on: Dallas Texas. June 1989.
47. "Immune monitoring in multiple sclerosis". Symposium on Multiple Sclerosis (Update 1989): Sponsored by the Multiple Sclerosis Society, Houston Texas, October 1989.
48. "End Stage Renal Disease and Potential Uses for EPO" Immunology Update Sponsored by The UpJohn Co., Houston, Texas, January, 1990.
49. "Overview on crossmatch results and clinical outcome in renal transplantation" and "Impact of HLA, transfusions, and recipient race on renal allograft survival". Presented at an Educational Workshop sponsored by The American Society for Histocompatibility and Immunogenetics, New Orleans LA. April 1990.
50. "Crossmatching procedures in organ transplantation". College of American Pathology (CAP) Conference on Laboratory Medicine in Transplantation Santa Fe, New Mexico, August 1990
51. Symposium: "Immunosuppression Made Manageable". Presented "To Convert or not to convert from cyclosporine? Atlanta, Georgia, October 1990.
52. Workshop Moderator and Presenter: "Immune Monitoring". Presented at The American Society for Histocompatibility and Immunogenetics, Los Angeles CA, November 1990.
53. Plenary Presentation: "The Present Status and Future Directions in HLA". The American

- Society for Histocompatibility and Immunogenetics Regional Workshop. San Antonio Texas, April, 1991.
54. Presenter and Commentator at: The Pediatric Renal Transplant Cooperative Study Workshop, Boston, MA, April, 1991.
 55. Invited Participant: "The Surgeon General's Workshop on Increasing Organ Donation", Washington, D.C., July, 1991.
 56. Plenary Presenter: "State of the art of transplant immunosuppression". Presented at a Symposium on "Immunosuppressant drugs for the prevention and treatment of organ transplant rejection and autoimmune diseases". Technology Management Group Conference, Boston, MA, October 1991.
 57. Workshop Coordinator and Plenary Speaker: "Pretransplant crossmatch considerations". Educational workshop at The American Society for Histocompatibility and Immunogenetics, Washington, D.C., October 1991.
 58. Testified before a Public Health Service Hearing "HIV-1 Infection in Human Organ and Tissue Transplantation". Washington, D.C., October, 1991.
 59. Invited participant at an inaugural meeting to organize a National Coalition on Organ Donation. Chicago, Illinois, October, 1991.
 60. Participant at a National Consensus Group Meeting on the "Detection and prevention of infectious diseases in organs and tissues for transplantation". Chicago Illinois, November 1991.
 61. "The relevance of immunological considerations in renal transplantation". Transplant Research Coordinating Committee of The NIH. Genetics and Transplantation Branch, NIAID-NIH, Washington, D.C., November, 1991.
 62. "Develop comprehensive guidelines for the prevention of HIV transmission from transplanted organs and tissues" Center for Disease Control, Atlanta, GA, December 1991.
 63. "HIV in Transplantation", Division of Organ Transplantation Annual Meeting. February 1992.
 64. Moderator at a Transplant Seminar: "The effect of immunosuppression therapy on opportunistic viral infections" Houston, Texas, March 1992.
 65. "Controversies in Organ Donation". Testified before The National Kidney Foundation Regional Forum Philadelphia, PA, March 1992.
 66. "Crossmatching Considerations". Co-chairman and plenary speaker at The ASHI Southern Regional Educational Workshop. Austin, Texas April, 1992.
 67. "The Crossmatch Controversy: Fact or Fiction?" Educational Workshop of The American Society of Histocompatibility and Immunogenetics. Kansas City, MO., October 1992.

68. Co-chairman and invited discussant on a "Steroid Withdrawal" Session at The North American Pediatric Renal Transplant Cooperative Study. Vancouver, British Columbia, October, 1992.
69. "Transplantation Immunology: An update for cardiac transplant physicians". Presentation of: Histocompatibility Testing: Role in Heart Transplantation. New Orleans, LA, November, 1992.
70. "Comparison of Crossmatch Match Results and Clinical Outcome for Heart, Liver and Kidney Transplant Recipients." The Seventh Annual Clinical Histocompatibility Workshop. Palm Springs, CA., February, 1993.
71. "Transplantation Immunology". Presented at Organ Transplantation 1993 - A Nursing Seminar. Houston, Texas, March 1993.
72. Symposium on: Crossmatching Techniques and The Highly Sensitized Transplant Patient", Presented at The American Society for Histocompatibility and Immunogenetics, Regional Educational Workshop. New Orleans, LA, March 1993.
73. "Flow Crossmatch Results in Transplantation". Presented at a Symposium on Hot Topics in Flow Cytometry, Sponsored by Becton-Dickinson Immunocytometry Systems, Houston, Texas, April 1993.
74. "Principles of HLA Matching and Donor Crossmatching". Presented at The First Sandimmune Asian Postgraduate Transplantation Course. Kuala Lumpur, Malaysia, April 1993.
75. "Immunologic Considerations in Transplantation". Presented at An Advanced Preceptorship of Transplantation Sponsored by Sandoz Pharmaceuticals, Inc., Taipei, Taiwan, April 1993.
76. "Immune Risk Factors - Impact on the Incidence and Diagnosis of Rejection". Presented at The 5th Asian Sandimmune Transplantation Workshop, Taipei, Taiwan, April 1993.
77. "Immunogenetics of Transplantation". Presented at The Sandimmune Asian Postgraduate Course, Taipei, Taiwan, April 1993.
78. "Clinical Relevance of PRA and Crossmatching in Solid Organ Transplantation". Sangstat Medical Corporation Menlo Park, CA., May 1993.
79. "Clinical Relevance of Flow Crossmatching in Renal Transplantation". Presented at a Symposium on Flow Cytometry, Sponsored by Becton-Dickinson Immunocytometry Systems, Tucson, AZ., June, 1993.
80. "Update on HLA in Transplantation", The Gulf Coast Blood Center Houston, Texas, July, 1993.
81. "Relevance of HLA matching in solid organ transplantation. The LifeGift Organ Procurement Organization. Houston Texas, August 1993.
82. "Flow Cytometry: Transplantation Applications", The Gulf Coast Blood Center Houston, Texas, September 1993.
83. "Crossmatch testing in solid organ transplantation". The LifeGift Organ Procurement

Organization. Houston Texas, September 1993.

84. "Donor-recipient crossmatching: Can a technique be too sensitive? or When is a positive crossmatch OK? Presented at an Educational Workshop of The American Society of Histocompatibility and Immunogenetics, Phoenix, Arizona, October 1993.
85. Pediatric Transplant Recipient Consensus Conference. Presented "Review of histocompatibility and crossmatch testing data for the NAPRTCS study cohort". Bethesda, Maryland, October 1993.
86. "Pediatric MLC-hyporesponsiveness". Presented to The North American Pediatric Renal Transplant Cooperative Study Workshop. Newport Beach, CA., April 1994.
87. "Transplant Immunology Considerations". The University of Texas Medical School and Hermann Hospital Symposium "Organ Transplantation in 1994". Houston, Texas, March 1994.
88. Plenary Speaker: "Immunologic Testing for Transplantation". Presented at The 20th Annual Meeting of The American Society for Histocompatibility and Immunogenetics, Pittsburgh, PA., October 1994.
89. Plenary Speaker: "The pretransplant crossmatch controversy". Presented at The South-Eastern Organ Procurement Foundation Histocompatibility Workshop. Asheville, N.C., May 1995.
90. "New concepts in delineating allosensitization in renal allograft recipients". Presented at Horizons in Organ Transplantation, The Grand Cayman Islands, April 1996.
91. "To crossmatch or not to crossmatch?" Invited participant in a pro and con debate at The American Society of Histocompatibility and Immunogenetics Annual Meeting, San Diego, CA., October 1996.
92. The First Canadian Round Table Discussion on ELISA-HLA Testing: Pre and Post Transplantation. Presentation of "Screening Methods and Rejection Risk Assessment". The Canadian Transplantation Society, Toronto, Canada, January 1997.
93. "The Clinical Relevance of anti-HLA antibodies pre and post cardiac transplantation". Presented at a Satellite Workshop of the 17th Annual International Society for Heart and Lung Transplantation, London, England, April 1997.
94. "Should/Can ELISA Assays Replace Serological Assays for PRA and Antibody Identification". Invited debate at the ASHI Southern Regional Educational Workshop, Houston, Texas, April 1997
95. "HLA typing and crossmatching for the clinician. Presented at a minicourse held during The 16th Annual Meeting of The American Society of Transplant Physicians, Chicago, Illinois, May 1997.
96. "Retransplantation following AHG negative crossmatch". Presented at the 29th International Conference on Transplantation and Clinical Immunology, Lyon, France, June 1997.
97. "Measurement of humoral and cellular immune hyporesponsiveness pre and post renal allotransplantation". Baylor College of Medicine - Texas Children's Hospital. Pediatric Dialysis

and Transplantation Rounds. Presented Houston Texas. June 1997.

98. "Can we predict chronic rejection? Humoral monitoring assays". Presented at The American Society of Transplant Physicians Symposium on "The Problem of Chronic Rejection". San Juan, Puerto Rico, January 1998.
99. Plenary Session Chairman: "Immunosuppression of the Future" Presented at the International Transplant Meeting "New Dimensions in Transplantation", Florence, Italy, February 1998.
100. "Post-Transplant MLR Reactivity". Presented at The Southern Regional Education Workshop of The American Society for Histocompatibility and Immunogenetics, Dallas, Texas, April 1998.
101. Co-Chairman, Clinical Sciences Symposium "Controversies in Organ Donation and Allocation: Balancing Competing Interests". Presented at The 17th Annual Meeting of The American Society of Transplant Physicians, Chicago, Illinois, May 1998.
102. Plenary Speaker: "Current controversies in HLA and crossmatching". Presented at The Second Congress of The Mexican Transplant Society, Merida Mexico, June 1998.
103. "Experience with PRA-STAT in acute and chronic rejection". Presented at a Satellite Symposium on "The Role of Antibody in Acute and Chronic Graft Rejection" held in conjunction with The 17th World Congress of The Transplantation Society, Montreal, Quebec, Canada, July 1998.
104. Chairperson for: "Kidney Transplantation - Immunologic Effects". Symposium held at The 17th World Congress of The Transplantation Society, Montreal, Quebec, Canada, July 1998.
105. "Immunologic Monitoring". Presented at an ASTP-ASTS Interdisciplinary Conference on Corticosteroid Withdrawal. St. Louis MO., September 1998.
106. "Biomarkers and surrogate end-points: Advancing clinical research and applications". An NIH-FDA Symposium. Presentation of "Post-transplant identification of hypo-responders". NIH, Bethesda, Maryland, April 1999.
107. "Rejection rates with modern immunosuppression" and "Bypassing the pretransplant crossmatch". Presented at the ASHI Central Regional Education Workshop. Detroit, Michigan, June 1999.
108. Plenary Presentation: "Impact of crossmatch tests in sensitized patients awaiting kidney transplants. Presented at an Annual Nephrology Course, Mexican Institute for Nephrological Research, Mexico City, Mexico, July 1999.
109. Plenary Speaker: "Immunological characterization of patients before and after transplantation". Presented at The 51st Annual Meeting of The American Association of Clinical Chemists. New Orleans LA, July 1999.
110. Plenary Speaker: "Understanding the technical aspects of tissue typing, PRA and the crossmatch". Sixth Congress of the Asian Society of Transplantation. Presented at a Pre-Congress Transplant Immunology Course. Suntec City, Singapore, September 1999.
111. Plenary Speaker: "Strategies in clinical management of the highly sensitized recipient". Presented at the Sixth Congress of the Asian Society of Transplantation, Suntec City, Singapore, September 1999.

112. "Posttransplant Immune Monitoring". Presented at a course "Posttransplant Immunosuppression: New Paradigms". The University of Minnesota Medical School, Department of Surgery, Minneapolis, MN, October 1999.
113. Teleconference Participant for Current Topics in Histocompatibility for HLA Technologists – The Crossmatch Controversy. Presented by Ronald H. Kerman, Howard Gebel and Bob Bray. Sponsored by Georgetown University Medical Center, Washington, D.C., April 2000.
114. Plenary Speaker: "Transplantation of the highly sensitized patient" and "Role of traditional and new screening techniques for determining patient allosensitization". 5th Annual Meeting of The Malaysian Society of Transplantation, Kuala Lumpur, May 2000.
115. "New methods to identify clinically relevant antibodies to HLA antigens. Presented at a combined Baylor College of Medicine and Texas Heart Institute - Transplant Grand Rounds. Houston, Texas, February 2001.
116. Presented "New methods to identify clinically relevant antibodies to HLA antigens. Are they relevant in the LVAD treated patient"? Texas Heart Institute Symposium "Immunological effects of heart assist devices". Houston, Texas, February 2001.
117. "Immunological assessment before transplantation". Sixth Banff Conference on Allograft Pathology Banff, Alberta, Canada, April 2001.
118. Moderator - discussant at a Workshop: "Managing the highly sensitized patient". Presented at the AST-ASTS Transplant 2001 Meeting. Chicago, IL, May 2001.
119. "Update on methods to detect HLA antibodies". Texas Transplantation Society, San Antonio, Texas, June 2001.
120. "Humoral assays as surrogate markers for chronic rejection". Presented at an AST/ASTS Symposium "Consensus Endpoints for Clinical Trials on Late Allograft Failure". Natcher Conference Center, Bethesda, MD. November 2001.
121. Co-Chairman and presenter: Parameters defining identification of HLA antibodies. Antibody Working Group Meeting, Sponsored by MedImmune, Inc., Houston Texas. February 2002.
122. Invited presenter at a National Consensus Meeting Regarding the Transplant Wait List. Sponsored by the NIAID, NKF, AST and ASTS. Philadelphia, PA., February 2002.
123. Invited Co-Presenter (with H. Gebel) at a Symposium: The Sensitized Patient. Presented "Making sense of sensitization". American Transplant Congress, Washington, D.C., April 2002.
124. Invited presenter at The Southern Regional Educational Workshop for The American Society for Histocompatibility and Immunogenetics. Presented "Relevance of HLA, Sensitization and Crossmatching for Liver Transplantation". Austin, TX., May 2002.
125. Invited Plenary Speaker at The Asian Pacific Congress of Nephrology. Presented "Pretransplant HLA Antibody: Risk for Rejection and Graft Loss". Pattaya, Thailand, February 2003.

126. Invited Symposium Speaker at the 23rd Annual Meeting of the International Society for Heart and Lung Transplantation. Presented "Clinically relevant alloantibodies in heart transplant patients." Vienna, Austria, April 2003.
127. Invited Presenter at the Seventh Banff Conference on Allograft Pathology. Presented "HLA antibody, donor reactivity and risk for rejection and graft loss." Aberdeen, Scotland June 2003.
128. Invited Presenter at the 11th Annual Meeting of The Israel Transplantation Society. Presented "Clinical relevance of HLA antibody and donor-specific reactivity in renal transplantation. Eilat, Israel June 2003.
129. Invited Participant and Presenter at a Conference to Analyze Humoral Rejection in Solid Organ Transplantation", National Institutes of Health (NIH), Bethesda, Maryland. April 2003.
130. Session Chairman and Presenter "How to define the highly sensitized patient". Transplant Immunosuppression 2003: The Continuing Challenges. Minneapolis, MN., October 2003.
131. Session Chairman and Presenter "CPT coding and billing for histocompatibility tests. Annual meeting of the American Society for Histocompatibility and Immunogenetics, Miami, Florida, October 2003.
132. Teleconference presenter for "Current Topics in Histocompatibility Laboratory Considerations – CPT Coding and Billing for Transplant Laboratory Tests. Presented by Drs. R.H. Kerman, P. Kimball and B. Lefor. Sponsored by Georgetown University Medical Center, Washington, D.C., March 2004.
133. Transplant Grand Rounds "Clinical Relevance of HLA Antibody Assays to Cardiac Allograft Rejection and Survival". Texas Heart Institute, Transplant Center, Houston, TX., March 2004.
134. ASHI Regional Educational Workshop. Presented "Immunological Considerations When Pairing Deceased-Donor Renal Allografts with Recipients for Successful Outcome. Houston, Tx., April 2004.
135. Plenary Speaker "Implications of Antibodies Before and After Thoracic Transplantation". International Society for Heart and Lung Transplantation. San Francisco, Ca. April 2004.
136. Symposium Presenter "Antibodies and Crossmatch: Past, Present and Future". American Transplant Congress, May 2004.
137. Co-chairperson and Symposium Presenter "Antibody and Cell Mediated Immunity in Heart and Lung Transplant Recipients". Presented at a Transplant Immunology Symposium at The International Society for Heart and Lung Transplantation. Philadelphia, PA. April 2005.
138. Symposium presenter: "Identification of HLA antibodies and their clinical relevance in solid organ transplantation. Presented at a Special Transplantation Immunology Symposium of The Transplantation Institute of The Warsaw Medical School, Department of General and Transplantation Surgery, Warsaw Poland, May 2005.
139. Presentation of "Observations and thoughts regarding immune evaluation results of transplant patients". Presented at The Israeli Society for Histocompatibility and Immunogenetics, Herzliya, Israel. June 2005.

140. Transplant Conference “Update on Pretransplant Immune Evaluation for Heart Transplantation”. Presented at The Texas Heart Institute, Houston, TX, September 2005.
141. Transplant Conference “Current Immune Evaluation Considerations for Solid Organ Transplantation”. Presented at The University of Minnesota Surgery – Transplant Conference. Minneapolis, MN, October 2005
142. Invited Session Co-chairman, International Conference on New Trends in Immunosuppression and Immunotherapy, Berlin, Germany, February 2006.
143. Invited Presenter and Participant. Retransplantation Conference (Sponsored by AST, ASTS, NIH, ASHI). “Immune considerations for heart and pediatric recipients”. Atlanta, GA, March 2006.
144. Pediatric Nephrology Transplant Rounds. Presented “Current immune considerations for solid organ transplant”. University of Texas Medical School, Houston, TX, March 2006.
145. Co-presenter in a debate session on “Controversies in immunological typing in organ allocation”. Presented “Pairing donors and recipients based on the absence of donor specific antibody reactivity and a negative flow cytometry crossmatch”. 7th Annual Symposium of The Polish Transplantation Society, Warsaw, Poland, May 2006.
146. Session Chairman and Presenter “CPT coding and billings for transplant laboratories”. Annual Meeting of the American Society for Histocompatibility and Immunogenetics. San Diego, CA, October 2006.
147. Nephrology Grand Rounds “Transplantation Histocompatibility Issues”. University of Texas Medical School, Houston, TX, February 2007.
148. “The Evolving Problem of Antibodies in Thoracic Transplantation: Antibodies and their targets”. Presented at The International Society for Heart and Lung Transplantation. San Francisco, CA, April 2007.
149. Invited Presenter “Understanding the highly sensitized patient”. Presented at Transplant Immunosuppression 2007. Minneapolis, MN, October 2007.
150. Invited Presenter “Antibodies and Antigens in Solid Organ Transplantation: Are They All Bad or Are Some Good?”. Presented at The International Meeting on New Trends in Immunosuppression and Immunotherapy. Berlin, Germany, February 2008.

C. MEETING ABSTRACTS

1. **Kerman, R.**, Clark, J. and Wheelock, E.F.: Mononuclear infiltrate into an air pouch: A new in vitro cell mediated immune assay. *Fed. Proc.* 32:973, Atlantic City, New Jersey, April 1973.
2. Wheelock, E.F., **Kerman, R.H.**, Clark, J. and Toy, S.: Cell mediated immunity in dormant friend virus infections. *Proc. Am. Assoc. Cancer Res.* 14:68, Atlantic City, New Jersey, April 1973.

3. Stefani, S., **Kerman, R.** and Abbate, J.: Serial studies of immunocompetence in head and neck cancer patients undergoing radiotherapy. Presented at The American Radium Society Meeting, San Juan, Puerto Rico, May 1975.
4. **Kerman, R.**, Stefani, S. and Geis, W.P.: Total and active T-cell dynamics in renal allograft recipients. Presented at The American Society Transplant Surgeons, Chicago, Illinois, May 1975.
5. **Kerman, R.**, Stefani, S., Smith, R., Ezdinli, E. and Geis, W.P.: Immunological evaluation of patients with solid tumors and hematological malignancies. Presented at the 1975 Cancer Symposium: Neoplasm Immunity: Mechanism, Chicago, Illinois, September, 1975.
6. Stefani, S., **Kerman, R.** and Abbate, J.: Immunological evaluation of patients with bronchogenic carcinoma. Presented at the American Society of Therapeutic Radiology, San Francisco, California, October, 1975.
7. Geis, W.P., Vaz, A.L. and **Kerman, R.H.**: Steroid sparing effect of ATG in high risk renal allograft survival. Presented at the American Society of Transplant Surgeons Meeting, Chicago, Illinois, May, 1976.
8. **Kerman, R.H.**, and Geis, W.P.: Prognostic significance of the active T-cell in renal allograft survival. Presented at the American Society Transplant Surgeons Meeting, Chicago, Illinois, May, 1976.
9. Stefani, S. and **Kerman, R.**: BCG and radiotherapy in bronchogenic carcinoma: Preliminary report. Presented at the American Society of Therapeutic Radiology, Atlanta, Georgia, October, 1976.
10. **Kerman, R.** and Stefani, S.: Radio and immunotherapy of lung cancer: A preliminary report. Presented at the 1977 Chicago Symposium: Immunotherapy of Solid Tumors, Chicago Illinois, February 24-25, 1977.
11. **Kerman, R.H.**, Ing, T.S., Hano, J.E., and Geis, W.P.: Prognostic significance of active T-RFC in renal allograft survival. Presented at The First International Symposium on Immunological Monitoring of the Transplant Recipient. London, Ontario, June 8-10, 1977.
12. **Kerman, R.H.** and Geis, W.P.: T-RFC monitoring of CMI events in renal allograft recipients. Presented at The First International Symposium on Immunological Monitoring on the Transplant Recipient. London, Ontario, June 8-10, 1977.
13. Ezdinli, E., Simonson, K., Icli, F. and **Kerman, R.**: Effects of single vs. multiple agent therapy on cell-mediated immunity. Proc. Amer. Assoc. Clin. Oncol. 18:355, Denver, Colorado, May, 1977.
14. Geis, W.P., Iwatsuki, S., Molnar, Z., Giacchino, J.L., **Kerman, R.H.**, Ing, T.S. and Hano, J.E.: Immunoblastic pseudo-lymphoma in renal allograft recipients. Presented at the Western Surgical Association, Las Vegas, Nevada, November 15, 1977.
15. **Kerman, R.H.**, Roesler, H. and Kahan, B.D.: Specific stimulation of active T-Rosette forming cells by 3M KC1 solubilized antigen. Fed. Proc., 1978. Presented at the FASEB-AAI Meeting, Atlanta, Georgia, June, 1978.

16. **Kerman, R.H.**, Floyd, M., Conner, W., McConnell, B.J., McConnell, R. and Kahan, B.D.: Correlation of active T-RFC and spontaneous blastogenesis with decreased renal allograft function. Presented at The American Association for Clinical Histocompatibility Testing, Boston, Massachusetts, June, 1978.
17. **Kerman, R.H.**, Roesler, H. and Kahan, B.D.: Increased active T-RFC with in vitro stimulation by soluble donor antigen. Presented at The Amer. Assoc. of Clin. Histocomp. Testing, Boston, Massachusetts, June, 1978.
18. **Kerman, R.H.**, Floyd, M., Conner, W., McConnell, R., McConnell, B.J., Van Buren, C.T. and Kahan, B.D.: Combined immunological and radionuclide techniques to monitor renal allograft rejection. Presented at the VII International Congress of The Transplantation Society, Rome, Italy, September, 1978.
19. **Kerman, R.H.**: Invited speaker to a special workshop "Immunological Monitoring of the Transplant Patients", VII International Congress of The Transplantation Society, Rome, Italy, September, 1978.
20. Kahan, B.D., **Kerman, R.** and McConnell, R.: Combination of immunological and radionuclide techniques diagnoses allograft rejection. Presented at the American College of Surgeons, San Francisco, California, October, 1978.
21. Michelson, J., McConell,R., **Kerman, R.** and Kahan, B.: Association of acute rejection episodes in renal transplant patients with scored results of computer analyzed data. Presented at the Southwest Society of Nuclear Medicine Meeting, March 16, 1979, San Antonio, Texas.
22. **Kerman, R.H.**, Macek, C. and Kahan, B.D.: Increase in 3 different E-rosette markers on human T cells following PHA activation. Fed. Proc. 38 (No. 3, Part II):1282. Presented at the Annual Meeting of The American Association of Immunologists, Dallas, Texas. April, 1979.
23. Van Buren, C.T., **Kerman, R.H.**, Van Buren, D. and Kahan, B.D.: Correlation of immune responsiveness with nutritional indices in chronic renal failure patients. Presented at the American Society for Parenteral and Enteral Nutrition, Annual Meeting, Chicago, Illinois, January - February, 1980.
24. **Kerman, R.H.** and Semchuk, R.: Delineation of a radioresistant T cell subpopulation. Fed. Proc. 39(3):945. Presented at the Annual Meeting of The American Association of Immunologists, Anaheim, California, April, 1980.
25. **Kerman, R.H.**: Effect of heat on the ability of human T cells to express the active T and total T receptors. Fed. Proc. 39(3):1137. Presented at the Annual Meeting of The American Association of Immunologists, April, 1980, Anaheim, California.
26. **Kerman, R.**, Peddada, L. and Kahan, B.D.: Correlation of hyperacute rejection with LDA and CDA vs ⁵¹Cr-labeled donor T and B cell targets. Presented at The American Association for Clinical Histocompatibility Testing, St. Louis, Missouri, April, 1980.
27. **Kerman, R.**, Floyd, M., Van Buren, C.T. and Kahan, B.D.: Improved allograft survival of strong responder-high risk cadaver recipients with adjuvant immunosuppressive therapy. Presented at the

- Annual Meeting of The American Association for Clinical Histocompatibility Testing, April, 1980.
28. **Kerman, R.**, Conklin, R., Cahall, D. and Kahan, B.D.: Association of cytomegalovirus and renal allograft survival. Presented at The American Association for Clinical Histocompatibility Testing, St. Louis, Missouri, April, 1980.
 29. **Kerman, R.**, Floyd, M., Van Buren, C.T. and Kahan, B.D.: Delineation of donor specific and nonspecific pretransplant immunocompetence as a predictor for LRD allograft survival. Presented at The American Association of Clinical Histocompatibility Testing, St. Louis, Missouri, April, 1980.
 30. **Kerman, R.H.**, Floyd, M., Van Buren, C.T., and Kahan, B.D.: Improved allograft survival of strong immune responder-high risk recipients with adjuvant immunosuppressive therapy. Presented at The American Society of Transplant Surgeons, Chicago, Illinois, May, 1980
 31. **Kerman, R.H.**, Floyd, M., Van Buren, C.T. and Kahan, B.D.: Correlation of nonspecific immune monitoring of renal allograft recipients with rejection and impaired renal function. Presented at The American Society of Transplant Surgeons, Chicago, Illinois May, 1980.
 32. **Kerman, R.**, Floyd, M., Van Buren, C.T. and Kahan, B.D.: Prolonged allograft survival of strong pretransplant immune responders treated with ATG. Presented at the VIIIth International Congress of The Transplantation Society, Boston, Massachusetts, June, 1980.
 33. **Kerman, R.**, Floyd, M., Van Buren, C.T. and Kahan, B.D.: Prediction of renal allograft survival based on pretransplant non-specific immunocompetence. Presented at The Second International Symposium on Immunological Monitoring of the Transplant Recipient, Leiden, The Netherlands, September, 1980.
 34. **Kerman, R.H.**, Floyd, M., Van Buren, C.T., McConnell, B.J., Mcconnell, R. and Kahan, B.D.: Delineation of renal allograft rejection and impaired renal function by serial measurement of non-specific immune parameters. Presented at The Second International Symposium on Immunological Monitoring of the Transplant Recipient, Leiden, The Netherlands, September, 1980.
 35. **Kerman, R.H.** and Kahan, B.D.: Increased expression of the active T-RFC receptor as a measure of allosensitization following in vitro stimulation of recipient lymphocytes by soluble donor HLA antigens. Presented at The Second International Symposium on Immunological Monitoring of the Transplant Recipient, Leiden, The Netherlands, September, 1980.
 36. **Kerman, R.H.**, Floyd, M., Van Buren, C.T. and Kahan, B.D.: Correlation of HLA A, B, and DR typing to cadaveric and living related renal allograft survival. Presented at The Second International Symposium on Immunological Monitoring of the Transplant Recipient, Leiden, The Netherlands, September, 1980.
 37. Floyd, M., **Kerman, R.**, Woo, J., Van Buren, C.T. and Kahan, B.D.: Relationships of beta-2-microglobulin metabolism, immune reactivity and renal allograft rejection. Presented at The Second International Symposium on Immunological Monitoring of the Transplant Recipient, Leiden, The Netherlands, September, 1980.

38. **Kerman, R.H.**, Van Buren, C.T., LeGrue, S.J. and Kahan, B.D.: Immunopharmacological monitoring of cadaveric renal allograft recipients receiving Cyclosporin A. Presented at The American Society of Transplant Surgeons, Chicago, Illinois, June, 1981.
39. **Kerman, R.H.**, Conklin, R., Cahall, D., Van Buren, C.T. and Kahan, B.D.: CMV and renal allograft rejection. Presented at a Symposium on Host Defenses to Intracellular Pathogens, Franklin Plaza Hotel, Philadelphia, Pennsylvania, June, 1981.
40. Schoenberg, L.P., Kahan, B.D. and **Kerman, R.H.**: The use of Cyclosporin A as immunosuppressive medication in renal transplantation. Presented at The National Kidney Foundation, Inc., Washington, D.C., November, 1981.
41. Ettenger, R., **Kerman, R.**, Arnett, J., Jordan, S., Warshaw, B., Harris, R., Wassner, S. and Fine, R.: Sensitization following donor-specific transfusions for live-related renal transplantation. American Society of Nephrology, Washington, D.C., November, 1981.
42. Flechner, S., Boileau, M., Payne, W., Van Buren, C., **Kerman, R.** and Kahan, B.: The use of Cyclosporin A in strong immune responder, high risk renal transplant recipients. American Urological Association, Kansas City, Kansas, 1982.
43. **Kerman, R.**, Van Buren, C., Payne, W., Flechner, S, Agostino, G., Conley, S., Brewer, E. and Kahan, B.: Influence of blood transfusions on immune responsiveness. Presented at The Transfusion and Transplantation Conference, Los Angeles, California, January-February 1982.
44. Agostino, G., Kahan, B.D. and **Kerman, R.H.**: Suppression of mixed leucocyte culture using mononuclear leukocytes from normals, uremics and allograft recipients. Presented at The American Association of Immunologists, New Orleans, Louisiana, April, 1982.
45. Agostino, G.J., Kahan, B.D. and **Kerman, R.H.**: Measurement of suppressor cell status in potential allograft recipients. Presented at The American Association of Clinical Histocompatibility Testing, San Francisco, California, April, 1982.
46. **Kerman, R.H.**, Van Buren, C., Flechner, S., Agostino, G., Conley, S., Brewer, E. and Kahan, B.D.: The influence of pretransplant blood transfusions from random donors on immune parameters affecting cadaveric allograft survival. Presented at The American Society of Transplant Surgeons, Chicago, Illinois, June, 1982.
47. Agostino, G., Kahan, B.D. and **Kerman, R.H.**: Suppression of mixed leucocyte culture using leucocytes from normal individuals, uremic individuals, and allograft recipients. Presented at The American Society of Transplant Surgeons, Chicago, Illinois, June, 1982.
48. Ettenger, R.B., **Kerman, R.**, Jordan, S.C., Warshaw, B.L., Harris, R. and Fine, R.: Sensitization after donor-specific transfusions for live-related renal transplantation. Presented at The International Congress of The Transplantation Society, Brighton, England, August, 1982.
49. Van Buren, C.T., **Kerman, R.H.**, Agostino, G., Flechner, S., Payne, W. and Kahan, B.D.: Effect of cyclosporine on immunoregulatory cells of renal allograft recipients. Presented at The International Congress of The Transplantation Society, Brighton, England, August, 1982.
50. **Kerman, R.H.**, Van Buren, C.T., Payne, W., Flechner, S. and Kahan, B.D.: Monitoring T cell

subsets and immune events in renal allograft recipients. Presented at The International Congress of The Transplantation Society, Brighton, England, August, 1982.

51. Flechner, S., **Kerman, R.**, Van Buren, C.T., Payne, W. and Kahan, B.D.: The use of cyclosporine and prednisone for high MLC haploidentical living related renal transplants. Presented at The International Congress of The Transplantation Society, Brighton, England, August, 1982.
52. Agostino, G., Kahan, B.D. and **Kerman, R.**: Detection of nonspecific suppressor cells from normal individuals, uremic patients and allograft recipients. Presented at The International Congress of The Transplantation Society, Brighton, England, August, 1982.
53. **Kerman, R.H.**, Agostino, G., Van Buren, C.T., Payne, W., Flechner, S., Conley S., Brewer, E. and Kahan, B.D.: Effect of blood transfusions on graft survival and immune responsiveness. Presented at The International Congress of The Transplantation Society, Brighton, England, August, 1982.
54. Kahan, B.D., **Kerman, R.**, Payne, W.D., Flechner, S. and Van Buren, C.T.: Immunopharmacologic studies of cyclosporine-treated renal allograft recipients. Fifth Tripartite Meeting, Society of University Surgeons, Salzburg, Austria, September, 1982.
55. **Kerman, R.H.**, Flechner, S., Van Buren, C.T., Payne, W., and Kahan, B.D.: Cyclosporine improves allograft survival in immunologically high-risk renal allograft recipients. Presented at the Third International Immunological Monitoring Symposium, Key Biscayne, Florida, November, 1982.
56. **Kerman, R.H.**, Van Buren, C.T., Payne, W., Flechner, S., and Kahan, B.D.: Detection of host presensitization to donor alloantigens utilizing a comprehensive immune crossmatch. Presented at the Third International Immunological Monitoring Symposium, Key Biscayne, Florida, November, 1982.
57. **Kerman, R.H.**, Payne, W., Van Buren, C.T., Flechner, S., and Kahan, B.D.: Immune monitoring of renal allograft recipients treated with cyclosporine or azathioprine using donor-specific and nonspecific assays as well as monoclonal T cell reagents. Presented at the Third International Immunological Monitoring Symposium, Key Biscayne, Florida, November, 1982.
58. **Kerman, R.H.**, Van Buren, C.T., Payne, W., Flechner, S., and Kahan, B.D.: Cyclosporine improves allograft survival in immunologically high-risk renal allograft recipients. Presented at The National Kidney Foundation, Clinical Dialysis and Transplant Forum, Chicago, December, 1982.
59. Flechner, S., **Kerman, R.H.**, Van Buren, C.T., Payne, W., and Kahan, B.D.: Successful transplantation of high mixed lymphocyte culture haploidentical living related donors using cyclosporine and prednisone. Presented at the American Urological Association, Las Vegas, Nevada, April, 1983.
60. **Kerman, R.H.**, Flechner, S., Van Buren, C.T., Payne, W., and Kahan, B.D.: Immunological monitoring of renal allograft recipients treated with cyclosporine. Presented at The First International Congress on Cyclosporine, Houston, Texas, May, 1983.
61. Van Buren, C., **Kerman, R.**, Agostino, G., Flechner, S., Payne, W.D., and Kahan, B.: Effect of

RONALD H. KERMAN, PH.D.

- cyclosporine on immunoregulatory cells of renal allograft recipients. Presented at The First International Congress of Cyclosporine, Houston, Texas, May, 1983.
62. Kahan, B.D., Van Buren, C., Flechner, S., Payne, W.D., and **Kerman, R.**: Improved outcome of 150 renal allografts in immunologically high risk recipients treated with cyclosporine. Presented at The First International Congress on Cyclosporine, Houston, Texas, May, 1983.
 63. Flechner, S.M., Van Buren, C., **Kerman, R.H.**, and Kahan, B.D.: The nephrotoxicity of cyclosporine in renal transplantation. Presented at The First International Congress on Cyclosporine, Houston, Texas, May, 1983.
 64. Flechner, S.M., Van Buren, C.T., **Kerman, R.**, and Kahan, B.D.: The effect of conversion from cyclosporine to azathioprine immunosuppression for intractable nephrotoxicity. Presented at The First International Congress on Cyclosporine, Houston, Texas May, 1983.
 65. **Kerman, R.H.**, Flechner, S., Van Buren, C.T., Payne, W., and Kahan, B.D.: Cyclosporine immunosuppression overcomes immunologic risk factors for recipients of cadaveric renal allografts. Presented at The American Society of Transplant Physicians, Chicago, Illinois, June, 1983.
 66. Flechner, S.M., **Kerman, R.H.**, Van Buren, C.T., and Kahan, B.D.: The high risk haploidentical living related recipient: Transplantation without blood transfusions and steroid withdrawal using cyclosporine. Presented at The American Society of Transplant Physicians, Chicago, Illinois, June, 1983.
 67. **Kerman, R.**, Van Buren, C.T., Flechner, S., and Kahan, B.D.: Correlation of visual, ⁵¹Cr-release and flow cytometry crossmatch results to graft survival. Presented at The Fourth International Symposium: Immune Monitoring of The Transplant Recipient, Houston, Texas, November, 1983.
 68. Rogers, A.J., **Kerman, R.H.**, and Kahan, B.D.: The pharmacokinetic and immunobiological activity of cyclosporine in man. Presented at The Fourth International Symposium: Immune Monitoring of The Transplant Recipient, Houston, Texas, November, 1983.
 69. **Kerman, R.H.**, Manner, C., Ford, K., and Hoots, K.: Comprehensive immune evaluation of 78 hemophiliacs. Presented at the New York Academy of Sciences Symposium on Acquired Immune Deficiency Syndrome, New York, New York, November, 1983.
 70. **Kerman, R.**, Van Buren, C.T., Flechner, S.M., and Kahan, B.D.: DRW6 and DR3 phenotypes correlating with immune response. Presented at of The American Association for Clinical Histocompatibility Testing, Chicago, Illinois, November, 1983.
 71. Van Buren, C.T., Flechner, S.M., **Kerman, R.H.**, Vaughn, W., and Kahan, B.D.: Cyclosporine improves outcome in high risk cadaveric renal allograft recipients. Presented at the First Meeting of The European Society for Organ Transplantation, Zurich, Switzerland, November, 1983.
 72. Sterling, R.P., Bradley, B.B., Khalil, K.G., **Kerman, R.H.**, and Conklin, R.H.: Comparison of biopsy proven pneumocystis pneumonia in acquired immune deficiency syndrome (AIDS) patients versus renal allograft patients. Presented at The Society for Thoracic Surgeons, San Antonio, Texas, January, 1984.

73. Rogers, A.J., **Kerman, R.H.**, and Kahan, B.D.: Correlation of immunopharmacokinetic profiles of cyclosporine-treated allograft recipients and rejection. Presented at The Society for University Surgeons - Residents' Meeting, Chicago, Illinois, February, 1984.
74. Van Buren, C.T., **Kerman, R.H.**, Flechner, S.M., Jarowenko, M.W., and Kahan, B.D.: Pharmacokinetics of cyclosporine. Presented at an International Symposium: The Use of Cyclosporine in Solid Organ Transplantation, Montreal, Canada, April, 1983.
75. **Kerman, R.H.**, Van Buren, C.T., Flechner, S.M., and Kahan, B.D.: DRW6 phenotype, immune responder status and renal allograft outcome. Presented at The American Society of Transplant Physicians, Chicago, Illinois, May, 1984.
76. **Kerman, R.H.**, Van Buren, C.T., Flechner, S.M., and Kahan, B.D.: Correlation of visual, ⁵¹CR-release and flow cytometry crossmatch results to graft survival. Presented at The American Society of Transplant Physicians, Chicago, Illinois, May, 1984.
77. **Kerman, R.H.**, Flechner, S.M., Van Buren, C.T., and Kahan, B.D.: Mechanism of cyclosporine immunosuppression detected by post-transplant immune evaluation. Presented at The American Society of Transplant Surgeons, Chicago, Illinois, May, 1984.
78. Rogers, A.J., Yoshimura, N., **Kerman, R.H.**, and Kahan, B.D.: Immunopharmacodynamic analysis of cyclosporine-treated renal allograft recipients. Presented at The American Society of Transplant Surgeons, Chicago, Illinois, May, 1984.
79. Flechner, S.M., **Kerman, R.**, Van Buren, C.T., and Kahan, B.D.: MLC hyporesponsiveness as a marker for steroid withdrawal in cyclosporine-treated living related renal allograft recipients. Presented at The American Society of Transplant Surgeons, Chicago, Illinois, May, 1984.
80. Flechner, S.M., Conley, S., Rose, G., Van Buren, C.T., **Kerman, R.**, and Kahan, B.D.: The impact of cyclosporine-prednisone therapy on pediatric renal transplantation. Presented at the Ninth International Congress of Nephrology, Los Angeles, June, 1984.
81. Flechner, S.M., Van Buren, C.T., Jarowenko, M., **Kerman, R.H.**, and Kahan, B.D.: The fate of patients converted from cyclosporine to azathioprine to improve renal function. Presented at The 10th International Transplantation Congress, Minneapolis, Minnesota, August, 1984.
82. Flechner, S.M., Van Buren, C.T., Conley, S.B., Rose, G., **Kerman, R.H.**, and Kahan, B.D.: The impact of cyclosporine on renal function and growth in pediatric renal transplant recipients. Presented at The 10th International Transplantation Congress, Minneapolis, Minnesota, August, 1984.
83. Flechner, S.M., **Kerman, R.H.**, Epps, L., Van Buren, C.T., and Kahan, B.D.: MLC hyporesponsiveness as a marker for steroid withdrawal in CsA-treated living related renal recipients. Presented at The 10th International Transplantation Congress, Minneapolis, Minnesota, August, 1984.
84. **Kerman, R.H.**, Van Buren, C.T., Flechner, S.M., and Kahan, B.D.: DRW6 phenotype, immune responder status and renal allograft outcome. Presented at The 10th International Transplantation Congress, Minneapolis, Minnesota, August, 1984.

RONALD H. KERMAN, PH.D.

85. Rogers, A.J., **Kerman, R.H.**, and Kahan, B.D.: Immunopharmacological analysis of cyclosporine-treated renal allograft recipients. Presented at The American College of Surgeons, San Francisco, California, October, 1984.
86. **Kerman, R.H.**, Van Buren, C.T., Flechner, S.M., Lorber, M., and Kahan, B.D.: Successful transplantation of cyclosporine-treated allograft recipients with serologically positive historical but negative preoperative donor crossmatches. Presented at The D. Bernard Amos Symposium, Durham, North Carolina, April, 1985.
87. Flechner, S.M., Van Buren, C.T., Lorber, M., **Kerman, R.H.**, Wideman, C., and Kahan, B.D.: Does cyclosporine influence results of cadaver retransplantation? Presented at the D. Bernard Amos Symposium, Durham, North Carolina, April, 1985.
88. Lorber, M., Flechner, S.M., Van Buren, C.T., **Kerman, R.H.**, Bartosh, J., and Kahan, B.D.: Cyclosporine toxicity: the effect of combined therapy using cyclosporine, azathioprine and prednisone. Presented at The D. Bernard Amos Symposium, Durham, North Carolina, April, 1985.
89. Lorber, M.I., Flechner, S.M., Van Buren, C.T., **Kerman, R.H.**, Bartosh, J., and Kahan, B.D.: Cyclosporine toxicity: the effect of combined therapy using cyclosporine, azathioprine and prednisone. Presented at The American Society of Transplant Physicians, Chicago, Illinois, May, 1985.
90. Flechner, S.M., Van Buren, C.T., Lorber, M., **Kerman, R.**, Wideman, C., and Kahan, B.D.: Does cyclosporine influence the results of cadaver retransplantation? Presented at The American Society of Transplant Physicians, Chicago, Illinois, May, 1985.
91. **Kerman, R.H.**, Van Buren, C.T., Flechner, S.M., Lorber, M., and Kahan, B.D.: Successful transplantation of cyclosporine-treated allograft recipients with serologically positive historical but negative preoperative donor crossmatches. Presented at the Annual Meeting of The American Society of Transplant Physicians. Chicago, Illinois, May, 1985.
92. Jarowenko, M., Pifer, L.L., **Kerman, R.**, and Kahan, B.D.: Serologic methods for the early diagnosis of pneumocystis carinii infection in renal allograft recipients. Presented at the Annual Meeting of The American Society of Transplant Surgeons, Chicago, Illinois, May, 1985.
93. Flechner, S.M., Barker, C., and **Kerman, R.H.**: Donor specific hyporesponsiveness is associated with decreased in-vitro cytotoxicity in cyclosporine and prednisone treated haploidentical LRD renal recipients. Presented at The International Symposium on Monitoring and Manipulation in Autoimmune Disease and Organ Transplantation, Chateau Montebello, Canada, July, 1985.
94. **Kerman, R.H.**, Krajewski, K., Hayden, J., Felkins, B., Faillace, L., and Dafny, N.: Immune responsiveness of methadone-treated patients. Presented at the American College of Clinical Pharmacology, Philadelphia, Pennsylvania, October, 1985.
95. **Kerman, R.H.**, Flechner, S.M., Van Buren, C.T., Lorber, M.I., Dawson, G., Falk, L., Gutierrez, R., and Kahan, B.D.: Investigation of HTLV-3 serology in a renal transplant population. Presented at The American Society of Transplant Physicians, Chicago, Illinois, May, 1986.

96. Flechner, S.M., Van Buren, C.T., **Kerman, R.H.**, Lorber, M.I., and Kahan, B.D.: Does cyclosporine improve the results of renal transplantation for HLA-identical (HLA-ID) recipients? Presented at The American Society of Transplant Physicians, Chicago, Illinois, May, 1986.
97. **Kerman, R.H.**, Flechner, S.M., Van Buren, C.T., Lorber, M.I., and Kahan, B.D.: Immunoregulatory mechanisms in cyclosporine renal allograft recipients. Presented at The American Society of Transplant Physicians, Chicago, Illinois, May, 1986.
98. Flechner, S.M., Barker, C.J., and **Kerman, R.H.**: Determinants of donor specific hyporesponsiveness (DSH) in haploidentical (HP-ID) LRD recipients immunosuppressed with cyclosporine (CsA) and prednisone. Presented at The American Society of Transplant Physicians, Chicago, Illinois, May, 1986.
99. Kahan, B.D., Mickey, R., Flechner, S.M., Lorber, M.I., Wideman, C.A., **Kerman, R.H.**, Terasaki, P., and Van Buren, C.T.: Multivariant analysis of risk factors impacting on immediate and eventual cadaver allograft survival in cyclosporine-treated recipients. Presented at The American Society of Transplant Surgeons, Chicago, Illinois, May, 1986.
100. Van Buren, C.T., Burstain, T.L., Frazier, O.H., Schnee, M.J.M., **Kerman, R.H.**, Lorber, M., Cooley, D., Colon, R., McAllister, H., and Kahan, B.D.: Predictors of rejection in cyclosporine treated cardiac recipients. Presented at The Eleventh International Transplantation Congress, Helsinki, Finland, August, 1986.
101. Flechner, S.M., Van Buren, C.T., **Kerman, R.H.**, Lorber, M.I., and Kahan, B.D.: Does cyclosporine improve the results of HLA-identical renal transplantation? Presented at The Eleventh International Transplantation Congress, Helsinki, Finland, August, 1986.
102. Flechner, S.M., Barker, C.J., and **Kerman, R.H.**: Determinants of donor specific hyporesponsiveness in haploidentical recipients. Presented at The Eleventh International Transplantation Congress, Helsinki, Finland, August, 1986.
103. **Kerman, R.H.**, Flechner, S.M., Van Buren, C.T., Lorber, M.I., Dawson, G., Gutierrez, R., and Kahan, B.D.: Investigation of HTLV-3 serology in a renal transplant population. Presented at The Eleventh International Transplantation Congress, Helsinki, Finland, August, 1986.
104. **Kerman, R.H.**, Flechner, S.M., Van Buren, C.T., Lorber, M.I., and Kahan, B.D.: The role of suppressor cells in cyclosporine-treated renal allograft recipients. Presented at The Eleventh International Transplantation Congress, Helsinki, Finland, August, 1986.
105. Kahan, B.D., Mickey, R., Flechner, S.M., Lorber, M.I., Wideman, C.A., **Kerman, R.H.**, Terasaki, P.I., and Van Buren, C.T.: Multivariant analysis of risk factors impacting on immediate and eventual cadaver allograft survival in cyclosporine-treated recipients. Presented at The Eleventh International Transplantation Congress, Helsinki, Finland, August, 1986.
106. Lorber, M.I., Flechner, S.M., Van Buren, C.T., Sorensen, K., **Kerman, R.H.**, and Kahan, B.D.: Management of immunosuppressive problems in renal allograft recipients. Presented at The Eleventh International Transplantation Congress, Helsinki, Finland, August, 1986.
107. **Kerman, R.H.**, Flechner, S.M., Van Buren, C.T., Lorber, M., Dawson, G., Falk, L., Gutierrez, R., Hollinger, B., and Kahan, B.D.: Incidence of HTLV-3 infection in dialysis and transplant patients

from one U.S. transplant center. Presented at The American Society for Histocompatibility and Immunogenetics, New Orleans, Louisiana, September, 1986.

108. **Kerman, R.H.**, Wolinsky, J.S., Nath, A., and Sears, E.S.: Serial immune evaluation of chronic progressive multiple sclerosis patients. Presented at The American Neurological Association, Boston, Massachusetts, October, 1986.
109. **Kerman, R.H.**, Van Buren, C.T., Lewis, R.M., and Kahan, B.D.: Successful transplantation of 100 untransfused cyclosporine-treated primary recipients of cadaveric donor renal allografts. Presented at The American Society of Transplant Physicians, Chicago, Illinois, May, 1987.
110. Johnson, P.C., Lewis, R.M. Golden, D., Oefinger, P.E., Van Buren, C.T., **Kerman, R.H.**, and Kahan, B.D.: Increased incidence, but lack of increased severity and mortality of CMV infection-positive kidneys treated with cyclosporine-prednisone. Presented at The American Society of Transplant Physicians, Chicago, Illinois, May, 1987.
111. **Kerman, R.H.**, Van Buren, C.T., Lewis, R.M., Frazier, O.H., Cooley, D. and Kahan, B.D.: The impact of HLA A, B and DR, blood transfusions and immune responder status on cardiac allograft recipients treated with cyclosporine. Presented at The American Society of Transplant Surgeons, Chicago, Illinois, May, 1987.
112. Lewis, R.M., Johnson, P.D., Golden, D., Van Buren, C.T., **Kerman, R.H.**, and Kahan, B.D.: The adverse impact of CMV infection on clinical outcome in cyclosporine-prednisone treated renal allograft recipients. Presented at The American Society of Transplant Surgeons, Chicago, Illinois, May, 1987.
113. Smith, A.Y., Van Buren, C.T., Lewis, R.M., **Kerman, R.H.**, and Kahan, B.D.: Short and long-term function of cadaveric kidneys from pediatric donors in recipients treated with cyclosporine. Presented at The American Society of Transplant Surgeons, Chicago, Illinois, May, 1987.
114. **Kerman, R.H.**, Wolinsky, J.S., Nath, A., and Sears, E.S.: Immunoregulation in MS patients treated with cyclosporine. Presented at The Second International Congress of Neuroimmunology, Philadelphia, PA., September, 1987.
115. **Kerman, R.H.**, Wolinsky, J.S., Nath, A., Sears, E.S., Franklin, G.M. and Nelson, L.M.: Immunoregulation in MS patients treated with cyclosporine. Presented at the American Neurological Association, San Francisco, CA., October, 1987.
116. **Kerman, R.H.**, Gochfeld, M., Nygren, M., Hansson, C., Rappe, C., Velez, H., Ghent-Gunther, T., Wilson, T.P., and Kahn, P.C.: Immunologic markers in veterans with and without herbicide exposure in Viet-Nam. Presented at "Dioxin '87 Symposium, Las Vegas, Nevada, October, 1987.
117. **Kerman, R.H.**, Van Buren, C.T., Lewis, R., and Kahan, B.D.: Impact of blood transfusion and HLA on cyclosporine treated renal transplant recipients. Presented at the Second International Congress on Cyclosporine, Washington, D.C., November, 1987.
118. Smith, A.Y., Van Buren, C.T., Lewis, R.M., **Kerman, R.H.**, Welsh, M., and Kahan, B.D.: The outcome of repeat cadaveric kidney transplants in recipients managed with cyclosporine. Presented at The Second International Congress on Cyclosporine, Washington, D.C., November, 1987.

119. Smith, A.Y., **Kerman, R.H.**, Van Buren, C.T., Lewis, R.M., and Kahan, B.D.: Pediatric cadaver donor kidneys in recipients treated with cyclosporine. Presented at The Second International Congress on Cyclosporine, Washington, D.C., November, 1987.
120. Didlake, R., Dreyfuss, K., **Kerman, R.H.**, Van Buren, C.T. and Kahan, B.D.: Impact of patient noncompliance to cyclosporine-prednisone immunosuppression in renal transplantation. Presented at The Second International Congress on Cyclosporine, Washington, D.C., November, 1987.
121. Lewis, R.M., Janney, R.P., Van Buren, C.T., **Kerman, R.H.**, Herson, J., Kerr, N.A., Golden, D.A., and Kahan, B.D.: A retrospective analysis of long-term renal allograft function associated with cyclosporine-prednisone immunosuppressive therapy. Presented at The Second International Congress on Cyclosporine, Washington, D.C., November, 1987.
122. Nath, A., Wolinski, J.S. and **Kerman, R.H.**: Effect of Cyclosporine on Rubella virus specific immune response in chronic progressive multiple sclerosis". Presented at The Annual Meeting of The American Academy of Neurology, April, 1988, Cincinnati, Ohio.
123. Lewis, R.M., Janney, R.P., Golden, D.A., Kerr, N.B., Van Buren, C.T., **Kerman, R.H.**, Herson, J and Kahan, B.D.: Stability of renal allograft function associated with long-term cyclosporine immuno-suppressive therapy: Five-year follow-up. Presented at The American Society of Transplant Physicians, May, 1988, Chicago, Illinois.
124. Kahan, B.D., **Kerman, R.H.**, Van Buren, C.T., Flechner, S.M., Golden, D.L., and Lewis, R.M.: Clinical outcome in 36 patients after at least one and up to 5 years of steroid withdrawal based upon specific mixed lymphocyte reaction hyporesponsiveness toward the living related donor. Presented at The Twelfth International Transplantation Congress, Sydney Australia, August, 1988.
125. Lewis, R.M., Van Buren, C.T., Macris, M., Frazier, O.H., Janney, R.P., McAndrew, J., **Kerman, R.H.**, and Kahan, B.D.: Evolution of renal function in cardiac vs. renal allograft recipients receiving long-term cyclosporine immunosuppressive therapy. Presented at The Twelfth International Transplantation Congress, Sydney Australia, August, 1988.
126. Smith, A.Y., Citterio, F., Welsh, M., **Kerman, R.H.**, and Kahan, B.D.: Interleukin-2 receptor as an immunodiagnostic tool to differentiate rejection versus nephrotoxicity. Presented at the Twelfth International Transplantation Congress, Sydney Australia, August, 1988.
127. Nath, A., **Kerman, R.H.**, Novak, I.S. and Wolinsky, J.S.: Immune responses in a patient with HIV infection and Myasthenia Gravis. Presented at The American Association of Neurology, San Francisco, CA., February, 1989.
128. **Kerman, R.H.**, Van Buren, C.T., Lewis, R.M., DeVera, V., Baghdasarian, V., Kahan, B.D.: Improved graft survival for flow cytometry and anti-human globulin crossmatch negative retransplant recipients. Presented at The American Society of Transplant Physicians, Chicago, Illinois, May 1989.
129. Kimball, P.M., **Kerman, R.H.** and Kahan, B.D.: Cellular activation signal generation as a potential marker for cyclosporine immunosuppression. Presented at The American Society of Transplant Physicians, Chicago, Illinois, May 1989.

RONALD H. KERMAN, PH.D.

130. Lewis, R.M., Kerr, N.B., Van Buren, C.T., **Kerman, R.H.**, Janney, R.P., Powers, P.L., Macris, M.P., Frazier, O.H. and Kahan, B.D.: Impact of long-term cyclosporine A (CsA) therapy on native kidneys vs. renal allografts: Serial renal function in cardiac and renal transplant recipients. Presented at The American Society of Transplant Physicians, Chicago, Illinois, May, 1989.
131. Vathsala, A., Verani, R., Schoenberg, L., Lewis, R.M., Van Buren, C.T., **Kerman, R.H.** and Kahan, B.D.: Proteinuria in cyclosporine-treated renal transplant recipients. Presented at The American Society of Transplant Physicians, Chicago, Illinois, May 1989.
132. Vega, J.D., Radovancevic, B., **Kerman, R.H.**, Moncrief, C.L., Duncan, J.M. and Frazier, O.H.: Influence of gender on allograft rejection and survival in cardiac transplantation. Presented at The American Heart Association Meeting, New Orleans, LA, November, 1989.
133. Meehan, M.A., **Kerman, R.H.** and LeMire, J.M.: Vitamin D₃ allows for expression of suppressor cell activity in human mixed lymphocyte reaction. Presented at The American Association of Immunologists, New Orleans, LA, April 1990.
134. **Kerman, R.H.**, Kimball, P.M., Van Buren, C.T., Lewis, R.M., DeVera, V., Baghdahsarian, V., Heydari, A., Kahan, B.D.: AHG and DTE/AHG procedures identify crossmatch appropriate donor-recipient pairings which result in improved graft survival. Presented at The American Society of Transplant Physicians, Chicago, Ill., May, 1990.
135. **Kerman, R.H.**, Kimball, P.M., Van Buren, C.T., Lewis, R.M. and Kahan, B.D.: Pretransplant immune responder status may contribute to renal allograft survival differences in black vs. white recipients. Presented at The American Society of Transplant Physicians, Chicago, Illinois, May, 1990.
136. Kimball, P.M., **Kerman, R.H.**, Kahan, B.D.: Cyclosporine suppression of intracellular activation signal generation is not mediated by propyl-peptidyl isomerase. Presented at The American Society of Transplant Physicians, Chicago, Illinois, May, 1990.
137. Kimball, P.M., **Kerman, R.H.** and Kahan, B.D.: Rapamycin inhibition of T-cell activation is synergistic but not identical to cyclosporine's mechanism of immunosuppression. Presented at The American Society of Transplant Physicians, Chicago, Illinois, May 1990.
138. Katz, S., **Kerman, R.H.**, Golden, D., and Kahan, B.D.: The benefits of pre-emptive transplantation do not engender increased risks. Presented at The American Society of Transplant Physicians, Chicago, Illinois, May 1990.
139. Knight, R., **Kerman, R.H.**, Welsh, M., Golden, D., Schoenberg, L., and Kahan, B.D.: Chronic rejection in the cyclosporine-prednisone era. Presented at The American Society of Transplant Physicians, Chicago, Illinois May 1990.
140. Radovancevic, B., Birovljev, S., Frazier, O.H., Vega, D., Mcallister, H., Lonquist, J.L., Burnett, C.M., Poindexter, S., Duncan, J.M., Sweeney, M., Kahan, B.D., Van Buren, C.T. and **Kerman, R.H.**: The relationship between HLA mismatch and the incidence of coronary artery disease in cyclosporine-treated recipients. Presented at The American Society of Transplant Surgeons, Chicago, Illinois, May 1990.
141. McCarthy, M., **Kerman, R.H.** and Wolinsky, J.S.: An immunodominant domain within the

RONALD H. KERMAN, PH.D.

- Rubella-virus capsid protein contains T-cell and B-cell determinants. Presented at The American Society for Virology, Salt Lake City, Utah, July 1990.
142. Lovett, A., McCarthy, M., **Kerman, R.H.** and Wolinsky, J.S.: Mapping of cell-mediated immunodominant domains with expressed Rubella-virus proteins. Presented at The American Society for Virology, Salt Lake City, Utah, July 1990.
143. Kimball, P.M. and **Kerman, R.H.**: Erythropoietin. A potential immunomodulator? Presented at The XIII International Congress of The Transplantation Society, San Francisco, CA, August 1990.
144. Kimball, P.M., **Kerman, R.H.** and Kahan, B.D.: Rapamycin and cyclosporine produce synergistic but non-identical mechanisms of immunosuppression. Presented at The XIII International Congress of The Transplantation Society, San Francisco, CA, August 1990.
145. Kimball, P.M., **Kerman, R.H.**, Kahan, B.D.: Cyclosporine suppression of intracellular activation signal generation is not mediated by prolyl-peptidyl isomerase. Presented at The XIII International Congress of The Transplantation Society, San Francisco, CA, August 1990.
146. **Kerman, R.H.**, Kimball, P.M. and Kahan, B.D.: Improved renal allograft survival for AHG and AHG/DTE crossmatch negative recipients. Presented at The XIII International Congress of The Transplantation Society, San Francisco, CA, August 1990.
147. **Kerman, R.H.**, Kimball, P.M., Kahan, B.D.: Stronger immune responsiveness of blacks vs. whites may account for renal allograft survival differences. Presented at The XIII International Congress of The Transplantation Society, San Francisco, CA, August 1990.
148. **Kerman, R.H.**, Kimball, P.M., Van Buren, C.T., Lewis, R.M., DeVera, V., Baghdasarian, V., Heydari, A. and Kahan, B.D.: Improved renal allograft survival for AHG and DTe/AHG negative recipients. Presented at The American Society for Histocompatibility and Immunogenetics, Los Angeles, CA, November 1990.
149. **Kerman, R.H.**, Radovancevic, B., Vega, D., Frazier, O.H., Kimball, P.M., McAllister, H., Sweeney, M., Kahan, B.D. and Van Buren, C.T.: The relationship between HLA mismatches, early rejection and the incidence of coronary artery disease in cardiac transplant recipients. Presented at The American Society for Histocompatibility and Immunogenetics, Los Angeles, CA, November 1990.
150. Kimball, P.M. and **Kerman, R.H.**: Erythropoietin. A potential immunomodulator? Presented at The American Society for Histocompatibility and Immunogenetics, Los Angeles, CA, November 1990.
151. Kimball, P.M., Airola, J., Moreno, L., **Kerman, R.H.** and Kahan, B.D.: Cyclophilin does not mediate cyclosporine suppression of activation signalling. Presented at The American Society for Histocompatibility and Immunogenetics, Los Angeles, CA, November 1990.
152. Kimball, P.M., Nelson, P., Hendrix, D., **Kerman, R.H.**, Kahan, B.D.: Rapamycin and cyclosporine synergistically inhibit T-cell proliferation. Presented at The American society for Histocompatibility and Immunogenetics, Los Angeles, CA, November 1990.

RONALD H. KERMAN, PH.D.

153. **Kerman, R.H.**, Kimball, P.M., Van Buren, C.T., Lewis, R.M., Cavazos, D. and Kahan, B.D.: Influence of race on crossmatch outcome and recipient eligibility for transplantation. Presented at The Tenth Annual Meeting of The American Society of Transplant Physicians, Chicago, Illinois, May 1991.
154. Kimball, P.M., **Kerman, R.H.**, Kahan, B.D.: Rapamycin suppression of T cell activation is regulated by the type of stimulus. Presented at the Tenth Annual Meeting of The American Society of Transplant Physicians, Chicago, Illinois, May, 1991.
155. Kimball, P.M. and **Kerman, R.H.**: Can erythropoietin modulate T-cell response? Presented at the Tenth Annual Meeting of The American Society of Transplant Physicians, Chicago, Illinois, May, 1991.
156. Kimball, P.M., **Kerman, R.H.**, Portman, R., Van Buren, C.T., Lewis, R.M., Kahan, B.D.: Pediatric patients have poorer renal allograft survival and stronger immune responses than adults. Presented at The Tenth Annual Meeting of The American Society of Transplant Physicians, Chicago, Illinois, May 1991.
157. Knight, R.J., **Kerman, R.H.**, Stepkowski, S.M., Kurlle, R., and Kahan, B.D.: Evaluation of two new murine monoclonal antibodies directed against the T cell receptors of man and rat. Presented at The Seventeenth Annual Meeting of The American Society of Transplant Surgeons, Chicago, Illinois, May, 1991.
158. **Kerman, R.H.**, Kimball, P.M., Van Buren, C.T., Lewis, R.M., Katz, S.M., Williams, J., Baghdasarian, V., Hartenstein, D. and Kahan, B.D.: The correlation of immunoregulatory subsets (T4+/2H4, T4+/4B4, T8+/2H4) to post transplant renal allograft status. Presented at the Annual Meeting of the American Society of Transplant Physicians, Chicago, Illinois, May, 1992.
159. **Kerman, R.H.**, Kimball, P.M., Van Buren, C.T., Katz, S.M., Lewis, R.M., McClain, J., Podbielski, J., Williams, J. and Kahan B.D.: Influence of HLA matching on rejections and short and long term primary cadaveric allograft survival. Presented at the Annual Meeting of the American Society of Transplant Physicians, Chicago, Illinois, May, 1992.
160. Lewis, R.M., Podbielski, J., Sprayberry, S., Van Buren, C.T., Katz, S., Rubin, M., **Kerman, R.**, Kimball, PM, Kahan, BD: Rate of change of renal allograft glomerular filtration rate (GFR) is independent of time post transplant and absolute GFR level in patients receiving long-term cyclosporine (CsA). Presented at the Annual Meeting of the American Society of Transplant Physicians, Chicago, Illinois, May 1992.
161. Kimball, P.M., **Kerman, R.H.**, and Kahan, B.D: Cyclosporine and rapamycin inhibit protein kinase C induction of the intracellular activation signal, ADR. Presented at the Annual Meeting of the American Society of Transplant Physicians, Chicago, Illinois May, 1992.
162. Scheinin, S., Radovanecevic, B., Duncan, J.M., Van Buren, C.T., Lewis, R.M., Kimball, P., Frazier, O.H., Kahan, B.D. and **Kerman, R.H.**: The relationship between donor-recipient HLA mismatches, rejection and death from coronary artery disease in cardiac transplant recipients. Presented at the International Heart Transplant Congress, Los Angeles, California, June, 1992.
163. Scheinin, S.A., Radovancevic, B., Kimball, P.M., Duncan, J.M., Van Buren C.T., **Kerman, R.H.**, Lewis, R., Franzier, O.H.: Successful cardiac transplantation after conversion of IgM positive crossmatch to negative utilizing dithiothreitol (DTE). Presented at the International Heart

Transplant Congress, Los Angeles, CA., June 1992.

164. Scheinin, S., Radovancevic, B., Kimball, P.M., **Kerman, R.H.**, Frazier, O.H.: The influence of HLA matching on cardiac allograft recipients treated with CsA and Prednisone. Presented at the Texas Transplant Society, June, 1992.
165. Kimball, P.M., **Kerman, R.H.**, Williams, J., Kahan, B.D.: Cyclosporine and rapamycin block protein kinase C mediated induction of the activation signal, activator of DNA replication (ADR), in cell-free assay. Presented at the XIV International Congress of the Transplantation Society, Paris, France, August 1992.
166. **Kerman, R.H.**, Katz, S., Baumann, L., Weldon, M., Kimball, P., and Wood, RP.: Positive pretransplant crossmatches predict early graft loss in liver allograft recipients. Presented at the Annual Meeting of the American Society for Histocompatibility and Immunogenetics. Kansas City, Missouri, October, 1992.
167. Kimball, P.M., **Kerman, R.H.**, Kahan, B.D.: Cell-free assay predicts proliferative suppression by cyclosporine and rapamycin. Presented at the Annual Meeting of the American Society for Histocompatibility and Immunogenetics. Kansas City, Missouri, October 1992.
168. **Kerman R.H.**, Kimball, P.M., Williams, J., Van Buren, C.T., Lewis, R.M., Kahan, B.D.: Lack of HLA and transfusion impact on rejection and allograft survival. Presented at The Annual Meeting of The American Society for Histocompatibility and Immunogenetics. Kansas City, MO. October, 1992.
169. **Kerman, R.H.**, Kimball, P.M., Lewis, R.M., Van Buren, C.T., and Kahan, B.D.: Sensitive crossmatch criteria improves retransplant graft survival. Presented at The Annual Meeting of The American Society for Histocompatibility and Immunogenetics, Kansas City, MO., October 1992.
170. **Kerman RH**, Kimball P, Williams J, Heydari A, Cavazos D, Katz S, Ozaki C, Clark J, Kahan BD, Wood RP: Positive Pretransplant Crossmatches Predict Early Graft Loss in Liver Allograft Recipients. Presented at The 12th Annual Meeting of The American Society of Transplant Physicians, Houston, Texas, May 1993.
171. Lewis R, Verani R, Vo C, Katz S, Van Buren CT, Radovancevic B, **Kerman R**, Frazier OH, Kahan BD.: Evaluating Chronic Renal Disease in Cardiac Allograft Recipients: Importance of Pretransplant Native Kidney Histology. Presented at the 12th Annual Meeting of the American Society of Transplant Physicians, Houston, Texas, May 1993.
172. **Kerman RH**, Van Buren CT, Kimball P, Scheinen S, Radovancevic B, Lewis R, Kahan BD, Frazier OH: Relationship Between HLA Mismatches, Rejection and Death from Coronary Artery Disease in Heart Transplant Recipients. Presented at The 19th Annual Meeting of The American Society of Transplant Surgeons, Houston, Texas, May 1993.
173. Kimball PM, Radovancevic B, Isom T, Meltzer M, Van Buren CT, Frazier OH, **Kerman RH**: Interleukin 6 levels identify rejection severity and steroid resistance among cardiac allograft recipients. Presented at the Annual Meeting of The American Society of Histocompatibility and Immunogenetics, Phoenix, Arizona October, 1993.

174. Kimball PM, Radovancevic B, Isom T, Williams J, Van Buren C, Frazier OH, **Kerman RH**: Evidence of early humoral-cellular alloreactivity following cardiac transplantation. Presented at The Annual Meeting of The American Society of Histocompatibility and Immunogenetics, Phoenix, Arizona, October 1993.
175. **Kerman RH**, Kimball PM, Williams J, Heydari A, Cavazos D, Katz S, Ozaki C, Clark J, Kahan BD, Wood RP.: Immunoregulatory mechanisms identified in liver transplant recipients. Presented at The Third International Congress on Cyclosporine Seville, Spain. March,1994.
176. **Kerman RH**, Lewis RM, Kimball P, Heydari A, Ruth J, Cavazos D, Williams J, Van Buren CT, and Kahan BD: "Retransplantation outcome, following NIH/AHG serological crossmatching, is not predicted by flow cytometry crossmatch results". Presented at the 13th Annual Meeting of The American Society of Transplant Physicians, Chicago, Illinois, May 1994.
177. **Kerman RH**, Sullivan K, Tejani A: Influence of HLA, crossmatching and immunosuppression on the graft survival of primary pediatric recipients of cadaveric renal allografts. Presented at The 15th International Transplantation Congress, Kyoto, Japan. August 1994.
178. Vorhaben R, Radovancevic B, Isom T, Sobinski J, Frazier OH, Kimball P, **Kerman RH**: Cytokine panel predicts early rejection and therapeutic response after cardiac transplantation. Presented at The 15th International Transplantation Congress, Kyoto, Japan, August 1994.
179. **Kerman RH**, Kimball P, Lewis R, Katz S, Heydari A, Cavazos D, Williams J, Ruth J, Van Buren CT and Kahan BD: Clinical significance of a flow cytometry crossmatch in sera from NIH-AHG crossmatch negative primary recipients. Presented at The American Society for Histocompatibility and Immunogenetics, Pittsburgh, PA., October 1994.
180. **Kerman RH**, Lewis R, Kimball P, Heydari A, Ruth J, Cavazos D, Williams J, Van Buren CT, Katz S, and Kahan BD: Retransplantation outcome, following NIH/AHG serological crossmatching, is not predicted by flow cytometry crossmatch results. Presented at The American Society for Histocompatibility and Immunogenetics, Pittsburgh, PA., October 1994.
181. **Kerman RH**, Sullivan K and Tejani A: Impact of HLA matching, type of crossmatch and immunosuppressive therapy on primary pediatric cadaver renal allograft survival. Presented at The American Society for Histocompatibility and Immunogenetics, Pittsburgh, PA., October 1994.
182. **Kerman RH**, Van Buren CT, Katz S, Lewis R, Heydari A, Ruth J, Cavazos D, Williams J, and Kahan BD: Past positive-current negative crossmatch considerations revisited. Presented at The American Society for Histocompatibility and Immunogenetics, Pittsburgh, PA., October 1994.
183. **Kerman RH**: Pretransplant anti-HLA IgG as measured by sHLA ELISA correlates with occurrence of first year rejection episodes. Presented at a Satellite Symposium "Screening and Matching by Soluble HLA: A Paradigm for Transplant Immunology. The European Federation of Immunogenetics Annual Meeting, Brighton, England. March 1995.
184. **Kerman RH**, Susskind B, Buelow R, Regan J, Pouletty P, Williams J, Gerolami K, Kerman DH, Van Buren CT, Katz SM, Kahan BD: Correlation of ELISA detected IgG and IgA anti-HLA antibodies in pretransplant sera with renal allograft rejection. Presented at The Annual Meeting of The American Society of Transplant Physicians, Chicago, Illinois, May 1995.

185. **Kerman RH**, Susskind BM, Slaton J, Lewis RM, Heydari A, Ruth J, Williams J, Van Buren CT, Katz SM, Kahan BD: Improved graft survival in 100 retransplant recipients following AHG negative crossmatching. Presented at The Annual Meeting of The American Society of Transplant Physicians, Chicago, Illinois, May 1995.
186. **Kerman RH**, Katz SM, Van Buren CT, Barakat O, Schoenberg L, Kahan BD: 10 year follow-up of MLR-hyporesponsive living related cyclosporine monotherapy treated renal allograft recipients. Presented at The Annual Meeting of The American Society of Transplant Physicians, Chicago, Illinois, May 1995.
187. Susskind B, **Kerman RH**, Browne BJ, Hartwell BA, Davis BG, Katz SM, Van Buren CT, Kahan BD: Serum IgA levels independently predict graft survival in non-white primary renal allograft recipients. Presented at The Annual Meeting of The American Society of Transplant Physicians, Chicago, Illinois, May 1995.
188. **Kerman RH**, Susskind BM, Slaton J, Lewis RM, Heydari A, Ruth J, Cavazos D, Williams J, Van Buren CT, Katz, SM, and Kahan BD: Improved graft survival in 100 retransplant recipients following AHG negative crossmatching. Presented at The 21st Annual Meeting of the American Society for Histocompatibility and Immunogenetics, Dallas, Texas October 1995.
189. **Kerman RH**, Susskind B, Buelow R, Regan J, Pouletty P, Williams J, Gerolami K, Kerman DH, Katz SM, Van Buren CT, and Kahan BD: ELISA detected IgG and IgA anti-HLA antibodies in pretransplant sera correlate with graft rejection. Presented at The 21st Annual Meeting of the American Society for Histocompatibility and Immunogenetics, Dallas, Texas October 1995.
190. Susskind B, **Kerman RH**, Browne BJ, Hartwell BA, Davis DG, Katz SM, Van Buren CT, Kahan BD: Improved graft survival in primary renal allograft recipients with elevated serum IgA. Presented at The 21st Annual Meeting of the American Society for Histocompatibility and Immunogenetics, Dallas, Texas October 1995.
191. **Kerman RH**, Katz SM, Van Buren CT, Barakat O, Schoenberg L, Kahan BD: 10-year follow-up of MLR-hyporesponsive cyclosporine monotherapy treated living related renal allograft recipients. Presented at The 21st Annual Meeting of the American Society for Histocompatibility and Immunogenetics, Dallas, Texas October 1995.
192. **Kerman RH**, Susskind B, Williams J, Gerolami K, Kerman D, Katz SM, Van Buren CT, Kahan BD: Pretransplant identification of patients at high risk of graft rejection by detection of anti-HLA IgG antibodies using PRA-STAT. Presented at The 2nd International Conference on New Trends in Clinical and Experimental Immunosuppression, Geneva, Switzerland, February 1996.
193. **Kerman RH**, Susskind B, Kerman D, Gerolami K, Williams J, Kalish R, Campbell M, Katz SM, Van Buren CT, Frazier OH, Radovancevic B, Kahan BD: Comparison of PRA-STAT sHLA-EIA, and AHG-% PRA to identify IgG anti-HLA antibodies in pretransplant sera of heart recipients: Correlation to rejection and post-transplant coronary artery disease. Presented at The International Heart and Lung Transplantation Meeting, New York, New York, February 1996.
194. **Kerman RH**, Susskind B, Katz SM, Van Buren CT, Kahan BD: Post renal transplant hypo-responders have fewer rejections and better graft survival than MLR-hyper-responders. Presented at The Annual Meeting of The American Society of Transplant Physicians, Dallas Texas, May 1996.

RONALD H. KERMAN, PH.D.

195. **Kerman RH**, Susskind B, Kerman D, Lam M, Gerolami K, Williams J, Kalish R, Campbell M, Katz SM, Van Buren CT, Frazier OH, Radovancevic B, Kahan BD: Comparison of PRA-STAT, sHLA and AHG-% PRA to identify IgG anti-HLA antibodies in pretransplant sera of heart recipients. Presented at The Annual Meeting of The American Society of Transplant Physicians, Dallas, Texas, May 1996.
196. **Kerman RH**, Susskind B, Kerman D, Lam M, Gerolami K, Williams J, Kalish R, Campbell M, Katz SM, Van Buren CT, Kahan BD: ELISA-detected anti-HLA antibodies in post-transplant renal allograft recipient sera correlate with chronic rejection. Presented at The Annual Meeting of The American Society of Transplant Physicians, Dallas, Texas, May 1996.
197. **Kerman RH**: Moderator and presenter at an ASTP workshop "Clinical relevance of anti-HLA antibodies pre and post-transplant". Presented at The Annual Meeting of The American Society of Transplant Physicians, Dallas, Texas, May 1996.
198. **Kerman RH**, Susskind B, Buelow R, Regan J, Pouletty P, Williams J, Gerolami K, Kerman DH, Lam M, Kalish R, Katz SM, Van Buren CT, Frazier OH, Radovancevic B, Kahan BD: Prognostic value of pretransplant serum screening of 493 renal and 130 cardiac recipients; Prediction of rejection and graft loss. Presented at The Annual Meeting of The American Society of Transplant Surgeons, Dallas, Texas, May 1996.
199. **Kerman RH**, Susskind B, Katz SM, Frazier OH, Radovancevic B, Van Buren CT, Kahan BD: PRA-STAT identifies high-risk alloimmune recipients. Presented at The 12th International Histocompatibility Conference, Paris, France, June 1996.
200. **Kerman RH**, Katz SM, Van Buren CT, Schoenberg L, Barakat O, Kahan BD: 10 year follow-up of MLR hyporesponsive living related cyclosporine monotherapy treated renal allograft recipients. Presented at The International Congress of The Transplantation Society, Barcelona, Spain, August 1996.
201. **Kerman RH**, Susskind B, Kerman DH, Gerolami K, Williams J, Kalish R, Campbell M, Katz SM, Van Buren CT, Kahan BD: Anti-HLA antibodies detected in post-transplant renal allograft recipient sera correlate with chronic rejection. Presented at The International Congress of The Transplantation Society, Barcelona, Spain August 1996.
202. **Kerman RH**, Susskind B, Katz SM, Van Buren CT, Kahan BD: Post renal transplant MLR hyporesponders have fewer rejections and better graft survival than MLR hyper-responders. Presented at The International Congress of The Transplantation Society, Barcelona, Spain, August 1996.
203. **Kerman RH**, Susskind B, Slaton J, Lewis RM, Heydari A, Ruth J, Cavazos D, Williams J, Van Buren CT, Katz SM, Kahan BD: Improved graft survival in 100 retransplant recipients following AHG negative crossmatching. Presented at The International Congress of The Transplantation Society, Barcelona, Spain, August 1996.
204. **RH Kerman**, BM Susskind, CT Van Buren, SM Katz, and BD Kahan. MLR hypo vs hyper responders have fewer rejections and better graft survival. Presented at The American Society of Histocompatibility and Immunogenetics Annual Meeting, San Diego, CA., October 1996.
205. **RH Kerman**, BM Susskind, SM Katz, CT Van Buren, and BD Kahan. ELISA-detected anti-HLA antibodies in posttransplant renal allograft recipient sera correlate with chronic rejection.

Presented at The American Society of Histocompatibility and Immunogenetics Annual Meeting, San Diego, CA., October 1996.

206. **R. Kerman**, B. Susskind, S. Katz, C. Van Buren, OH. Frazier, B. Radovancevic, B. Kahan. Comparison of PRA-STAT, sHLA-EIA and AHG-% PRA to identify IgG anti-HLA antibodies in pretransplant sera of heart recipients: Correlation to rejection and posttransplant coronary artery disease. Presented at The American Society of Histocompatibility and Immunogenetics Annual Meeting, San Diego, CA., October 1996.
207. **RH Kerman**, BM Susskind, S. Katz, OH Frazier, B. Radovancevic, CT Van Buren, BD Kahan. PRA-STAT identifies high-risk, alloimmune recipients. Presented at The American Society of Histocompatibility and Immunogenetics Annual Meeting, San Diego, CA., October 1996.
208. B. Susskind, T. Martin, W Haddon, J Reveille, **RH Kerman** and BD Kahan. Validation of serologically equivalent DNA typing of HLA-B27 by PCR-SSP. Presented at The American Society of Histocompatibility and Immunogenetics Annual Meeting, San Diego, CA., October 1996.
209. B Susskind, T Martin, W Haddon, **R Kerman** and BD Kahan. Isolation of DNA from human serum suitable for PCR-SSP. Presented at The American Society of Histocompatibility and Immunogenetics Annual Meeting, San Diego, CA., October 1996.
210. B Susskind, T Martin, W Haddon, **R Kerman** and BD Kahan. Molecular HLA class II typing using serum derived from DNA. Presented at The American Society of Histocompatibility and Immunogenetics Annual Meeting, San Diego, CA., October 1996.
211. BM Susskind, **RH Kerman**, SM Katz, CT Van Buren and BD Kahan. Impact of donor age, sex and race (factors that reflect renal mass/nephron dose) on graft outcome: a single center study. Presented at The American Society of Histocompatibility and Immunogenetics Annual Meeting, San Diego, CA., October 1996.
212. **Kerman RH**, Susskind BM, Ruth J, Lam M, Katz SM, Van Buren CT, Kahan BD: Anti-HLA antibody determination by anti-globulin (AHG), Quickscreen (QS), or PRA-STAT: Comparative testing results and clinical correlation. Presented at the 16th Annual meeting of The American Society of Transplant Physicians, Chicago, Illinois, May 1997.
213. Susskind, B, **Kerman RH**, Gregory J, La T, Van Buren CT, Katz SM, Kahan BD: Comparison between complement-dependent cytotoxicity (CDC) and ELISA-based crossmatch (XM) methods for detection of IgG anti-donor antibodies. Presented at the 16th Annual Meeting of The American Society of Transplant Physicians, Chicago, Illinois, May 1997.
214. Susskind, B, Sica N, Tate K, Dang M, **Kerman RH**, and Kahan BD: Evaluation of mechanical device to facilitate washing of crossmatch trays. Presented at The American Society for Histocompatibility and Immunogenetics, Atlanta, Georgia, October 1997.
215. Susskind B, **Kerman RH**, Gregory J, Van Buren CT, Katz S and Kahan BD: Comparison of complement-dependent cytotoxicity and ELISA-based crossmatch methods. Presented at The American Society for Histocompatibility and Immunogenetics, Atlanta, Georgia, October 1997.
216. **Kerman RH**, Susskind B, Vaidya S, Ruth J, Lam M, Katz SM, Van Buren CT and Kahan BD: Anti-HLA antibody determination by antiglobulin (AHG, Quickscreen or PRA-STAT:

- Comparative testing results and Clinical correlation. Presented at The American Society for Histocompatibility and Immunogenetics, Atlanta, Georgia, October 1997.
217. **Kerman RH**, Susskind B, Katz S, Van Buren CT and Kahan BD: Immune evaluation parameters correlating with posttransplant hyporesponsiveness. Presented at The American Society for Histocompatibility and Immunogenetics, Atlanta, Georgia, October 1997.
218. **Kerman RH**, Susskind B, Ruth J, Katz S, Van Buren C, Kahan B. Can an immune, non-reactive (anti-HLA) recipient be transplanted without a donor-specific crossmatch? Presented at The 17th Annual Meeting of The American Society of Transplant Physicians, Chicago, Illinois, May 1998.
219. Susskind B, **Kerman R**, Nelson R, Gregory J, Ruth J, Bayat A, Tate K, Dang M, Sweeton J, Van Buren C, Katz S, Kahan B: Efficacy and clinical relevance of ELISA-based crossmatching (XM) relative to the complement dependent cytotoxicity (CDC) XM. Presented at The 17th Annual Meeting of The American Society of Transplant Physicians, Chicago, Illinois, May 1998.
220. Susskind B, **Kerman R**, Ruth J, Warnell S, Van Buren C, Katz S, Kahan B: Re-evaluation of the correlation between PRA-STAT reactivity and renal allograft outcome in light of extensive redefinition of the HLA antigen panel. Presented at The 17th Annual Meeting of The American Society of Transplant Physicians, Chicago, Illinois, May 1998.
221. **Kerman RH**, Susskind B, Katz S, Van Buren C, Kahan B: Impact of race, transfusions and pregnancy on renal allograft outcome in female recipients. Presented at The 17th Annual Meeting of The American Society of Transplant Physicians, Chicago, Illinois, May 1998.
222. Przybylowski P, Bologna M, Radovancevic B, Frazier OH, Susskind B, Van Buren C, Katz S, Kahan B, **Kerman R**: The role of flow cytometry detected IgG and IgM anti-donor antibodies in cardiac allograft recipients. Presented at The 24th Annual Meeting of The American Society of Transplant Surgeons, Chicago, Illinois, May 1998.
223. **Kerman RH**: Susskind B, Katz S, Van Buren C, Kahan B: Impact of race, transfusions and pregnancy on renal allograft outcome in female recipients. Presented at The 17th World Congress of The Transplantation Society, Montreal, Quebec, Canada, July 1998.
224. Przybylowski P, Bologna M, Radovancevic B, Frazier OH, Susskind B, Van Buren C, Katz S, Kahan B, **Kerman R**: The role of flow cytometry detected IgG and IgM anti-donor antibodies in cardiac allograft recipients. Presented at The 17th World Congress of The Transplantation Society, Montreal, Quebec, Canada, July 1998.
225. Clark J, **Kerman R**, Susskind B, Katz S, Van Buren C, Kahan B: Correlation of pretransplant allosensitization with severity of biopsy rejection. Presented at The 17th World Congress of The Transplantation Society, Montreal, Quebec, Canada, July 1998.
226. **Kerman RH**, Susskind B, Katz S, Van Buren CT, Kahan BD: Impact of race, transfusions and pregnancy on renal allograft outcome in female recipients Presented at The American Society for Histocompatibility and Immunogenetics Annual Meeting, Vancouver, Canada, October 1998.
227. **Kerman RH**, Przybylowski P, Bologna M, Radovancevic B, Frazier OH, Susskind B, Van Buren CT, Katz S, Kahan BD: The role of flow cytometry detected IgG and IgM anti-donor antibodies in cardiac allograft recipients. Presented at The American Society for Histocompatibility and Immunogenetics Annual Meeting, Vancouver, Canada October 1998.

228. Clark J, **Kerman R**, Susskind B, Katz S, Van Buren C, Kahan B: Correlation of pretransplant allosensitization with severity of biopsy rejection. Presented at The Americana Society for Histocompatibility and Immunogenetics Annual Meeting, Vancouver, Canada, October 1998.
229. **Kerman RH**, Susskind B, Ruth J, Katz S, Van Buren CT, Kahan BD: Can an immunologically, non-reactive potential allograft recipient be transplanted without a donor specific crossmatch? Presented at The American Society for Histocompatibility and Immunogenetics Annual Meeting, Vancouver, Canada, October 1998.
230. **Kerman RH**, Przybylowski P, Bologna M, Susskind B, Van Buren CT, Katz SM, Radovancevic B, Frazier OH and Kahan BD: The role of flow cytometry detected IgG and IgM anti-donor antibodies in cardiac allograft recipients” Presented at The International Society for Heart and Lung Transplantation, San Francisco, CA, April 1999.
231. **Kerman RH**, Susskind B, Buyse I, Pryzbylowski P, Ruth J, Warnell S, Dang M, Van Buren CT, Katz SM and Kahan BD: Flow cytometry detected IgG is not a contraindication to renal allotransplantation: The presence of IgM may be beneficial to outcome. Presented at The 18th Annual American Society of Transplantation, Chicago, Illinois, May 1999
232. Buyse IM, Warnell S, Rubinstein J, Kahan BD and **Kerman RH**: Cytokine genotyping in Caucasian and African-American renal allograft recipients. Presented at The 25th Annual Meeting of The American Society for Histocompatibility and Immunogenetics, New Orleans, LA., October 1999.
233. **Kerman RH**, Susskind B, Buyse I, Pryzbylowski P, Ruth J, Warnell S, Bayat A, Dang M, Van Buren CT, Katz SM, Gruber S, Kahan BD: Flow cytometry detected IgG is not a contraindication to renal allotransplantation: The presence of IgM may be beneficial to outcome. Presented at The 25th Annual Meeting of The American Society for Histocompatibility and Immunogenetics, New Orleans, LA., October 1999.
234. Buyse IM, Ruth J, Warnell S, Kahan BD, **Kerman RH**: HLA typing for solid organ transplantation: DNA vs serology? Presented at The 25th Annual Meeting of The American Society for Histocompatibility and Immunogenetics, New Orleans, LA., October 1999.
235. Gruber SA, Katz SM, Kaplan B, **Kerman RH**: Initial success of solitary pancreas transplants without regard to HLA mismatching. Presented at a course “Posttransplant Immunosuppression: New Paradigms”. The University of Minnesota Medical School, Department of Surgery, Minneapolis, MN., October 1999.
236. **Kerman RH**, Buyse IM, Warnell S, McKissick E, Garcia C, and Kahan BD. Cytokine genotyping in Caucasian and African-American renal allograft recipients. Presented at the Joint AST-ASTS Meeting, Transplant 2000, Chicago, Illinois, May 2000.
237. **Kerman RH**, Katz SM, Van Buren CT, and Kahan BD. Addition of Rapamycin to Cyclosporine-Prednisone based immunosuppression reduces the clinical risk of pretransplant anti-HLA allosensitization. Presented at the Joint AST-ASTS Meeting, Transplant 2000, Chicago, Illinois, May 2000.
238. **Kerman RH**, Katz SM, Van Buren CT, Ruth JA, McKissick E, Rasmussen S, Kahan BD. Serial postoperative immune monitoring of humoral allosensitization identifies immunologically high

- risk recipients. Presented at the Joint AST-ASTS Meeting, Transplant 2000, Chicago, Illinois, May 2000.
239. Gebel HM, Bray RA, Ruth JM, Zibari GB, McDonald JC, Kahan BD, **Kerman RH**: Flow PRA to detect clinically relevant HLA antibodies. Presented at the International Congress of the Transplantation Society, Rome Italy, August 2000.
240. **Kerman RH**, Katz SM, Van Buren CT, Ruth JM, McKissick E, Rasmussen S, Kahan BD: Posttransplant immune monitoring of anti-HLA antibody. Presented at the International Congress of the Transplantation Society, Rome Italy, August 2000.
241. **Kerman RH**, Katz SM, Van Buren CT, Garcia C, Kahan BD: Addition of rapamycin to cyclosporine-prednisone based immunosuppression reduces the clinical risk of pretransplant anti-HLA antibody. Presented at the International Congress of the Transplantation Society, Rome Italy, August 2000.
242. **Kerman RH**, Katz SM, Van Buren CT, Ruth JA, McKissick E, Rasmussen S, Kahan BD: Serial posttransplant immune monitoring of anti-HLA antibody. Presented at the 26th Annual Meeting of The American Society for Histocompatibility and Immunogenetics. Orlando Florida, October 2000.
243. **Kerman RH**, Radovancevic B, Przybylowski P, Thomas C, Frazier OH, Kahan BD: LVAD treated heart recipients do not have deleterious HLA antibody. Presented at the 26th Annual Meeting of The American Society for Histocompatibility and Immunogenetics. Orlando Florida, October 2000.
244. Gebel HM, Bray RA, Kahan BD, **Kerman RH**: Clinical relevance of pretransplant HLA antibodies detectable only by Flow PRA in renal allograft recipients. Presented at the 26th Annual Meeting of The American Society for Histocompatibility and Immunogenetics. Orlando Florida, October 2000.
245. Przybylowski P, Radovancevic B, Thomas C, Frazier OH, Garcia C, McKissick E, Rasmussen S, Kahan BD. **Kerman RH**: LVAD treated heart recipients do not have deleterious HLA antibody. Presented at The International Society for Heart and Lung Transplantation. Vancouver, Canada, April 2001.
246. **Kerman RH**, Gebel H, Garcia C, Rasmussen S, Garner S, Van Buren CT, Katz SM, Knight R, Kahan BD, Bray RA: Pretransplant HLA antibodies detected by Flow PRA in Rapamycin treated renal allograft recipients are a significant risk factor for rejection. Presented at the AST-ASTS Transplant 2001 Meeting. Chicago, IL., May 2001.
247. Przybylowski P, Gebel H, Bray RA, Radovancevic B, Frazier OH, Garcia C, Rasmussen S, Garner S, Kahan BD, **Kerman RH**: Flow PRA detected antibodies can identify relevant flow cytometric crossmatches among cardiac allograft recipients. Presented at the AST-ASTS Transplant 2001 Meeting. Chicago, IL., May 2001.
248. **Kerman RH**, Roberts L, Bray R, Gebel H, Gupta B, Kathuria P, Govearts T, Schram R, Medlock R: Accelerated rejection following a husband to wife transplant: A wife remembers. Presented at the American Society for Histocompatibility and Immunogenetics. San Francisco, CA., October 2001.

249. **Kerman RH**, Gebel H, Garcia C, Rasmussen S, Gibson H, Sahai R, Van Buren C, Katz S, Knight R, Kahan B, Bray R: Pretransplant HLA antibodies detected by flow PRA in Rapamycin treated renal allograft recipients are a significant risk factor for rejection. Presented at The American society for Histocompatibility and Immunogenetics, San Francisco, CA., October 2001.
250. Przybylowski P, Gebel H, Bray R, Radovancevic B, Frazier OH, Garcia C, Rasmussen S, Sahai R, Gibson H, Kahan BD and **Kerman RH**: Flow PRA detected antibodies can identify clinically relevant flow cytometric positive crossmatches among cardiac allograft recipients. Presented at The American Society for Histocompatibility and Immunogenetics, San Francisco, CA., October 2001.
251. **Kerman R.**, Gibson H., Van Buren CT, Garcia C, McKissick E, Olivarez C, Knight R, Katz S, Kahan BD: Donor mismatching, transplant and graft loss result in similar recipient sensitization not affecting retransplant graft survival. Presented at The American Transplant Congress, Washington, D.C., May 2002.
252. **Kerman RH**, Gebel H, Bray R, Garcia C, Gibson H, Radovancevic B, Knight R, Przybylowski P, Katz S, Van Buren CT, Kahan BD: HLA antibody and donor reactivity define patients at risk for rejection or graft loss. Presented at The American Transplant Congress, Washington, D.C., May 2002.
253. Katz S, Lappin J, Wood P, Ozaki C, Abrams J, Kahan BD and **Kerman RH**: Relevance of HLA antibodies to rejection and graft loss in liver recipients. Presented at The American Transplant Congress, Washington, D.C., May 2002.
254. Knight R, **Kerman R**, Zela S, Van Buren CT, Katz S, and Kahan BD: Induction Immunosuppression for pancreas transplantation utilizing thymoglobulin, sirolimus and reduced dose cyclosporine. Presented at The American Transplant Congress, Washington, D.C., May 2002.
255. Kerman RH, Gebel H, Bray R: HLA antibody and donor reactivity define patients at risk for rejection or graft loss. Presented at The International Congress of Histocompatibility and Immunogenetics, Seattle, Washington, May 2002.
256. Katz S, Lappin J, Wood P, Ozaki C, Abrams J, Kahan BD and **Kerman RH**: Relevance of HLA antibodies to rejection and graft loss in liver recipients. Presented at The International Congress of Histocompatibility and Immunogenetics, Seattle, Washington, May 2002.
257. **Kerman R.**, Gibson H., Van Buren CT, Garcia C, McKissick E, Olivarez C, Knight R, Katz S, Kahan BD: Donor mismatching, transplant and graft loss result in similar recipient sensitization not affecting retransplant graft survival. Presented at The International Congress of Histocompatibility and Immunogenetics, Seattle, Washington, May 2002.
258. Kerman **RH**, Katz SM, Lappin J, Ozaki C, Abrams J, Kahan BD, Wood P: Relevance of HLA antibodies to rejection and graft loss in liver recipients. Presented at The International Liver Transplantation Society, Chicago, IL., June 2002.

RONALD H. KERMAN, PH.D.

259. Katz S, Lappin J, Wood P, Ozaki C, Abrams J, Kahan BD and **Kerman RH**: Relevance of HLA antibodies to rejection and graft loss in liver recipients. Presented at The International Congress of The Transplantation Society, Miami, FLA., August 2002.
260. **Kerman RH**, Gebel H, Bray R, Garcia C, Gibson H, Radovancevic B, Knight R, Przybylowski P, Katz S, Van Buren CT, Kahan BD: HLA antibody and donor reactivity define patients at risk for rejection or graft loss. Presented at The International Congress of The Transplantation Society, Miami, FLA., August 2002.
261. **Kerman R.**, Gibson H., Van Buren CT, Garcia C, McKissick E, Olivarez C, Knight R, Katz S, Kahan BD: Donor mismatching, transplant and graft loss result in similar recipient sensitization not affecting retransplant graft survival. Presented at The International Congress of The Transplantation Society, Miami, FLA., August 2002.
262. Knight, R.J., **Kerman, R.H.**, Zela S., Podder H, Van Buren C.T., Katz, S.M., and Kahan, B.D.: Thymoglobulin, sirolimus and reduced dose cyclosporine provides excellent rejection prophylaxis for pancreas transplantation. Presented at the International Congress of The Transplantation Society, August 2002, Miami, FL.
263. **Kerman R.**, Gibson H., Van Buren CT, Garcia C, McKissick E, Olivarez C, Knight R, Katz S, Kahan BD: Donor mismatching, transplant and graft loss result in similar recipient sensitization not affecting retransplant graft survival. Presented at The Annual ASHI Meeting, Nashville, TN., October 2002.
264. **Kerman RH**, Gebel H, Bray R, Garcia C, Gibson H, Radovancevic B, Knight R, Przybylowski P, Katz S, Van Buren CT, Kahan BD: HLA antibody and donor reactivity define patients at risk for rejection or graft loss. Presented at The Annual ASHI Meeting, Nashville, TN., October 2002.
265. Katz S, Lappin J, Wood P, Ozaki C, Abrams J, Kahan BD and **Kerman RH**: Relevance of HLA antibodies to rejection and graft loss in liver recipients. Presented at The Annual ASHI Meeting, Nashville, TN., October 2002.
266. **Kerman RH**, Gibson H, Garcia C, McKissick E, Rasmussen S, Ballew C, Acorda N, Przybylowski P, Thomas C, Kahan BD, Radovancevic B: Cell mediated responsiveness of heart transplant recipients. Presented at the American Transplant Congress 2003, Washington, D.C., June 2003.
267. **Kerman RH**, Knight RJ, Gibson H, Garcia C, McKissick E, Rasmussen S, Ballew C, Acorda N, Katz SM, Van Buren CT, and Kahan BD: Choice of induction therapy for sirolimus treated renal recipients based upon immune risk factors. Presented at the American Transplant Congress 2003, Washington, D.C., June 2003.
268. **Kerman RH**, Gibson H, Garcia, C, McKissick E, Rasmussen S, Ballew C, Acorda, Katz SM, Knight RJ, Van Buren CT, and Kahan BD: A new assay to measure cell mediated responsiveness of renal allograft recipients: correlation to HLA AB. Presented at the American Transplant Congress 2003, Washington, D.C., June 2003.

269. **Kerman RH**, Knight RJ, Katz SM, Gibson H, Garcia C, McKissick E, Rasmussen S, Ballew C, Acorda N, Van Buren CT, and Kahan BD: Are HLA antibodies always associated with rejection? Presented at the American Transplant Congress 2003, Washington, D.C., June 2003.
270. **Kerman RH**, Knight RJ, Gibson H, McKissick E, Rasmussen S, Ballew C, Acorda N, Katz S, Van Buren CT, Kahan BD: Choice of induction therapy for Sirolimus treated renal recipients based upon immune risk factors. Presented at The Annual Meeting of The American Society for Histocompatibility and Immunogenetics. Miami, Florida. October 2003.
271. **Kerman RH**, Gibson H, McKissick E, Rasmussen S, Ballew C, Acorda N, Katz SM, Knight RJ, Van Buren CT, Kahan BD: A new assay to measure cell-mediated responsiveness of renal and heart allograft recipients. Presented at The Annual Meeting of The American Society for Histocompatibility and Immunogenetics. Miami, Florida, October 2003.
272. **Kerman RH**, Fernandez I, Podder H, Knight RJ, Katz SM, Van Buren CT, and Kahan BD: Clinical relevance of HLA antibody (specificity and titer) and donor specific flow cytometry crossmatches. Presented at the HLA and Transplantation Conference, Los Angeles CA., January 2004.
273. Przyblowski P, Radovancevic B, Frazier OH, Smart F, Acorda N, Juarez P, Nemeth LA, Kahan BD, **Kerman R**: The relevance of HLA antibody and donor specific FCXM to rejection and graft survival in cardiac allograft recipients. Presented at The International Society for Heart and Lung Transplantation. San Francisco, CA. April 2004.
274. **Kerman RH**, Fernandez I, Podder H, Knight RJ, Katz SM, Van Buren CT, Kahan BD: Clinical relevance of HLA antibody (specificity and titer) and donor specific FCXM in sirolimus-treated renal allograft recipients. Presented at the American Transplant Congress, Boston, MA., May 2004.
275. **Kerman RH**, Gibson H, Acorda N, Guidry N, Podder H, Knight RJ, Van Buren CT, Katz SM, Kahan BD: Clinical relevance of HLA antibodies before and after renal transplantation. Presented at the American Transplant Congress, Boston, MA., May 2004.
276. **Kerman R**, Przyblowski P, Radovancevic B, Frazier OH, Smart F, Acorda N, Juarez P, Nemeth LA, Kahan BD,: The relevance of HLA antibody and donor specific FCXM to rejection and graft survival in cardiac allograft recipients. Presented at the American Transplant Congress, Boston, MA., May 2004.
277. Knight R, Csapo Z, Benavides C, Schoenberg L, **Kerman R**, Podder H, Katz S, Van Buren C, Kahan B: Five-year follow-up after prednisone withdrawal using sirolimus-cyclosporine immunosuppression for renal transplantation. Presented at the American Transplant Congress, Boston MA., May 2004.
278. Ye Zhang, Robert Kirken, Lucrezia Furian, Slawa Janczewska, Ziumei Qu, Mouer, Wang, **Ronald Kerman**, Stanislaw Stepkowski. STAT5a/b transcription factors are important for T but not B cell functions during allograft rejection. American Transplant Congress, Boston, MA, May 2004

279. **Kerman RH**, Fernandez I, Podder H, Knight RJ, Katz SM, Van Buren CT, Kahan BD: Clinical relevance of HLA antibody (specificity and titer) and donor specific flow cytometry crossmatches in sirolimus-treated renal allograft recipients. Presented at The International Congress of The Transplantation Society, Vienna Austria, September 2004.
280. **Kerman RH**, Acorda N, Guidry N, Podder H, Knight RJ, Van Buren CT, Katz SM, Kahan BD: Clinical relevance of HLA antibodies before and after renal transplantation. Presented at The International Congress of The Transplantation Society, Vienna Austria, September 2004.
281. **Kerman R**, Radovancevic B, Frazier OH, Smart F, Acorda N, Juarez P, Nemeth LA, Kahan BD,: The relevance of HLA antibody and donor specific FCXM to rejection and graft survival in cardiac allograft recipients. Presented at The International Congress of The Transplantation Society, Vienna Austria, September 2004.
282. Knight R, **Kerman R**, Podder H, Katz S, Van Buren C and Kahan B: Graft survival and immune regulation of pancreas-kidney allograft recipients induced with thymoglobulin, sirolimus and cyclosporine. Presented at The International Congress of The Transplantation Society, Vienna Austria, September 2004.
283. Csapo Z, Knight R, Podder H, **Kerman R**, Katz S, Van Buren C, Kahan B: Transplantation of single pediatric donor kidneys into adult recipients. Presented at The International Congress of The Transplantation Society, Vienna Austria, September 2004.
284. Stepkowski S., Zhang Y., Janczewska S., Furian L., X. Qu, Wang M., Kerman R., Kirken R.: SOCS3, GATA-3 and c-Maf control function of th2-type regulatory cells in transplantation tolerance. Presented at The International Congress of The Transplantation Society, Vienna Austria, September 2004.
285. Stepkowski S., Zhang Y., Furian L., Janczewska S., X. Qu, Wang M., **Kerman R.**, Kirken R.: STAT5a/b control survival of t cells by regulating the function of pro- and anti-apoptotic genes during allograft rejection. Presented at The International Congress of The Transplantation Society, Vienna Austria, September 2004.
286. Knight R, Csapo Z, Benavides-Viveros C, Schoenberg L, **Kerman R**, Podder H, Katz S, Van Buren C, and Kahan B: Long-term follow-up after prednisone withdrawal using sirolimus-cyclosporine immunosuppression for renal transplantation. Presented at The International Congress of The Transplantation Society, Vienna Austria, September 2004.
287. **Kerman RH**, Fernandez I, Podder H, Knight RJ, Katz SM, Van Buren CT, Kahan BD: Clinical relevance of HLA antibody (specificity and titer) and donor specific flow cytometry crossmatches in sirolimus-treated renal allograft recipients. Presented at The American Society for Histocompatibility and Immunogenetics Annual Meeting, San Antonio, Texas. October 2004.
288. **Kerman RH**, Acorda N, Guidry N, Podder H, Knight RJ, Van Buren CT, Katz SM, Kahan BD: Clinical relevance of HLA antibodies before and after renal transplantation. Presented at The American Society for Histocompatibility and Immunogenetics Annual Meeting, San Antonio, Texas. October 2004.
289. **Kerman R**, Przyblowski P, Radovancevic B, Frazier OH, Smart F, Acorda N, Juarez P, Nemeth LA, Kahan BD,: The relevance of HLA antibody and donor specific FCXM to rejection and graft survival in cardiac allograft recipients. Presented at The American Society for Histocompatibility and Immunogenetics Annual Meeting, San Antonio, Texas. October 2004.

290. Knight RJ, **Kerman RH**, Schoenberg L., Podder, H., Katz SM, Van Buren CT, Kahan BD. Two year outcomes of thymoglobulin versus basiliximab induction combined with sirolimus and reduced dose cyclosporine (CsA) for high versus low risk immune responder renal transplant recipients. Presented at The American Transplant Congress, Seattle Washington, May 2005.
291. Qu X, Zhang Y, Furian L., Janczewska S, **Kerman R**, Stepkowski S.: Stat 5 a/b transcription factors are critical for stable transplantation tolerance. Presented at The American Transplant Congress, Seattle Washington, May 2005.
292. Qi Y, Qu X, Feng Z, Kirken R, **Kerman R**, Stepkowski S. Both IL-10 producing CD4+ CD25+ T cells and CD4+ T helper 2 cells regulate transplantation tolerance. Presented at The American Transplant Congress, Seattle Washington, May 2005.
293. **Kerman R**, Stepkowski S, Knight RJ, Katz SM, Van Buren CT, Roberts L, McKissick E, Young E, Guidry N, Acorda N, Podder H, Kahan BD. Soluble CD30 as an immune risk factor for renal allograft rejection and loss. Presented at The American Transplant Congress, Seattle Washington, May 2005.
294. Qi Y. Qu X. Zhang Y, Feng Z, Kirken RA, Wang ME, **Kerman R**, Stepkowski SM. Stat6-dependent Th2 regulatory cells contribute to tolerance and are controlled by SOCS3, GATA3 and C-Maf but not Foxp3. American Transplant Congress, Seattle, WA, May 2005
295. Podder H, **Kerman R**, Katz SM, Knight R, Van Buren CT, Acorda N, Kahan BD. Successful therapy of antibody mediated rejection. Presented at The European Society of Transplantation, Geneva Switzerland, October 2005.
296. Knight RJ, **Kerman R**, McKissick E, Lawless A, Podder H, Katz SM, Van Buren CT, Kahan BD. Immunosuppression minimization after kidney pancreas transplantation (SPK) utilizing Thymoglobulin induction and Sirolimus maintenance therapy. Presented at The American Transplant Congress, Seattle, WA, May 2005.
297. Qu X, Qi Y, Zhang Y, Kirken R, Furian L, Wang M, **Kerman R**, Stepkowski S. Stat5alb but not Stat4 or Stat6 transcription factors are critical for CO4 + CO25+ function in transplantation. Presented at The American Transplant Congress, Seattle, WA, May 2005.
298. **Kerman R**, Stepkowski S, Knight R, Katz SM, Mckissick E, Young E, Acorda N, Hosek K, Baron V, Boatwright M, Hoover A, Tu T, Van Buren CT, Kahan BD. Immunological identification of high-risk re-transplant recipients. Presented at The American Transplant Congress. Seattle, WA, May 2005
299. Qi Y, Qu X, Zhang, Y, Zehuni F, Kirken R, Wang M, **Kerman R**, Stepkowski S. Interleukin (IL) 4-Stat6 driven T-helper12 pro-tolerogenic environment is controlled by SOCS3, GATA3 and C-Maf. Presented at The American Transplant Congress, Seattle, WA, May 2005.
300. **Kerman R**, McKissick E, Acorda N, Young E, Guidry N, Stepkowski S, Kahan BD, Smith D, Nemeth L, Radovancevic R, Radovancevic B. The lack of clinical correlation in measuring cell mediated responsiveness in heart transplant recipients. Presented at The American Society for Histocompatibility and Immunogenetics. Washington D.C. October 2005.

301. Roberts L, **Kerman R**. Automation for molecular typing provides process efficiencies for the small to medium size HLA laboratory. Presented at The American Society for Histocompatibility and Immunogenetics. Washington D.C. October 2005.
302. Knight RJ, **Kerman R**, McKissick E, Lawless A, Podder H, Katz SM, Van Buren CT, Kahan BD. Immunosuppression minimization after kidney pancreas transplantation (SPK) utilizing Thymoglobulin induction and Sirolimus maintenance therapy. Presented at The World Transplant Congress, Boston, MA, July 2006.
303. Qu X, Qi Y, Zhang Y, Kirken R, Furian L, Wang M, **Kerman R**, Stepkowski S. Stat5alb but not Stat4 or Stat6 transcription factors are critical for CO4 + CO25+ function in transplantation. Presented at The World Transplant Congress, Boston, MA July 2006.
304. **Kerman R**, Stepkowski S, Knight R, Katz SM, Mckissick E, Young E, Acorda N, Hosek K, Baron V, Boatwright M, Hoover A, T. Tu, Van Buren CT, Kahan BD. Immunological identification of high-risk re-transplant recipients. Presented at The World Transplant Congress, Boston, MA July 2006.
305. Qi Y, Qu X, Zhang Y, Zehuni F, Kirken R, Wang M, **Kerman R**, Stepkowski S. Interleukin (IL) 4-Stat6 driven T-hilper12 pro-tolerogenic environment is controlled by SOCS3, GATA3 and C-Maf. Presented at The World Transplant Congress, Boston, MA, July 2006.
306. Qi Y, Qu X, Zhang Y, Feng Z, Kirken R, Mouer, Wang, **Kerman R**, Stepkowski S. Both IL10-producing CD4+ CD25+ and CD4+ T helper 2 cells regulate transplantation tolerance. Presented at The World Transplant Congress, Boston, MA, July 2006.
307. Qi Y, Qu X, Zhang Y, Feng Z, Kirken R, Mouer, Wang, **Kerman R**, Stepkowski S. TGF- β SWITCH CD4+CD25- INTO CD4+CD25+Foxp3+ REGULATORY NETWORK. Presented at The World Transplant Congress, Boston, MA, July 2006.
308. Qi Y, Qu X, Zhang Y, Feng Z, Kirken R, Mouer, Wang, **Kerman R**, Stepkowski S. Stat6-dependent Th2 regulatory cells are controlled by SOCS3, GATA-3 and c-maf but Foxp3. Presented at The World Transplant Congress, Boston, MA, July 2006.
309. Qi Y, Qu X, Zhang Y, Feng Z, Kirken R, Mouer, Wang, **Kerman R**, Stepkowski S. STAT6-DRIVEN Th2 ENVIRONMENT PROMOTES GENERATION OF IL10-PRODUCING CD4+CD25+Foxp3+ REGULATORY (Tr1) CELLS. Presented at The World Transplant Congress, Boston, MA, July 2006.
310. Qu X, Zhang Y, Feng Z, Qi Y, Kirken R, Furian L, Janczewska S, Mouer, Wang, **Kerman R**, Stepkowski S. STAT5a/b TRANSCRIPTION FACTORS ARE CRITICAL FOR STABLE TRANSPLANTATION TOLERANCE. Presented at The World Transplant Congress, Boston, MA, July 2006.
311. **Kerman RH**, Stpekowski S, Knight R, Katz S, McKissick E, Young E, Acorda N, Hosek K, Baron V, Hoover A, Tu T, Van Buren CT, Kahan B. Clinical relevance of crossmatch results, HLA, non-HLA antibodies for renal allograft recipients. Presented at The Annual Meeting of The American Society for Histocompatibility and Immunogenetics. San Diego, CA, October 2006.

RONALD H. KERMAN, PH.D.

312. **Kerman R**, Stepkowski S, Knight R, Van Buren CT, Roberts L, Boody P, McKissick E, Young E, Guidry N, Acorda N, Podder H, Kahan BD. Soluble CD30 as an immune risk factor for renal allograft loss. Presented at The Annual Meeting of The American Society for Histocompatibility and Immunogenetics. San Diego, CA, October 2006.
313. **Kerman R**, Stepkowski S, Knight R, Katz S, McKissick E, Young E, Acorda N, Hosek K, Baron V, Hoover A, Tu T, Van Buren CT, Kahan BD. Deceased suppression activity displayed by immunologically high risk African American and highly sensitized renal allograft recipients. Presented at The Annual Meeting of The American Society for Histocompatibility and Immunogenetics. San Diego, CA, October 2006.
314. **Kerman R**, Stepkowski S, Hoover A, Tu T, Hosek K, Baron V, Reverdin S, Varughese E, Radovancevic R, Frazier O, Radovancevic B. Clinical relevance of crossmatch results, HLA and non-HLA antibodies for cardiac allograft recipients. Presented at The International Society for Heart and Lung Transplantation. San Francisco, CA, April 2007.
315. Reverdin S, Vaurughese E, Radovancevic R, Hoover K, Tu T, Hosek K, Victor B, Stepkowski S, Radovancevic B, Frazier O, **Kerman R**. Impact of pre-transplant statin treatment on sensitization and crossmatch results of cardiac allograft recipients. Presented at The International Society for Heart and Lung Transplantation. San Francisco, CA, April 2007.
316. **Kerman R**, Stepkowski S, Podder H, Knight R, Katz s, McKissick E, Acorda N, Hosek K, Baron V, Hoover A, Tu T, Van Buren CT, Kahan B. Effect of pre and/or post transplant statin therapy on HLA antibody, rejections and graft survivals of renal allograft recipients. Presented at The American Transplant Congress. San Francisco, CA, May 2007.
317. **Kerman R**, Stepkowski S, Hoover A, Tu T, Hosek K, Baron V, Reverdin S, Varughese E, Radovancevic R, Frazier O, Radovancevic B. Clinical relevance of crossmatch results, HLA and non-HLA antibodies for cardiac allograft recipients. Presented at The American Transplant Congress. San Francisco, CA, April 2007.
318. Reverdin S, Vaurughese E, Radovancevic R, Hoover K, Tu T, Hosek K, Victor B, Stepkowski S, Radovancevic B, Frazier O, **Kerman R**. Impact of pre-transplant statin treatment on sensitization and crossmatch results of cardiac allograft recipients. Presented at The American Transplant Congress. San Francisco, CA, April 2007.
319. **Kerman R**, Stepkowski S, Podder H, Knight R, Katz S, McKissick E, Acorda N, Hosek K, Baron V, Hoover A, Tu T, Van Buren CT, Kahan B. Successful renal transplantation of recipients with low-titer, donor-specific HLA antibody and a negative flow cytometry crossmatches. Presented at The American Transplant Congress. San Francisco, CA, April 2007.

D. PEER REVIEWED ARTICLES

1. **Kerman, R.**, Segre, D. and Myers, W.L.: Altered response to pneumococcal polysaccharide in offspring of immunologically paralyzed mice. *Science* 156:1514, 1967.
2. **Kerman, R.**, Segre, D. and Myers, W.L.: The role of immune and natural specific antibodies in immunologic paralysis and immunity of mice to pneumococcal polysaccharide Type III. *J. Immunol.* 104:655,1970.
3. **Kerman, R.** and Segre, D.: Anti-pneumococcal polysaccharide Type III hemolytic plaques in

- mice: Cellular response in immunity and immunologic paralysis. *J. Immunol.* 104:1262, 1970.
4. **Kerman, R.** and Harris, T.N.: Resistance to denaturation by periodate of a dialyzable histocompatibility antigen. *Proc. Soc. Exp. Biol. Med.* 141:179-183, 1972.
 5. **Kerman, R.H.**, Harris T.N. and Harris, S.: Preparation of a dialyzable histocompatibility antigen from Balb/c mice. *Proc. Natl. Acad. Sci.* 69:223-227, 1972.
 6. Smith, R.A., **Kerman, R.**, Ezdinli, E. and Stefani, S.: A modified assay for the detection of human adult active rosette forming cells. *J. Immunol. Meth.* 8:175-184, 1975.
 7. Stefani, S., **Kerman, R.** and Abbate, J.: Immune evaluation of lung cancer patients undergoing radiation therapy. *Cancer* 37:2792-2796, 1976.
 8. Stefani, S., **Kerman, R.** and Abbate, J.: Serial studies of immunocompetence of patients undergoing radiotherapy for malignancies of the head and neck. *Am. J. Roentgenol.* 126:880-886, 1976.
 9. **Kerman, R.H.** and Geis, W.P.: Total and active T-cell kinetics in renal allograft recipients. *Surgery* 79:398-407, 1976.
 10. **Kerman, R.**, Smith, R., Stefani, S. and Ezdinli, E.: Active T-rosette forming cells in the peripheral blood of cancer patients. *Cancer Res.* 36:3274-3278, 1976.
 11. **Kerman, R.**, Smith, R., Ezdinli, E. and Stefani, S.: Unification and technical aspects of total T, active T and B lymphocyte rosette assays. *Immunol. Comm.* 5(7-8):685-694, 1976.
 12. Dodson, M.G., **Kerman, R.H.**, Lange, C.F., Stefani, S. and O'Leary, J.A.: T and B cells in pregnancy. *Obstet. Gynecol.* 49:299-302, 1977.
 13. Marshack, M., Toto, P. and **Kerman, R.H.**: Delayed hypersensitivity in the hamster cheek pouch. *J. Immunol. Meth.* 15:325-330, 1977.
 14. Stefani, S. and **Kerman, R.H.**: Lymphocyte response to PHA before and after radiation therapy in patients with carcinomas of the head and neck. *J. Laryngol. Otol.* 91:605-609, 1977.
 15. **Kerman, R.H.**, Ing, T.S., Hano, J.E. and Geis, W.P.: Prognostic significance of the active T-RFC in renal allograft survival. *Surgery* 82:607-612, 1977.
 16. **Kerman, R.H.** and Stefani, S.: PHA stimulation of lymphocytes from patients with lung cancer. *Oncology* 34:10-12, 1977.
 17. Marshack, M., Toto, P. and **Kerman, R.H.**: Immunotherapy of chemically- induced tumors in the hamster cheek pouch with dinitrochlorobenzene. *J. Dental Res.* 57:625-630, 1978.
 18. Geis, W.P., Iwatsuki, S., Molnar, Z., Giacchino, J.L., **Kerman, R.H.**, Ing, T.S. and Hano, J.E.: Immunoblastic pseudo-lymphoma in renal allograft recipients. *Arch. Surg.* 113:461-466, 1978.
 19. Dodson, M., Klegerman, M., **Kerman, R.H.**, Lange, C., Tessler, J. and O'Leary, J.: Bechet

- syndrome: With immunologic evaluation. *Obstet. Gynecol.* 51:621-625, 1978.
20. Dodson, M.G., Klegerman, M.E., Menon, M., **Kerman, R.H.**, Lange, C.F. and O'Leary, J.A.: Establishment and characterization of a squamous cell carcinoma of the vulva in tissue culture and immunological evaluation of the host. *Am. J. Obstet. Gynecol.* 131:606-619, 1978.
 21. **Kerman, R.H.** and Geis, W.P.: T-RFC monitoring of CMI events in renal allograft recipients. *Transplant. Proc.* 10:633-635, 1978.
 22. **Kerman, R.H.**, Ing, T.S., Hano, J.E. and Geis, W.P.: Predictive value of active T-RFC in renal allograft survival. *Transplant. Proc.* 10:637-638, 1978.
 23. Kahan, B.D., **Kerman, R.H.**, and McConnell, R.: Combination of immunological and radionuclide techniques to diagnose rejection. *Surg. Forum* 29:364-366, 1978.
 24. **Kerman, R.H.** and Stefani, S.S.: Effect of BCG immunotherapy on the active T and total T-RFC in patients with lung cancer. *Cancer Immunol. Immunother.* 4:41-47, 1978.
 25. Kahan, B.D., Floyd, M., Oka, T., Van Buren, C.T. and **Kerman, R.H.**: Immunological techniques in clinical renal transplantation. I. Cross-Match Methods, *Jap. J. Transplant.* 14:1-13, 1979.
 26. Kahan, B.D., Floyd, M., Oka, T., Van Buren, C.T. and **Kerman, R.H.**: Immunological techniques in clinical renal transplantation. II. Immunological Monitoring Post-allografting. *Jap. J. Transplant.* 14:14-25, 1979.
 27. **Kerman, R.H.**, Floyd, M., Conner, W., McConnell, R., McConnell, B.J., Van Buren, C.T. and Kahan, B.D.: Combined immunological and radionuclide techniques to monitor renal allograft rejection. *Transplant. Proc.* 11:1229-1231, 1979.
 28. Geis, W.P., Giacchino, J.L., Buckingham, J.M., Bansal, V.K., Iwatsuki, S., **Kerman, R.H.**, Ing, T.S. and Hano, J.E.: Does suppression of T-RFC determine in vivo immunosuppressive effect of ATG? *Transplant. Proc.* 11:1433-1434, 1979.
 29. **Kerman, R.H.**, Floyd, M., Van Buren, C.T. and Kahan, B.D.: Improved allograft survival of strong immune responder-high risk recipients with adjuvant ATG therapy. *Transplantation* 30:450-454, 1980.
 30. **Kerman, R.H.**, Floyd, M., Van Buren, C.T. and Kahan, B.D.: Prolonged allograft survival of strong pretransplant immune responders treated with ATG. *Transplant. Proc.* 13:332-335, 1981.
 31. **Kerman, R.H.**, Floyd, M., Van Buren, C.T. and Kahan, B.D.: Correlation of non-specific immune monitoring with rejection or impaired function of renal allografts. *Transplantation* 32:16-23, 1981.
 32. **Kerman, R.H.**, Floyd, M., Van Buren, C.T., and Kahan, B.D.: Prediction of cadaveric allograft survival based on pretransplant nonspecific immunocompetence. *Transplant. Proc.* 13:1533-1535, 1981.
 33. **Kerman, R.H.**, Floyd, M., Van Buren, C.T. and Kahan, B.D.: Serial measurement of nonspecific immune parameters of chronically hemodialyzed renal failure patients. *J. Clin. Immunol.* 1:163-

168, 1981.

34. **Kerman, R.H.**, Van Buren, C., Payne, W., Flechner, S., Agostino, G., Conley, S., Brewer, E. and Kahan, B.D.: Influence of blood transfusions on immune responsiveness. *Transplant. Proc.* 14:335-337, 1982.
35. Kahan, B.D., Van Buren, C.T., Lin, S.N., Ono, Y., Agostino, G., LeGrue, S., Boileau, M., Payne, W. and **Kerman, R.H.**: Immunopharmacologic monitoring of Cyclosporin A-treated recipients of cadaveric kidney allografts. *Transplantation* 34:36-45, 1982.
36. Ono, Y., **Kerman, R.H.** and Kahan, B.D.: Natural cell-mediated cytotoxicity and suppressor activity for natural cell-mediated cytotoxicity in long-term renal transplant patients. *Transplantation* 34:103-107, 1982.
37. Van Buren, C.T., **Kerman, R.H.**, Agostino, G., Payne, W., Flechner, S. and Kahan, B.D.: The cellular target of Cyclosporin A action in man. *Surgery* 92:167-174, 1982.
38. Agostino, G.J., Kahan, B.D. and **Kerman, R.H.**: Suppression of mixed leucocyte culture using leucocytes from normal individuals, uremic individuals and allograft recipients. *Transplantation* 34:367-371, 1982.
39. Ettenger, R.B., **Kerman, R.**, Jordan, S.C., Warshaw, B.L., Harris, R. and Fine, R.: Sensitization following donor-specific transfusions for living related renal transplantation. *Transplant. Proc.* 15:943-945, 1983.
40. Van Buren, C.T., **Kerman, R.H.**, Agostino, G., Flechner, S., Payne, W., and Kahan, B.D.: Effect of cyclosporine on immunoregulatory cells of renal allograft recipients. *Transplant. Proc.* 15:527-530, 1983.
41. Agostino, G., Kahan, B.D. and **Kerman, R.**: Detection of nonspecific suppressor cells from normal individuals, uremic patients and allograft recipients. *Transplant. Proc.* 15:724-728, 1983.
42. **Kerman, R.H.**, Van Buren, C.T., Payne, W., Flechner, S. and Kahan, B.D.: Monitoring T cell subsets and immune events in renal allograft recipients. *Transplant. Proc.* 15:1170-1172, 1983.
43. **Kerman, R.H.**, Agostino, G., Van Buren, C.T., Payne, W., Flechner, S., Conley, S., Brewer, S. and Kahan, B.D.: Effect of blood transfusions on graft survival and immune responsiveness. *Transplant. Proc.* 15:1022-1025, 1983.
44. Flechner, S., **Kerman, R.**, Van Buren, C.T., Payne, W., and Kahan, B.D.: The use of cyclosporine and prednisone for high MLC haploidentical living related renal transplants. *Transplant. Proc.* 15:442-445, 1983.
45. **Kerman, R.H.**, Van Buren, C.T., Payne, W., Flechner, S., Agostino, G., Conley, S., Brewer, E., and Kahan, B.D.: The influence of pretransplant blood transfusions from random donors on immune parameters affecting cadaveric allograft survival. *Transplantation* 36:50-54, 1983.
46. **Kerman, R.H.**, Flechner S., Van Buren, C.T., Payne, W., and Kahan, B.D.: Cyclosporine improves allograft survival in immunologically high risk renal allograft recipients. *Transplant. Proc.* 15:1909-1911, 1983.

47. **Kerman, R.H.**, Van Buren, C.T., Payne, W., Flechner, S., and Kahan, B.D.: Immune monitoring of patients treated with cyclosporine or azathioprine using donor-specific and nonspecific assays as well as monoclonal T cell reagents. *Transplant. Proc.* 15:1971-1973, 1983.
48. **Kerman, R.H.**, Payne, W., Van Buren, C.T., Flechner, S., and Kahan, B.D.: Detection of host presensitization to donor alloantigens utilizing a comprehensive immune crossmatch. *Transplant. Proc.* 15:1815-1816, 1983.
49. Verani, R.R., Bergman, D., and **Kerman, R.H.**: Glomerulopathy in acute and chronic rejection: Ultrastructural characteristics and relationship to graft survival. *Am. J. Nephrology* 3:253-256, 1983.
50. Flechner, S.M., Payne, W.D., Van Buren, C., **Kerman, R.**, and Kahan, B.D.: The effect of cyclosporine on early graft function. *Transplantation* 36:268-272, 1983.
51. Van Buren, C., **Kerman, R.**, Agostino, G., Flechner, S., Payne, W.D, and Kahan, B.: Effect of cyclosporine on immunoregulatory cells of renal allograft recipients. *Transplant. Proc.* 15:2293-2297, 1983.
52. Kahan, B.D., Van Buren, C., Flechner, S., Payne, W.D, and **Kerman, R.**: Cyclosporine immunosuppression mitigates immunologic risk factors in renal allotransplantation. *Transplant. Proc.* 15:2469-2478, 1983.
53. Flechner, S.M., Van Buren, C., **Kerman, R.H.**, and Kahan, B.D.: The nephrotoxicity of cyclosporine in renal transplantation. *Transplant. Proc.* 15:2689-2694, 1983.
54. Flechner, S.M., Van Buren, C.T., **Kerman, R.**, and Kahan, B.D.: The effect of conversion from cyclosporine to azathioprine immunosuppression for intractable nephrotoxicity. *Transplant. Proc.* 15:2869-2873, 1983.
55. **Kerman, R.H.**, Flechner, S., Van Buren, C.T., Payne, W. and Kahan, B.D.: Immunological monitoring of renal allograft recipients treated with cyclosporine. *Transplant. Proc.* 15:2302-2305, 1983.
56. **Kerman, R.H.**, Van Buren, C.T., Flechner, S.M., and Kahan, B.D.: Correlation of visual, ⁵¹Cr-release and flow cytometry crossmatch results to graft survival. *Transplant Proc.* 16:1430-1433, 1984.
57. Flechner, S.M., **Kerman, R.H.**, Van Buren, C., and Kahan, B.D.: Successful transplantation of cyclosporine-treated haploidentical living-related renal recipients without blood transfusions. *Transplantation* 37:73-76, 1984.
58. Rogers, A.J., **Kerman, R.H.**, and Kahan, B.D.: The pharmacokinetic and immunobiological activity of cyclosporine in man. *Transplant. Proc.* 16:1634-1636, 1984.
59. Van Buren, C.T., Flechner, S.M., **Kerman, R.H.**, Vaughn, W., and Kahan, B.D.: Cyclosporine improves outcome in high risk cadaveric renal allograft recipients. *Transplant. Proc.* 16:1162-1166, 1984.
60. Kahan, B.D., Van Buren, C.T., Flechner, S.M., Jarowenko, M., and **Kerman, R.H.**: Cyclosporine:

A revolution in renal transplantation. *Nefrologia Mexicana* 5:65-81, 1984.

61. Flechner, S.M., **Kerman, R.H.**, Van Buren, C.T., Epps, L., and Kahan, B.D.: The use of cyclosporine in living related renal transplantation: Donor specific hyporesponsiveness and steroid withdrawal. *Transplantation* 38:685-691, 1984.
62. Rogers, A.J., Yoshimura, N., **Kerman, R.H.**, and Kahan, B.D.: Immunopharmacodynamic evaluation of cyclosporine-treated renal allograft recipients. *Transplantation* 38:657-664, 1984.
63. Rogers, A.J., **Kerman, R.H.**, and Kahan, B.D.: Pharmacodynamic analyses of cyclosporine-treated renal allotransplant recipients. *Surg. Forum* 35:380-382, 1984.
64. **Kerman, R.H.**, Manner, C., Ford, K., and Hoots, K.: Comprehensive immune evaluation of 78 hemophiliacs. *Ann. N.Y. Acad. Sc.* 437:540-543, 1984.
65. Sterling, R.P., Bradley, B.B., Khalil, K.T., **Kerman, R.H.**, and Conklin, R.H.: Comparison of biopsy proven pneumocystis carinii pneumonia in acquired immune deficiency patients and renal allograft recipients. *Ann. Thoracic Surg.* 38:494-499, 1984.
66. Maddox, A-M., Kahan, B.D., Tucker, S., **Kerman, R.**, and Jordan, R.: Remission in the skin infiltrate of a patient with mycosis fungoides treated with cyclosporine. *J. Am. Acad. Dermatol.* 12 (Part 2):952-956, 1985.
67. Flechner, S.M., Van Buren, C.T., Jarowenko, M., **Kerman, R.H.**, and Kahan, B.D.: The fate of patients converted from cyclosporine to azathioprine to improve renal function. *Transplant. Proc.* 17:1227-1230, 1985.
68. Flechner, S.M., **Kerman, R.**, Epps, L., Van Buren, C.T., and Kahan, B.D.: MLC hyporesponsiveness as a marker for steroid withdrawal in CsA-treated living related renal recipients. *Transplant. Proc.* 17:1260-1264, 1985.
69. **Kerman, R.H.**, Van Buren, C.T., Flechner, S.M., and Kahan, B.D.: DRw6 phenotype, immune responder status and renal allograft outcome. *Transplant. Proc.* 17:44-46, 1985.
70. **Kerman, R.H.**, Van Buren, C.T., Flechner, S.M., Lorber, M., and Kahan, B.D.: Successful transplantation of cyclosporine treated allograft recipients with serologically positive historical but negative preoperative donor crossmatches. *Transplantation* 40:615-619, 1985.
71. Flechner, S.M., Van Buren, C.T., Conley, S.B., Rose, G., **Kerman, R.H.**, and Kahan, B.D.: The impact of cyclosporine on renal function and growth in pediatric renal transplant recipients. *Transplant. Proc.* 17:1284-1288, 1985.
72. Flechner, S.M., Lorber, M., Van Buren, C.T., **Kerman, R.**, and Kahan, B.D.: The case against conversion to azathioprine in cyclosporine-treated renal recipients. *Transplant. Proc.* 17:276-281, 1985.
73. Lorber, M.I., Flechner, S.M., Van Buren, C.T., **Kerman, R.H.**, and Kahan, B.D.: Cyclosporine, azathioprine and prednisone as treatment for cyclosporine-induced nephrotoxicity in renal transplant recipients. *Trnasplant. Proc.* 17:282-285, 1985.
74. Weiland, A.P., Daskal, Y., **Kerman, R.H.**, Smalling, R.W., Williams, J.P., and Walker, W.E.:

- Aids prodrome in an apparently normal man following coronary artery bypass: new significance of postoperative bleeding. *J. Texas Heart Institute* 12:195-197, 1985.
75. Kahan, B.D., Van Buren, C.T., Lorber, M.I., Flechner, S.M., Wideman, C.A., and **Kerman, R.H.**: Optimization of cyclosporine immunosuppression for renal transplantation. *Transplant. Proc.* 17(Suppl. 2):35-43, 1985.
76. Flechner, S.M., Van Buren, C.T., Lorber, M., **Kerman, R.H.**, Wideman, C., and Kahan, B.D.: Does cyclosporine influence results of cadaver retransplantation? *Human Immunol.* 14:305-313, 1985.
77. **Kerman, R.H.**, Van Buren, C.T., Flechner, S.M., Lorber, M., and Kahan, B.D.: The beneficial effect of cyclosporine on renal transplantation at a single U.S. transplant center. *Transplant. Proc.* 17:2193-2195, 1986.
78. Appel, S.H., Stockton-Appel, V., Stewart, S.S., and **Kerman, R.H.**: Amyotrophic lateral sclerosis: Associated clinical disorders and immunological evaluations. *Arch. Neurol.* 43:234-238, 1986.
79. Jarowenko, M., Pifer, L., **Kerman, R.**, and Kahan, B.D.: Serologic methods for the early diagnosis of pneumocystis carinii infection in renal allograft recipients. *Transplantation* 41:436-442, 1986.
80. Flechner, S.M., Van Buren, C.T., **Kerman, R.H.**, Lorber, M.I., Barker, C.J., Golden, D.L., and Kahan, B.D.: Long-term results in cyclosporine therapy in recipients of mismatched living related kidneys. *Transplant. Proc.* 18(No. 2, Suppl. 1):44-49, 1986.
81. Flechner, S.M., Barker, C., and **Kerman, R.H.**: Donor specific MLC hyporesponsiveness is associated with decreased in-vitro cytotoxicity in cyclosporine and prednisone treated haplodidentical LRD renal recipients. *Transplant. Proc.* 18:750-753, 1986.
82. **Kerman, R.H.**, Van Buren, C.T., Flechner, S.M., Lorber, M., and Kahan, B.D.: Successful renal allograft survival for cyclosporine treated recipients displaying positive historical crossmatches. *Transplant. Proc.* 18:680-682, 1986.
83. Wiseman, C., Rao, V.S., Bakke, A., **Kerman, R.**, Bouzaglou, A., Presant, C., McKenna, R.J., Smith, J.D. and Sakulsky, S.B.: Increased T-helper lymphocytes following active specific intralymphatic immunotherapy of cancer. *Jrnl. Biological Response Modifiers* 5:490-497, 1986.
84. Flechner, S.M., Conley, S.B., Rose, G., Van Buren, C., **Kerman, R.**, Lorber, M., and Kahan, B.D.: Cyclosporine and prednisone immunosuppression in pediatric recipients of renal allografts. In Wolfe, E.D., and Provoost A.P. (eds.): *Ciclosporin in pediatric renal transplantation*. Series 4, pp 95-104. Foris Publ., Dordrecht-Holland Providence-USA, 1986.
85. Kahan, B.D., Yoshimura, N., Pellis, N.R., Burstain, T., Van Buren, C.T., Leinikki, P., Schreiber, R.D., Roesel, T.R., and **Kerman, R.H.**: Pharmacodynamic assays of the immunosuppressive action of cyclosporine therapy in transplant recipients. *Transplant Proc.*, 18 (Suppl 5):238-251, 1986.

86. Kahan, B.D., Mickey, R., Flechner, S.M., Lorber, M.I., Wideman, C.A., **Kerman, R.H.**, Terasaki, P., and Van Buren, C.T.: Multivariant analysis of risk factors impacting on immediate and eventual cadaver allograft survival in cyclosporine-treated recipients. *Transplantation*, 43:65-78, 1987.
87. Burstain, T.L., Frazier, O.H., Schnee, M.J.M., **Kerman, R.H.**, Lorber, M., Colon, R., McAllister, H., Kahan, B.D., and Van Buren, C.T.: Predicators of rejection in cyclosporine treated cardiac recipients. *Transplant. Proc.*, 19:2531-2533, 1987.
88. Flechner, S.M., Van Buren, C.T., **Kerman, R.H.**, Lorber, M., and Kahan, B.D.: Does cyclosporine improve the results of HLA-identical renal transplantation? *Tranplant. Proc.*, 19:1485-1488, 1987.
89. **Kerman, R.H.**, Flechner, S.M., Van Buren, C.T, Lorber, M., Dawson, G., Gutierrez, R., and Kahan, B.D.: Investigation of HTLV-3 serology in a renal transplant population. *Transplant. Proc.*, 19:2172-2175, 1987.
90. Kahan, B.D., Mickey, R., Flechner, S.M., Lorber, M.I., Wideman, C.A., **Kerman, R.H.**, Terasaki, P.I., and Van Buren, C.T.: Multivariant analysis of risk factors impacting on immediate and eventual cadaver allograft survival in cyclosporine-treated recipients. *Transplant. Proc.*, 19:1835-1838, 1987.
91. **Kerman, R.H.**, Flechner, S.M., Van Buren, C.T., Lorber, M., and Kahan, B.D.: The role of suppressor cells in cyclosporine-treated renal allograft recipients. *Transplant. Proc.*, 19:1580-1583, 1987.
92. Lorber, M.I., Flechner, S.M., Van Buren, C.T., Sorensen, K., **Kerman, R.H.**, and Kahan, B.D.: Management of immunosuppressive problems in renal allograft recipients. *Transplant. Proc.*, 19:1951-1954, 1987.
93. **Kerman, R.H.**, Flechner, S.M., Van Buren, C.T., Lorber, M., Dawson, G., Falk, L., Gutierrez, R., and Kahan, B.D.: Investigation of HTLV-3 serology in a renal transplant population. *Transplantation*, 43:244-248, 1987.
94. **Kerman, R.H.**, Flechner, S.M., Van Buren, C.T., Lorber, M.I., and Kahan, B.D.: Immunoregulatory mechanisms in cyclosporine renal allograft recipients. *Transplantation*, 43:205-210, 1987.
95. Lorber, M., Flechner, S.M., Van Buren, C.T., **Kerman, R.H.**, and Kahan, B.D.: Cyclosporine toxicity: the effect of combined therapy using cyclosporine, azathioprine and prednisone. *Am. J. Kidney Dis.* 16:476-484, 1987.
96. **Kerman, R.H.**, Van Buren, C.T., Lewis, R.M. and Kahan, B.D.: Successful transplantation of 100 untransfused cyclosporine-treated primary recipients of cadaveric donor renal allografts. *Transplantation* 45:37-40, 1988.
97. Johnson, P.C., Lewis, R.M., Golden, D., Oefinger, P.E, Van Buren, C.T., **Kerman, R.H.**, and Kahan, B.D.: The Impact of CMV infection on sero-negative recipients of seropositive donor kidneys vs seropositive recipients treated with cyclosporine-prednisone immunosuppression. *Transplantation* 45:116-121, 1988.

98. **Kerman, R.H.**, Van Buren, C.T., Lewis, R.M., Frazier, O. Howard, Cooley, D., and Kahan, B.D.: The impact of HLA A, B and DR, blood transfusions and immune responder status on cardiac allograft recipients treated with cyclosporine. *Transplantation* 45:333-337, 1988.
99. Lewis, R.M., Johnson, P.C., Golden, D., Van Buren, C.T., **Kerman, R.H.**, and Kahan, B.D.: The adverse impact of CMV infection on clinical outcome in cyclosporine-prednisone treated renal allograft recipients. *Transplantation* 45:353-359, 1988.
100. Smith, A.Y., Van Buren, C.T., Lewis, R.M., **Kerman, R.H.** and Kahan, B.D.: Short and long-term function of cadaveric kidneys from pediatric donors in recipients treated with cyclosporine. *Transplantation* 45:360-367, 1988.
101. Didlake, R., Dreyfuss, K., **Kerman, R.H.**, Van Buren, C.T., and Kahan, B.D.: Patient non-compliance: a major cause of late graft failure in cyclosporine-treated renal transplants. *Transplant Proc.* 20 (Suppl. 3):63-69, 1988.
102. Smith, A.Y., Van Buren, C.T., Lewis, R.M., **Kerman, R.H.**, Welsh, M., and Kahan, B.D.: The outcome of repeat cadaveric kidney transplants in recipients managed with cyclosporine. *Transplant Proc.* 20 (Suppl 3):180-193, 1988.
103. Smith, A.Y., **Kerman, R.H.**, Van Buren, C.T., Lewis, R.M., and Kahan, B.D.: Pediatric cadaver donor kidneys in recipients treated with cyclosporine. *Transplant Proc.* 20 (Suppl 3):215-221, 1988.
104. **Kerman, R.H.**, Van Buren, C.T., Lewis, R.M., and Kahan, B.D.: Impact of blood transfusion and HLA on cyclosporine-treated renal transplant recipients. *Transplant Proc.* 20 (Suppl. 3):264-269, 1988.
105. Lewis, R.M., Janney, R.P., Van Buren, C.T., **Kerman, R.H.**, Herson, J., Kerr, N.A., Golden, D.A., and Kahan, B.D.: A retrospective analysis of long-term renal allograft function associated with cyclosporine-prednisone immunosuppressive therapy. *Transplant Proc.* 20 (Suppl.3):534-539, 1988.
106. **Kerman, R.H.**, Wolinsky, J.S., Nath, A. and Sears, E.S.: Serial immune evaluation of cyclosporine and placebo treated chronic progressive multiple sclerosis patients. *J. Neuroimmunol* 18:325-321, 1988.
107. Van Buren, C.T., **Kerman, R.H.**, Lewis, R.M., and Kahan, B.D.: Relationship of HLA matching to race and access of kidney transplantation. *N Engl J Med.* 319:1092-1093, 1988.
108. Nath, A., Wolinsky, J.S., and **Kerman, R.H.**: Effect of cyclosporine on Rubella-virus specific immune response in chronic progressive multiple sclerosis. *J. Neuroimmunol* 22:143-148, 1989.
109. Lewis, R.M., Janney, R.P., Golden, D.A., Kerr, N.B., Van Buren, C.T., **Kerman, R.H.**, and Kahan, B.D.: Stability of renal allograft function associated with long-term cyclosporine immunosuppressive therapy: five year follow-up. *Transplantation* 47:266-272, 1989.
110. Kahan, B.D., **Kerman, R.H.**, Van Buren, C.T., Flechner, S.M., Golden, D.L., and Lewis, R.M.: Clinical outcome in 36 patients after at least one year and up to 5 years of steroid withdrawal

based upon specific mixed lymphocyte reaction hyporesponsiveness toward the living related donor. *Transplant Proc.*, 21:1579-1580, 1989.

111. Lewis, R.M., Van Buren, C.T., Macris, M., Frazier, O.H., Janne, R.P., McAndrew, J., **Kerman, R.H.**, and Kahan, B.D.: Evolution of renal function in cardiac vs. renal recipients receiving long-term cyclosporine immunosuppressive therapy. *Transplant Proc.* 21:1523-1524, 1989.
112. Smith, A.Y., Citterio, F., Welsh, M., **Kerman, R.H.**, and Kahan, B.D.: Interleukin-2 receptor as an immunodiagnostic tool to differentiate rejection versus nephrotoxicity. *Transplant Proc.*, 21:1462-1464, 1989.
113. Dunn, J., Vathsala, A., Golden, D., **Kerman, R.**, Lawen, J., Van Buren, C.T., Lewis, R. and Kahan, B.D.: Impact of race on the outcome of renal transplantation under cyclosporine-prednisone at The University of Texas Medical School at Houston. *Transplant Proc* 21:3946-3948, 1989.
114. Lewis, R., Ken, W., Van Buren, C., Lowry, P., Sandler, L., Frazier, O.H., Powers, P., Corriere Jr., J., **Kerman, R.**, Kahan, B.: Comparative Evaluation of Urographic contrast media, insulin and ^{99m}Tc-DTPA clearance methods for determination of glomerular filtration rate in clinical transplantation. *Transplantation* 48:790-796, 1989.
115. **Kerman, R.H.**, Van Buren, C.T., Lewis, R.M. and Kahan, B.D.: Blood transfusion experience for cyclosporine-prednisone treated renal allograft recipients at The University of Texas Medical School at Houston. *In* *Clinical Transplants 1988*, P. Terasaki (ed) UCLA Tissue Typing Laboratory, Los Angeles, CA.
116. Vathsala, A., Verani, R., Schoenberg, L., Lewis, R.M., Van Buren, C.T., **Kerman, R.H.** and Kahan, B.D.: Proteinuria in cyclosporine-treated renal transplant recipients. *Transplantation* 49:35-41, 1990.
117. **Kerman, R.H.**, Van Buren, C.T., Lewis, R.M., DeVera, V., Baghdasarian, V., Gerolami, K., Kahan, B.D.: Improved graft survival for flow cytometry and anti-human globulin crossmatch negative retransplant recipients. *Transplantation* 49:52-56, 1990.
118. Kimball, P.M., **Kerman, R.H.**, Kahan, B.D.: Sensitivity of intracellular signals responsible for cell cycle progression to cyclosporine. *Transplantation* 49:186-191, 1990.
119. Nath, A., **Kerman, R.H.**, Novak, I.S. and Wolinsky, J.S.: Immune studies in human immunodeficiency virus infection with Myesthenia Gravis: A case report. *Neurology* 40:581-583, 1990.
120. Lewis, R.M., Van Buren, C.T., **Kerman, R.H.**, Conley, S.B., Radovencevic, B., Frazier, O.H. and Kahan, B.D.: A review of long-term cyclosporine used in renal transplantation. *Clin. Transplantation* 4:313-320, 1990.
121. Lewis, R.M., Van Buren, C.T., Radovancevic, B., Frazier, O.H., Janney, R.P., Powers, P.L., Giannakis, J.G., Macris, M.P., **Kerman, R.H.** and Kahan, B.D.: Impact of long-term cyclosporine A (CsA) therapy on native kidneys vs. renal allografts: Serial renal function in cardiac and renal transplnt recipients. *Jrnl Heart Transplantation*, 10:63-70, 1991.

122. Kimball, P.M., **Kerman, R.H.** and Kahan, B.D.: Cyclosporine suppression of intracellular activation signal generation is not mediated by prolyl-peptidyl isomerase. *Transplant Proc*, 23:323-324, 1991.
123. Kimball, P.M. and **Kerman, R.H.**; Erythropoietin. A potential immunomodulator? *Transplant Proc* 23:336, 1991.
124. **Kerman, R.H.**, Kimball, P.M., Van Buren, C.T., Lewis, R.M., DeVera, V., Baghdahsarian, V., Heydari, A., and Kahan, B.D.: Improved renal allograft survival for AHG and DTE/AHG crossmatch negative recipients. *Transplant. Proc.* 23:400-402, 1991.
125. **Kerman, R.H.**, Kimball, P.M., Van Buren, C.T., Lewis, R.M. and Kahan, B.D.: Stronger immune responsiveness of blacks vs. whites may account for renal allograft survival differences. *Transplant Proc.* 23:380-382, 1991.
126. Kimball, P.M., **Kerman, R.H.** and Kahan, B.D.: Rapamycin and cyclosporine produce synergistic but non-identical mechanisms of immunosuppression. *Transplant Proc.*, 23:1027-1028, 1991.
127. Kimball, P.M., **Kerman, R.H.** and Kahan, B.D.: Rapamycin and cyclosporine produce synergistic but non-identical mechanisms of immunosuppression. *Transplantation* 51:486-490, 1991.
128. Kimball, P.M., **Kerman, R.H.** and Kahan, B.D.: Cyclosporine suppression of T-cell activation signalling is not mediated by prolyl-peptidyl-isomerase. *Transplantation* 51:509-513, 1991.
129. Katz, S.M., **Kerman, R.H.**, Golden, D.L., Grevel, J., Camel, S., Lewis, R.M., Van Buren, C.T., and Kahan, B.D.: Preemptive renal transplantation: an analysis of benefits and hazards in 85 cases. *Transplantation* 51: 351-355, 1991.
130. Knight, R., **Kerman, R.H.**, Welsh, M., Golden, D.L., Schoenberg, L., and Kahan, B.D.: Chronic rejection in primary renal allograft recipients under the cyclosporine-prednisone immunosuppressive therapy. *Transplantation*, 355-359, 1991.
131. **Kerman, R.H.**, Kimball, P.M., Van Buren, C.T., Lewis, R.M., DeVera, V., Baghdahsarian, V., Heydari, A., and Kahan, B.D.: AHG and DTE/AHG procedures identify crossmatch-appropriate donor recipient pairings which result in improved graft survival. *Transplantation* 51: 316-320, 1991.
132. **Kerman, R.H.**, Kimball, P.M., Van Buren, C.T., Lewis, R.M. and Kahan, B.D.: Possible contribution of pretransplant immune responder status to renal allograft survival differences of black versus white recipients. *Transplantation* 51: 338-342, 1991.
133. Katz, S.M., **Kerman, R.H.**, Golden, D.L., Grevel, J., Camel, S., Lewis, R.M., Van Buren, C.T. and Kahan, B.D.: Preemptive renal transplantation: an analysis of benefits and hazards in 85 cases. *Transplantation* 51:351-355, 1991.
134. Knight, R., **Kerman, R.H.**, Golden, D., Schoenberg, L., and Kahan, B.D.: Chronic rejection in primary cadaver renal allograft recipients under cyclosporine immunosuppressive therapy. In Burdick, J.F., Solez, K., Racusen and Williams, G.M. (eds.): Kidney Transplant Rejection: Diagnosis and Treatment, Marcel Dekker, Inc., New York, Chapter 21, pgs. 627-636, 1991.

RONALD H. KERMAN, PH.D.

135. Meehan, M.A., **Kerman, R.** and LeMire, J.: 1-25, dihydroxy-vitamin D₃ enhances the generation of non-specific suppressor cells while inhibiting the induction of cytotoxic cells in a human MLR. *Cellular Immunology* 140:400-409, 1992.
136. **Kerman, R.H.**, Kimball, P.M., Van Buren, C.T., Lewis, R.M., Cavazos, D., Heydari, A., and Kahan, B.D.: Influence of race on crossmatch outcome and recipient eligibility for transplantation. *Transplantation* 53:64-67, 1992.
137. Lewis, R.M., Katz, S., Van Buren, C.T., **Kerman, R.H.** and Kahan, B.D.: Mechanisms and amelioration of acute renal allograft failure in the cyclosporine era. *Renal Failure* 14 (3):267-284, 1992.
138. **Kerman, R.H.**, Kimball, P.M., Lindholm, A., Van Buren, C.T., Katz, S., Lewis, R.M., McClain, J., Podbielski, J., Williams, J., and Kahan, B.D.: Influence of HLA matching on rejections and short and long term primary cadaveric allograft survival. *Transplantation* (In Press)
139. Kimball, P.M., **Kerman, R.H.**, Van Buren, C.T., Lewis, R.M., Katz, S., Kahan, B.D.: Cyclosporine and rapamycin affect protein kinase C induction of the intracellular activation signal, activator of DNA replication (ADR). *Transplantation* 55:1128-1132, 1993.
140. McCarthy, M., Lovett, A., **Kerman, R.H.**, Overstreet, A., and Wolinski, J.S.: Immunodominant T-Cell epitopes of rubella virus structural proteins defined by synthetic peptides. *Journal of Virology* 67:(2), 1993.
141. Kimball, P.M., **Kerman, R.H.**, Williams, J., and Kahan, B.D.: Cyclosporine and rapamycin block protein kinase C mediated induction of the activation signal, activator of DNA replication (ADR) in cell-free assay. *Transplantation Proceedings* 25(1):518-519, 1993.
142. Kimball, P.M., **Kerman, R.H.**, Van Buren, C.T., Lewis, R.M., Katz, S., Kahan, B.D.: Cyclosporine and rapamycin affect protein kinase C induction of the intracellular activation signal, activator of DNA replication (ADR). *Transplantation* 55:1128-1132, 1993.
143. Lewis, R.M., Podbielski, J., Sprayberry, S.T., Van Buren, C.T., Katz, S., Rubin, M., **Kerman, R.H.**, Kimball, P.M., and Kahan, B.D.: Stability of renal allograft filtration rate associated with long term use of cyclosporine A. *Transplantation* 55:1014-1017, 1993.
144. **Kerman, R.H.**, Kimball, P.M., Lindholm, A., Van Buren, C.T., Katz, S., Lewis, R.M., McClain, J., Podbielski, J., Williams, J., and Kahan, B.D.: Influence of HLA matching on rejections and short and long term primary cadaveric allograft survival. *Transplantation* 56:1242-1247, 1993.
145. **Kerman, R.H.**, Kimball, P.M., Lindholm, A., Van Buren, C.T., Katz, S.M., Lewis, R.M., Podbielski, J., Williams, J. and Kahan, B.D.: Immune risk factors: Impact on the incidence and diagnosis of rejection. *Transplant. Proc* 25 (No. 4, Suppl 3): 23-25, 1993.
146. Lewis, R.M., Podbielski, J., Munsell, M., Katz, S.M., Van Buren, C.T., **Kerman, R.H.** and Kahan, B.D.: Optimization and long-term evaluation of renal function in Sandimmun -treated renal allograft recipients. *Transplantation Proceedings* 25 (No. 4, Suppl 3): 10-12, 1993.
147. Katz, S.M., Kimball, P.M., Ozaki, C., Monsour, H., Clark, J., Williams, J., Heydari, A., Cavazos,

- D., Kahan, B.D., Wood, R.P., and **Kerman, R.H.**: Positive pretransplant crossmatches predict early graft loss in liver allograft recipients. *Transplantation* 57: 616-620, 1994.
148. **Kerman, R.H.**, Kimball, P.M., Scheinen, S., Radovancevic, B., Van Buren, C.T., Kahan, B.D. and Frazier, O.H.: The relationship between donor-recipient HLA mismatches, rejection and death from coronary artery disease in cardiac transplant recipients. *Transplantation* 57:884-888, 1994.
149. Lewis, R., Verani, R., Vo, C., Katz, S., Van Buren, C.T., Radovancevic, B., **Kerman, R.**, Frazier, O.H., Kahan, B.D.: Evaluation of chronic renal disease in cardiac transplant recipients: Importance of pretransplant native kidney histology. *Jrnl Heart Lung Transplantation* 13:376-380, 1994.
150. Jones, C.M., Poddar, S., Goldstein, R., Krupen, K.I., Prince, C., Shadduck, R.K. and **Kerman, R.H.**: Human MCF activates monocytes to produce IL-1 but not TNF or CSF-1. *Immunol*, 190:303-316, 1994.
151. **Kerman, R.H.**, Kimball, P.M., Williams, J., Heydari, A., Cavazos, D., Katz, S., Ozaki, C., Clark, J., Kahan, B.D. and Wood, R.P. Immunoregulatory mechanisms identified in liver transplant recipients. *Transplant Proc* 26:2857-2858, 1994.
152. Knight, R.J., Kurrle, R., McClain, J., Racenberg, J., Baghdhasarian, V., **Kerman, R.**, Lewis, R., Van Buren, C.T. and Kahan, B.D.: Clinical evaluation of induction immunosuppression with a murine IgG-2b monoclonal antibody (BMA-031) directed toward the human alpha-beta T-cell receptor. *Transplantation* 57:1581-1588, 1994.
153. Lewis, R., Podbielski, J., Munsell, M., Katz, S., Van Buren, C.T., **Kerman, R.** and Kahan, B.D.: Stability of renal allograft glomerular filtration rate in the cyclosporine era: 2-year follow-up. *Transplant Proc* 26:2619-2621, 1994.
154. **Kerman, R.H.**, Sullivan, K., and Tejani, A.: Influence of HLA, crossmatching and immunosuppression on the graft survival of primary pediatric recipients of cadaveric renal allografts. *Transplant Proc* 27:656-657, 1995.
155. Kimball, P., Radovancevic, B., Isom, T., Sobinski, J., Frazier, O.H., Vorhaben, R., **Kerman, R.H.**: Cytokine panel predicts early rejection and therapeutic response after cardiac transplantation. *Transplant Proc.* 27:1286-1287, 1995.
156. Brod, S.A., Khan, M., Bright, J., Sriram, S., Marshall, G.O., Henninger, E.M., **Kerman, R.H.**, Wolinsky, J.S.: Decreased CD3 mediated interferon-gamma production in relapsing-remitting multiple sclerosis. *Annals of Neurology* 37:546-549, 1995.
157. Brod, S.A., Khan, M., **Kerman, R.H.**, Pappola, M., Wolinsky, J.S.: Oral administration of human or murine interferon alpha suppresses relapses and modifies adoptive transfer in EAE. *Jrnl Neuroimmunology* 58:61-69, 1995.
158. **Kerman, R.H.**, Susskind, B., Buelow, R., Regan, J., Pouletty, P., Williams, J., Gerolami, K., Kerman, D.H., Van Buren, C.T., Katz, S.M., Kahan, B.D.: Correlation of ELISA detected IgG and IgA anti-HLA antibodies in pretransplant sera. *Transplantation* 62:201-205, 1996.
159. **Kerman, R.H.**, Katz, S.M., Van Buren, C.T., Barakat, O., Schoenberg, L., Kahan, B.D.: 10 year

- follow-up of MLR-hyporesponsive living related cyclosporine monotherapy treated renal allograft recipients. *Transplant Proc* 29:198-199, 1997.
160. **Kerman, R.H.**, Susskind, B., Kerman, D.H., Lam, M., Gerolami, K., Williams, J., Kalish, R., Campbell, M., Katz, S.M., Van Buren, C.T., Kahan, B.D.: Anti-HLA antibodies detected in post-transplant renal allograft recipient sera correlate with chronic rejection. *Transplant Proc* 29:1515-1516, 1997.
161. **Kerman, R.H.**, Susskind, B., Slaton, J., Lewis, R.M., Heydari, A., Ruth, J., Cavazos, D., Williams, J., Van Buren, C.T., Katz, S.M., Kahan, B.D.: Improved graft survival in 100 retransplant recipients following AHG-negative crossmatching. *Transplant Proc* 29:1451-1453, 1997.
162. **Kerman, R.H.**, Susskind, B., Katz, S.M., Van Buren, C.T., Kahan, B.D.: Post renal transplant hypo-responders have fewer rejections and better graft survival than MLR-hypo-responders. *Transplant Proc* 29:1410-1411, 1997.
163. Brod SA, **Kerman RH**, Nelson LD, Marshall GD, Henniger EM, Khan M, Jin R, Wolinsky JS: Ingested IFN has biological effects in humans with relapsing-remitting multiple sclerosis. *Multiple Sclerosis* 3:1-7, 1997.
164. Lindsey JW, **Kerman RH**, Wolinsky JS: T Cell-T Cell activation in multiple sclerosis. *Multiple Sclerosis* 3:238-242, 1997.
165. **Kerman RH**, Susskind B, Kerman DH, Lam M, Gerolami K, Williams J, Kalish R, Campbell M, Katz SM, Van Buren CT, Frazier OH, Radovancevic B, Fife S, Kahan BD: Comparison of PRA-STAT, sHLA-EIA, and AHG-PRA to identify alloreactivity in pretransplant sera of heart recipients: Correlation to rejection and posttransplant coronary artery disease. *J Heart and Lung Transplantation* 17:789-798, 1998.
166. Susskind B, **Kerman R**, Nelson R, Gregory J, Ruth J, Bayat A, Tate K, Dang M, Sweeton J, Van Buren C, Katz S, Kahan B. Comparison between ELISA and cytotoxic crossmatch procedures for detecting IgG anti-donor antibodies. *Transplantation* 66:1823-1826, 1998.
167. **Kerman RH**, Susskind B, Ruth J, Katz S, Van Buren CT, Kahan BD: Can an immunologically, non-reactive potential allograft recipient be transplanted without a donor-specific crossmatch? *Transplantation* 66:1833-1834, 1998.
168. Przybylowski P, Bologna, M, Radovancevic B, Frazier OH, Van Buren CT, Katz SM, Kahan BD, **Kerman RH**: The role of flow cytometry detected IgG and IgM anti-donor antibodies in cardiac allograft recipients. *Transplantation* 67:258-262, 1999.
169. Clark J, **Kerman R**, Susskind B, Katz S, Van Buren C, Kahan B: Correlation of pretransplant allosensitization with severity of biopsy rejection. *Transplant Proc* 31:751-752, 1999.
170. **Kerman RH**, Susskind B, Buyse I, Przybylowski P, Ruth J, Warnell S, Dang M, Van Buren CT, Katz SM and Kahan BD: Flow cytometry detected IgG is not a contraindication to renal allotransplantation: The presence of IgM may be beneficial to outcome. *Transplantation* 68:1855-1858, 1999.
171. Gruber SA, Katz SM, Kaplan B, Clark J, Chen PC, El-Sabroun R, **Kerman RH**: Initial results of

- solitary pancreas transplants performed without regard to donor/recipient HLA mismatching. *Transplantation* 70:388-391, 2000.
172. Gebel HM, Bray RA, Ruth JM, Zibari GB, McDonald JC, Kahan BD, **Kerman RH**: Flow PRA to detect clinically relevant HLA antibodies. *Transplant Proc.* 33:477, 2001.
173. **Kerman RH**, Katz SM, Van Buren CT, Ruth JM, McKissick E, Rasmussen S, Kahan BD: Posttransplant immune monitoring of anti-HLA antibody. *Transplant Proc* 33:401, 2001.
174. **Kerman RH**, Katz SM, Van Buren CT, Garcia C, Kahan BD: Addition of Rapamycin to Cyclosporine-Prednisone based immunosuppression reduces the clinical risk of pretransplant anti-HLA antibody. *Transplant Proc* 33:402, 2001.
175. Racusen LC, Colvin R, Solez K, Mihatsch MJ, Halloran P, Campbell P, Cecka M, Cosyns JP, Demetris AJ, Fishbein MC, Fogo A, Furness P, Gibson IW, Glotz D, Hayry P, Hunsicker L, Kashgarian M, **Kerman R**, Magil A, Morozumi K, Nickleit V, Randhawa P, Regele H, Seron D, Seshan S, Sund S, Trpkov K. Antibody mediated rejection criteria: An addition to the Banff '97 classification of renal allograft rejection. *American Journal of Transplantation* 3:708-714, 2003.
176. Knight, R.J., **Kerman, R.H.**, Zela, S., Podder H, Van Buren, C.T., Katz, S.M., and Kahan, B.D.: Thymoglobulin, sirolimus and reduced dose cyclosporine provides excellent rejection prophylaxis for pancreas transplantation. *Transplantation* 75(8):1301-1306, 2003
177. Kahan, B.D., Knight R, Schoenberg L, Podbielski J, **Kerman RH**, Mahalati K, Yakupoglu Y, Aki FT, Katz S and Van Buren CT: Ten years of Sirolimus therapy for human renal transplantation: The University of Texas at Houston Experience. *Transplant Proc* 35: (Suppl 3A), 25S-34S., 2003.
178. Bray R, Nickerson PW, **Kerman RH**, Gebel H. Evolution of HLA antibody detection technology emulating biology. *Immunology Research*, 2003.
179. Knight, R.J. Zela S, Schoenberg L, Podder H, **Kerman RH**, Katz S, Van Buren CT, and Kahan, B.D.: The Effect of pancreas transplantation on peripheral vascular disease complications. *Transplant Proc* 36(4), 1069-1071, May 2004.
180. Knight, R.J, **Kerman RH**, Schoenberg L, Podder H, Katz S, Van Buren CT, and Kahan, B.D.: The selective use of basiliximab versus thymoglobulin in combination with sirolimus for cadaveric renal transplant recipients at low risk versus high risk for delayed graft function. *Transplantation* 78(6), 904-910; September 2004.
181. Zhang Y, Kirken RA, Furian L, Janczewska S, Qu X, Hancock WW, Wang ME, Tejpal N, **Kerman R**, Kahan B, Stepkowski SM. Allograft rejection requires Stat5a/b-regulated anti-apoptotic activity in T but not in B cells. *Journal of Immunology* 176:128-137, 2006.
182. **Kerman RH**, Stepkowski S. Clinical significance of HLA antigens and non-HLA antigens in solid organ transplantation. *Current Opinion in Organ Transplantation* 11:418-424, 2006.
183. Podder H, **Kerman R**, Illoh O, Kahan B. Sick cell disease: A formidable enemy of the transplant. In, *Clinical Transplants 2006*, Terasaki PI (ed), Terasaki Foundation Laboratory, Los Angeles, CA, pages 570-571.

E. INVITED ARTICLES

1. **Kerman, R.H.:** New developments in transplantation immunology. *The Cancer Bulletin* 33(6):281-286, 1981.
2. **Kerman, R.H.:** Effect of blood transfusion on renal allograft survival: Immunological considerations. *Am. J. Kidney Diseases* 2:125-127, 1981.
3. **Kerman, R.H.** and Kahan, B.D.: Immunological evaluation of transplant rejection: Pre and postoperative indices detecting immune responsiveness. **In** Hayry, P. (ed.): Present and Future

Trends in Clinical Transplantation. Ann. Clin. Res. 13:244-263, 1981.

4. **Kerman, R.H.:** Editorial: Influence of HLA A, B and DR antigen matching in transfused cadaver renal transplant patients. Cleveland Clinic Quarterly 50:216-217, 1983.
5. Kahan, B.D., Van Buren, C.T., Flechner, S.M., Jarowenko, M., Yasumura, T., Rogers, A.J., Yoshimura, N., LeGrue, S., Drath, D., and **Kerman, R.H.:** Clinical and experimental studies with cyclosporine in renal transplantation. Surgery 97:125-140, 1985.
6. Kahan, B.D., **Kerman, R.H.**, Wideman, C.A., Flechner, S.M., Jarowenko, M., and Van Buren, C.T.: Impact of cyclosporine on renal transplant practice at The University of Texas Medical School at Houston. Am. J. Kidney Dis. 5:288-295, 1985.
7. Kahan, B.D., **Kerman, R.H.**, Flechner, S.M., Lorber, M.I., and Van Buren, C.T.: Clinical results of ciclosporin-prednisone therapy in renal transplantation. Contr. Nephrol. 51:36-39, 1986.
8. Kahan, B.D., **Kerman, R.H.**, Flechner, S.M., Lorber, M.I., and Van Buren, C.T.: Impact of Sandimmune on renal transplant results at the University of Texas Medical School at Houston. **In** Kahan, B.D.(ed.). Proceedings of The Second Asian Cyclosporine Workshop, pp 17-22. Excerpta Medica Asia Ltd. Hong Kong, 1986.
9. **Kerman, R.H.:** To be or not to be transfused: That is the question in the cyclosporine era! Transplantation and Immunology Letter, Vol. IV (No 3): 2, November, 1987.
10. **Kerman, R.H.:** Pretransplant 51-Chromium release crossmatch assays. Transplantation and Immunology Letter, Vol V (No. 1):7-11, 1988.
11. **Kerman, R.H.:** Effects of cyclosporine immunosuppression in man. Transplant Proc. 20 (Suppl 2):143-152, 1988.
12. **Kerman, R.H.:** Transfusions in non-renal transplantation. Transplantation Proc. 20:1071-1073, 1988.
13. **Kerman, R.H.** The role of crossmatching in organ transplantation. Arch Pathol Lab Med. 115:255-259, 1991.
14. **Kerman, R.H.:** Crossmatching controversy: Is the crossmatch result a contraindication to transplantation? American Society of Histocompatibility and Immunogenetics Quarterly 17(4):25-29, 1993.
15. **Kerman, R.H.:** To match or not to match? That is the question! **In** Clinical Transplants 1993, Terasaki PI and Cecka MJ (eds), UCLA Tissue Typing Laboratory, Los Angeles, CA., pg. 431-433 1994.
16. **Kerman RH**, Orosz C, Lorber M: Clinical relevance of anti-HLA antibodies pre and post transplantation. In, Advances in Organ Transplantation, Sayegh M and Neylan JF, Eds., The American Journal of The Medical Sciences 313:275-278, 1997.
17. **Kerman RH:** Crossmatch techniques for re-transplantation. Transplantation and Immunology Letter 13(4):8-9, 1997.

18. **Kerman, R.H.:** Can we predict chronic rejection? Humoral immune assays. *Graft* Vol, No 2 (Suppl II): 66-67, 1998.
19. **Kerman RH:** Posttransplant immune serological markers may be predictive of chronic rejection. *Annals of Transplantation*. 5(2):24-28, 2000.
20. Kasiske BL, Cangro CB, Hariharan S, Hricik DE, **Kerman RH**, Roth D, Rush DN, Vasquez MA, Weir MR., for the American Society of Transplantation. The evaluation of renal transplant candidates: Clinical Practice Guidelines. *Amer Jrnl Transplantation*, Supplement 1: Vol 2:5-95, 2001.
21. **Kerman RH:** Crossmatching methods to detect and assess sensitization. *Transplantation and Immunology Letter* 19 (2): 2003.

F. CHAPTERS

1. **Kerman, R.** and Stefani, S.: Immunological evaluation of patients with solid tumors before and after radiotherapy. *In* Crispen, R.G. (ed.): Neoplasm Immunity: Mechanisms, pp. 109-120. University of Illinois Press, 1976.
2. **Kerman, R.H.**, and Stefani, S.: Radio and immunotherapy of lung cancer: A preliminary report. *In* Crispen, R.G. (ed.): Neoplasm Immunity-Solid Tumor Therapy, pp. 29-35. Franklin Institute Press, 1977.
3. Stefani, S. and **Kerman, R.:** Prognostic significance of pre-therapy delayed hypersensitivity and

- T-cell levels in patients with lung cancer. **In** Nieburgs, H.E. (ed.): Proceedings of the Third International Symposium on the Detection and Prevention of Cancer, Vol. 1, Part II, pp. 785-797. Marcel Dekker, Inc., 1978.
4. Stefani, S. and **Kerman, R.H.**: Prognostic value of the immunologic profile in inoperable lung cancer patients treated by radiation. **In** Muggia, F. and Rozenzweig, M. (eds.): Lung Cancer (Progress in Cancer Research and Therapy), Vol. 11, pp. 465-470. Raven Press, Inc., New York, 1979.
 5. **Kerman, R.H.**: Identification of human T and B lymphocytes. **In** Natelson, S., Pesce, A.J. and Dietz, A.A.: Clinical Immunochemistry: Chemical and Cellular Bases and Applications in Disease, pp. 12-20. American Association for Clinical Chemistry, 1979.
 6. **Kerman, R.** and Kahan, B.D.: Clinical histocompatibility testing in renal transplantation: Potential keys to alloimmune specificity and reactivity. **In** Reisfeld, R. and Ferrone, S. (eds.): Current Trends in Histocompatibility, Vol. 2, pp. 201-226. Plenum Press, 1981.
 7. **Kerman, R.H.** and Kahan, B.D.: Assessment of immune parameters of transplant recipients on immunosuppressive therapy. **In** Dean, J. and Padarathsingh, M. (eds.): Biological Relevance of Immune Suppression as Induced by Genetic, Therapeutic and Environmental Factors, pp. 82-97. Van Nostrand Reinhold Co., New York, 1981.
 8. Kahan, B.D., **Kerman, R.H.**, Agostino, G., Friedman, A. and LeGrue, S.J.: The action of Cyclosporin A on human lymphocytes. **In** White, D.J.G. (ed.): Cyclosporin A, pp. 281-293. Elsevier-Biomedical Press, Amsterdam, 1982.
 9. **Kerman, R.H.**, Conklin, R., Cahall, D., Van Buren, C.T. and Kahan, B.D.: CMV and renal allograft survival. **In** Eisenstein, T. and Friedman, H. (eds.): Host Defense to Intracellular Pathogens, pp. 517-519. Plenum Press, Inc., New York, 1983.
 10. Kahan, B.D., Van Buren, C.T., Flechner, S.M., Rogers, A.J., Yoshimura, N., and **Kerman, R.H.**: Pharmacologic and immunologic monitoring of cyclosporine-treated renal allograft recipients. **In** Paul, L.C. (ed.): Management of Cyclosporin in Renal Transplantation, pp. 40-54. Actua Sandoz, 1985.
 11. Van Buren, C.T., Flechner, S.M., Wideman, C.A., and **Kerman, R.H.**: Allograft rejection in renal allograft recipients under cyclosporine-prednisone immunosuppressive therapy. **In** Williams, G.M., Burdick, J.F., and Solez, K. (eds.): Kidney Transplant Rejection: Diagnosis and Treatment, pp. 411-422. Marcel Dekker, Inc., New York, 1986.
 12. **Kerman, R.H.**, and Kahan, B.D.: The role of immune evaluation in transplantation. **In** Cerilli, J. (ed.): Organ Transplantation and Replacement. J.B. Lippincott Co., pp. 379-393, Philadelphia, 1987
 13. Smith, A.Y., Van Buren, C.T., Lewis, R.M., **Kerman, R.H.**, and Kahan, B.D.: Factors determining renal transplant outcome at The University of Texas Medical School at Houston. **In** Terasaki, P. (ed): Clinical Transplants - 1987, pp. 155-166. UCLA Tissue Typing Laboratory, Los Angeles, CA.
 14. **Kerman, R.H.**: Immune monitoring considerations in transplantation. **In** Flye, M.W. (ed.):

Principles of Organ Transplantation. W.B. Saunders Co., pp. 135 - 154. Philadelphia, 1988.

15. Knight, R., **Kerman, R.H.**, Golden, D., Schoenberg, L., and Kahan, B.D.: Chronic rejection in primary cadaver renal allograft recipients under cyclosporine immunosuppressive therapy. **In** Burdick JF, Solez K, Racusen and Williams GM. (eds): Kidney Transplant Rejection: Diagnosis and Treatment, Marcel Dekker, Inc., 21:627-636, 1991.
16. **Kerman, R.H.**: Crossmatching considerations in organ transplantation. **In** Tejani, A. and Fine, R. (eds.): Pediatric Renal Transplantation John Wiley & Sons, pgs. 51-67, 1994.
17. **Kerman, R.H.**: The major histocompatibility complex in human transplantation. **In** Tejani, A. and Fine, R. (eds.): Pediatric Renal Transplantation John Wiley & Sons, pgs. 69-85, 1994.
18. **Kerman, R.H.**: Relevance of histocompatibility testing in clinical transplantation. **In** Kahan B.D., (ed): Surgical Clinics of North America, W.B. Saunders Co., Publs. 74:1015-1028, 1994.
19. **Kerman, R.H.**: Preoperative histocompatibility considerations in human heart transplantation. **In**: Frazier OH, Macris MP, Radovancevic B, eds. Support and replacement of the failing heart. Philadelphia, PA., JB Lippincott, pgs. 109-120, 1995.
20. **Kerman RH**, Susskind BM, Slaton J, Lewis RM, Heydari A, Ruth J, Williams J, Van Buren CT, Katz SM, Kahan BD: Retransplantation following AHG-negative crossmatches. Published in Retransplantation, Touraine, J.L, Traeger, J., Betuel, H., Dubernard, J.M., Revillard, J.P., Dupuy, C. (eds) Kluwer Academic Publishers, The Netherlands, pgs 167-177, 1997.
21. **Kerman, R.H.**: Understanding pretransplant crossmatching. **In**, Primer on Transplantation. Norman DJ and Suki WN, Eds., The American Society of Transplant Physicians, Publ; pgs 61-68, 1998.
22. **Kerman RH**: Immunogenetics, Histocompatibility and Crossmatching for Kidney Transplantation. **In**: Kahan BD and Ponticelli C, (eds). Published in Principles and Practice of Renal Transplantation, Dunitz, London (2000).
23. **Kerman RH**: The HLA System and Crossmatching for Renal Transplantation. **In**: Fine, R., Harmon WE, and Tejani, A. (eds). Pediatric Solid Organ Transplantation, Munksgaard, Copenhagen. Pgs 59-73, 2000
24. **Kerman RH**: Clinical Consequences of HLA Antibody and Donor Specific Reactivity. **In**: Weir MR (ed) Medical Management of Kidney Transplantation, Lippincott, Williams and Wilkins, Philadelphia, PA. Pgs. 18-25, 2004.
25. **Kerman RH**: Understanding the Sensitized Transplant Recipient. **In**: Heart Failure Clinics. M.R. Mehra ed, Elsevier, Maryland, 3: 1-9, 2007

G. BOOKS

1. **Kerman, R.H.** (Guest Editor): Proceedings of The Fourth International Symposium on Immunological Monitoring of the Transplant Recipient. *Transplant. Proc.* 16(6), 1984.
2. **Kerman, R.H.** Invited Guest Section Editor (Histocompatibility) for *Current Opinion in Transplantation*. Volume 11:418-443, 2006

